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Abstract
Breast cancer accounts for 522,000 deaths worldwide each year and is the most common
cancer in women. It is classified according to the cell of origin and its expression of
several receptors: oestrogen and progesterone receptors, and human epidermal growth
factor receptor 2 (HER2).
Historically, HER2-positive breast cancers had a worse survival prognosis than oestrogen
or progesterone receptor-positive cancers, but the development of HER2-targeted
therapies led to significant survival improvements. Despite this, patients often present
with de novo resistance, or will develop acquired resistance to targeted therapies.
Several resistance mechanisms have been identified but attempts to target them have
failed. Thus, it is of paramount importance to identify the mechanisms used, to prevent
development of resistance or resensitise tumours to HER2-targeted therapies. Objectives
of this study were: to understand the link between epithelial to mesenchymal transition
(EMT) and loss of HER2, seen in a model of acquired resistance to the HER2-targeted
therapy, sapatinib, and to characterise and validate tumours from a sapatinib-treated
spontaneous mouse model of HER2-positive breast cancer.
The EMT-linked transcription factor ZEB1 was associated with acquired resistance to
sapatinib in tumours that had undergone EMT and concurrently lost HER2. Generation
of drug resistant cell lines failed to recapitulate the in vivo phenotype. Transient
overexpression of ZEB1 in vitro did not induce clear EMT or loss of HER2, despite
a trend towards lower HER2 expression. However, we found that treatment of cells
with ERBB2 shRNA, the gene encoding HER2, increased levels of ZEB1 and enhanced
migration, but did not induce overt EMT. This may be the result of differing PTEN
status between in vivo and in vitro models.
Treatment of a spontaneous mouse model of HER2-positive breast cancer with sapatinib
revealed that progressing tumours had an increase in proteins associated with cellular
iron homeostasis. Further investigation revealed increased heme oxygenase-1 (HO-1),
iron exporter ferroportin and altered iron storage.
To ascertain if modulation of dietary iron intake could affect the development of resistance
to sapatinib, mice were given a control or iron-deficient diet and treated with vehicle or
sapatinib. This showed that in sapatinib-treated mice fed an iron-deficient diet, HO-1
was not increased as in tumours from mice fed a iron-low control diet.
We looked at the possibility of HER2-targeting therapies inducing ferroptosis, an iron-
dependent form of cell death. Sapatinib-treated tumours from mice on a iron-low control
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diet had increased cyclooxygenase 2 (COX2), a marker of ferroptosis, which was not
seen in sapatinib-treated tumours from mice on an iron-deficient diet. Additionally, in
vitro drug treatments with HER2-targeting agents showed that SKBR3 cell death could
be rescued by iron chelation.
HO-1 overexpression in SKBR3 cells revealed increased autophagic flux and resistance to
HER2-targeted therapies. Inhibition of autophagy reversed resistance, rendering them
susceptible to sapatinib- and lapatinib-induced cell death. Further, increased autophagic
flux was seen in all progressive tumours on sapatinib. The increased resistance to
sapatinib in mice fed an iron-deficient diet was also associated with increased autophagic
flux, although this was HO-1-independent.
Taken together, the results presented here provide a novel mechanism of cell death
induced by HER2-targeting agents in vitro and in vivo. We have shown that increased
HO-1 and reducing dietary iron can affect the development of resistance to sapatinib,
which is reliant on autophagy induction. Further, inhibiting autophagy can resensitise
cells to sapatinib and lapatinib treatment.
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Lay summary
The most common cancer in women is breast cancer: in 2012, there were 1.7 million
new cases worldwide. Treatment is tailored according to what the cancer cells express
on their surface. The main molecules are oestrogen receptor, progesterone receptor and
human epidermal growth factor receptor 2 (HER2). For cancers driven by HER2, drugs
have been designed that stop it signalling.
Although these drugs were revolutionary, up to 60% of patients don’t respond initially
and a further 70% of patients will stop responding within two years of treatment. These
cancers are then classed as resistant. To overcome resistance, we need to understand
how it develops in the first place. We used a mouse model that develops breast cancers
driven by HER2 and treated it with a therapy targeting HER2, called sapatinib.
When we used this model to look at resistance acquired over time, we saw that cells
in some of the resistant tumours had changed their shape and expression of different
molecules. Rather than being rounded they had become more elongated and ‘spindle’
shaped, indicating that they had undergone a process called epithelial to mesenchymal
transition (EMT). As well as this, they had lost expression of HER2.
By looking at how this process was driven, we found a molecule called ZEB1 was
increased in these tumour cells and was maintaining the spindle shape and EMT. By
overexpressing ZEB1 in cells, we found that it did not result in the same loss of HER2
seen in the mouse model. Conversely, when we modelled loss of HER2, we saw some
features related to EMT increased, including ZEB1 expression and migration.
To look at resistance another way, we treated mice with sapatinib continuously, rather
than cyclically as was used to develop acquired resistance. By doing this, we found that
tumours from sapatinib-treated mice had changes in cellular iron homeostasis. This
manifested as increases in some molecules which regulate cellular iron and iron deposits
outside of cells.
Because of these results, we looked at whether altering dietary iron intake could affect
the development of resistance in the mouse model. Mice given an iron-deficient diet
developed tumours which progressed on sapatinib more rapidly and were less likely to
respond to treatment than mice on a iron-low control diet.
Next, we looked at the possibility that HER2-targeted therapies were inducing a form
of iron-dependent cell death called ferroptosis. Sapatinib-treated mice on a iron-low
control diet had higher expression of a marker of ferroptosis, COX2, than mice on
the iron-deficient diet. By looking in cells, we saw increased oxidation of lipids after
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treatment with HER2-targeted therapies. Additionally, death induced by these therapies
could be rescued by removing iron from the environment.
When we overexpressed a molecule seen in the tumours from mice fed a iron-low control
diet, HO-1, we found that they were resistant to HER2-targeted therapies and ferroptosis.
In the mouse models and in cells, expression of HO-1 was associated with a recycling
process in cells called autophagy, meaning self-eating. This process was also seen in mice
fed an iron-deficient diet, although it was independent of HO-1 expression. Inhibiting
autophagy was able to resensitise cells to HER2-targeted therapies and ferroptosis.
Overall, we have shown a new way that HER2-targeted therapies can cause cell death,
which can be modulated by dietary iron. Exploiting this could help patients to avoid
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Worldwide, breast cancer is the most common cancer in women; in 2012, there were
1.7 million new cases and 522,000 deaths. [1] It is a heterogeneous disease which can
be ductal or lobular in origin. [2] Invasive ductal carcinoma (IDC), originating from the
cells lining the ducts, accounts for 80% of all diagnosed breast cancers. [3] Molecular
characterisation of IDC allows treatment to be tailored to specific subtypes of IDC, due
to their different protein expression profiles (table 1.1). [1,4]
The luminal A and B subtypes are hormone receptor positive (table 1.1; oestrogen
receptor (ER)+, progesterone receptor (PR)+). [4] Ki67, a proliferation index marker,
is also used to categorise tumours to molecular classifications and is an indicator of
proliferating cells. [4] The luminal A and B subtypes have better outcomes than human
epidermal growth factor receptor 2 (HER2) and basal/triple negative subtypes, as they
can be treated with hormone therapies. [1] Selective oestrogen receptor modulators are
most commonly used in pre-menopausal women, whereas aromatase inhibitors, which
inhibit oestrogen production, are used in post-menopausal women. [4]
Triple negative cancers tend to be basal-like, lacking expression of hormone receptors
and HER2. These cancers have poorer survival rates than hormone receptor-positive and
HER2-positive cancers. [4] Treatment focuses on chemo- and radiotherapy. [3] However,
many BRCA1/2 mutant breast cancers have a basal/triple negative pathology and are
more responsive to cisplatin-based chemotherapy and poly(ADP-ribose) polymerase
(PARP) inhibitors than BRCA wild-type tumours. [6,7]
The HER2 subtype of breast cancer is characterised by high levels of HER2 on the
cell surface. This accounts for approximately 15-20% of breast cancers. [2,4] Prior to
HER2-targeted therapies, these tumours had a worse prognosis than luminal cancers.
However, survival rates have improved. [1]
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Table 1.1. Molecular classification of invasive ductal carcinoma
Subtype Protein Expression Profile
Luminal A ER+ and/or PR+, HER2-, Ki67low
Luminal B ER+ and/or PR+, HER2±, Ki67high
Basal/Triple negative ER-, PR-, HER2-
HER2 ER-, PR-, HER2+
ER: oestrogen receptor; HER2: human epidermal growth factor receptor 2; PR:
progesterone receptor; Allison [4], Hammond et al. [5]
1.2 HER2 signalling pathways
HER2 is a member of the human epidermal growth factor receptor (EGFR) family
which consists of four members (HER1, HER2, HER3 and HER4). They have structural
homology: an extracellular ligand binding domain with four regions, a transmembrane
domain and an intracellular tyrosine kinase domain (fig 1.1). [8]
Once ligand is bound to the extracellular domain, the receptors dimerise. Although
EGFR (HER1), HER3 and HER4 all have known ligands, none have been identified
for HER2. [9] Upon ligand binding to EGFR, HER3 or HER4, the receptors undergo a
conformational change, revealing their dimerisation arms and allowing them to form
dimers with other family members. Ligands for each receptor are detailed in table 1.2.
HER2 is in a fixed formation which mimics the ligand-bound conformation of the other
family members, with the dimerisation arm exposed. [10] Due to this, HER2 is the
preferential binding partner for other HER family members. [10]
When dimerised, the receptors undergo autophosphorylation at tyrosine residues on
the intracellular domain, although HER3 does not possess tyrosine kinase activity and
thus can’t form homodimers. [12] From this, downstream signalling pathways such as
phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and mitogen-activated protein
kinase (MAPK) are activated (fig 1.1). [13] Under normal physiological conditions, HER2
forms heterodimers due to its lack of ligand binding, but when overexpressed it is able
to form homodimers and signal in a ligand-independent manner. [10]
Both EGFR and HER2 are stabilised by the protein chaperone heat shock protein
90 (HSP90). Clients of HSP90 include a wide range of kinases, steroid receptors and
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Table 1.2. EGFR family ligand binding specificity
Receptor














Abbreviations: EGF: epidermal growth factor; TGF-α: transforming growth factor α;
HB-EGF: heparin-binding EGF-like growth factor; NRG: neuregulin. Wieduwilt and
Moasser [11]
transcription factors. [14] Although studies have shown that HER2 is more reliant on
HSP90 for its continued expression than EGFR, HSP90 prevents signalling through
HER2 homodimers. [15–17]
1.2.1 PI3K/AKT pathway
Phosphorylation of HER family members results in the activation of the PI3K family.
PI3Ks are heterodimers consisting of catalytic and regulatory subunits. [13] Class I PI3Ks,
the main class to have a role in cancer progression, convert phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3). [18] This process
is reversed by phosphatase and tensin homolog (PTEN), which dephosphorylates PIP3
back to PIP2 (fig 1.1). [19]
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PIP3 binds to AKT, resulting in its phosphorylation by phosphoinositide-dependent
kinase 1 (PDK1) and mammalian target of rapamycin complex 2 (mTORC2). [20,21] AKT
then activates downstream targets involved in proliferation, migration, protein synthesis
and cell survival. [12,22]
AKT can be inactivated by dephosphorylation, a process which is carried out by protein
phosphatase 2A (PP2A) and PH domain leucine-rich repeat protein phosphatases
(PHLPP) 1 and 2. [23,24]
1.2.2 MAPK pathway
Three MAPK pathways have been documented, but activation through HER family
members results in preferential activation of the extracellular signal-regulated kinase
(ERK) pathway. [22] The ERK pathway is activated through the adapter protein growth
factor receptor-bound protein 2 (GRB2) and a guanine nucleotide exchange factor, son
of sevenless (SOS). [25] SOS catalyses guanosine diphosphate/guanosine triphosphate
(GDP/GTP) exchange, thus activating RAS. [25] RAS binds to RAF, promoting its
phosphorylation and dimerisation. Once phosphorylated, RAF activates MAPK/ERK
kinase 1/2 (MEK1/2) and ERK1/2 (fig 1.1). [26]
Activated ERK1/2 can regulate cytosolic targets or translocate to the nucleus where it
phosphorylates transcription factors. Cytosolic targets of ERK1/2 control migration,
cell adhesion, and ion channels and receptors. [27] There is some cross-over between the
MAPK and PI3K pathways; activated RAS is able to bind to and activate the p110
catalytic subunit of PI3K. [28]
The ERK pathway can be inhibited by Sprouty proteins, MAPK phosphatases and
scaffolding proteins which regulate RAF localisation. [29–31] ERK also negatively regulates
SOS and RAF by phosphorylation, reducing their activity. [22]
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Figure 1.1. Schematic representation of HER2 signalling pathways. Once human
epidermal growth factor 2 (HER2) forms a homo- or heterodimer, the C-terminal domain
becomes transphosphorylated. Downstream signalling pathways, including phosphoinositide
3-kinase (PI3K)/protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) pathways,
become activated resulting in proliferation, differentiation, increased protein synthesis and
survival and decreased apoptosis. Abbreviations: ERK1/2: extracellular signal-regulated
kinase 1/2; GRB2: growth factor receptor-bound protein 2; GDP: guanosine diphosphate;
GTP: guanosine triphosphate; MEK1/2 :MAPK/ERK kinase 1/2; PIP2: phosphatidylinositol
4,5-bisphosphate; PIP3: phosphatidylinositol 3,4,5-trisphosphate; P: phosphorylation; SOS: son
of sevenless.
1.3 HER2 targeting agents
HER2-targeted therapies are monoclonal antibodies, targeting the extracellular domain
of HER2, or small molecule tyrosine kinase inhibitors which specifically target the
intracellular domain of HER2 (fig 1.2). All of these therapies work by preventing
activation of HER2 and downstream signalling, amongst other mechanisms of action. [32–36]
The gold-standard treatment for HER2-positive breast cancer is the monoclonal antibody
trastuzumab, [37] which irreversibly binds the extracellular domain, region IV, of the
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protein. It does not prevent receptor dimerisation but inhibits activation of the
PI3K/AKT and MAPK pathways. [32] Pertuzumab, another monoclonal antibody used
in the treatment of HER2-positive breast cancer, has a complementary mechanism of
action to trastuzumab; by irreversibly binding to extracellular domain II, it inhibits
receptor dimerisation and prevents downstream signalling. [33,38]
Both trastuzumab and pertuzumab induce antibody-dependent cell-mediated cytotoxicity
(ADCC). [33,39] Recruitment of Natural Killer (NK) cells to tumour cells results in CD16-
mediated ADCC and cell death. [32] Additionally, HER2 internalisation and degradation
can be triggered by trastuzumab, resulting in presentation of HER2 fragments to immune
cells and tumour cell lysis. [40] Trastuzumab emtansine, an antibody-drug conjugate,
relies on the internalisation of HER2 upon trastuzumab binding and its subsequent
degradation, releasing emtansine. Emtansine is then able to act specifically on HER2-
positive cells, binding to microtubules which inhibits their polymerisation, leading to
cell cycle arrest and death. [41]
Lapatinib, sapatinib and neratinib are small molecule tyrosine kinase inhibitors which
bind to EGFR and HER2. [34–36] Sapatinib and neratinib additionally bind to HER3 and
HER4, respectively. [35,36] All three are competitive inhibitors of the ATP-binding pocket
within the intracellular domain of HER family members. Of the tyrosine kinase inhibitors,
only neratinib binds irreversibly as it forms covalent bonds, rather than the hydrogen
bonds formed by lapatinib and sapatinib. [35,36,42] All three agents work by inhibiting
phosphorylation of HER2 and its dimerisation partners, therefore inhibiting downstream
pathway activation. [34–36] Pharmacokinetics of sapatinib and lapatinib in phase I studies
showed similar distribution and plasma concentration after administration, with both
molecules primarily being excreted through the faeces within 24 to 48 hours. [43,44]
Lapatinib is mainly metabolised by CYP3A4 and CYP3A5. This information is not
available for sapatinib, but it has been suggested it is partly metabolised by CYP2D6 in
vitro.
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Figure 1.2. Schematic representation of HER2-targeting agents. Human epidermal growth
factor 2 (HER2) consists of an extracellular domain, a single transmembrane domain and an
intracellular domain. The extracellular domain is split into four regions. The first and third
are associated with ligand binding in other HER family members, although there is no known
ligand for HER2. The second region is involved in receptor dimerisation and is the target for
monoclonal antibody pertuzumab. In other HER family members, the fourth region interacts
with residues on the second region when the receptors are inactive. However, HER2 is always
in an active state. Trastuzumab, a monoclonal antibody, binds to the fourth region, but this
does not prevent HER2 dimerisation. Trastuzumab emtansine, an antibody-drug conjugate,
retains the HER2-binding capacity of trastuzumab but results in cell cycle arrest and cytotoxicity
once HER2 is internalised and degraded, as emtansine inhibits microtubule polymerisation.
The intracellular region contains a catalytic tyrosine kinase domain and phosphorylation sites
which activate intracellular signalling pathways. Small molecule inhibitors lapatinib, neratinib
and sapatinib all bind to this intracellular region, preventing phosphorylation and downstream
signalling.
1.3.1 Current treatment regimens
Currently, trastuzumab in combination with chemotherapy agent paclitaxel is the first-
line treatment for patients with HER2-positive breast cancer in the neoadjuvant and
adjuvant setting (before and after surgery, respectively). [37] Pertuzumab is approved in
cases of recurrent or metastatic breast cancer in combination with trastuzumab and
docetaxel. [45]
Trastuzumab and pertuzumab are not administered as single agents, as they have
worse overall response rates (ORR) than chemotherapy alone. [46] In combination with
chemotherapy regimens, there is a marked increase in ORR. Additionally, combined
pertuzumab and trastuzumab with docetaxel gives greater ORR than either trastuzumab
or pertuzumab in combination with docetaxel. [46,47]
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Despite patients’ disease progressing on trastuzumab, removing this from their treatment
regimen can result in rapid proliferation and tumour regrowth. [48,49] Although continuation
of trastuzumab treatment is commonplace worldwide, the UK’s National Institute for
Health and Care Excellence (NICE) does not approve continuation beyond progression. [50]
Lapatinib is indicated in cases of advanced or metastatic breast cancer in combination
with capecitabine. [51] In metastatic, hormone receptor-positive disease, lapatinib has
been indicated in combination with aromatase inhibitor letrozole, which has been shown
to significantly enhance ORR. [52,53] In breast cancer that has progressed on trastuzumab
therapy, combination therapy of lapatinib plus trastuzumab has been shown to prolong
progression free survival (PFS) and overall survival (OS). [54]
However, treatment with trastuzumab emtansine, indicated in patients with recurrent
disease or who have progressed on trastuzumab, has greater survival benefits compared
with lapatinib and capecitabine. [55] Trastuzumab emtansine resulted in prolonged OS,
PFS and ORR compared with lapatinib plus capecitabine. [56]
Neratinib has recently been indicated by the US Food and Drug Administration (FDA)
for the treatment of early stage breast cancer after one year of trastuzumab-based
adjuvant therapy. [57] However, it was rejected by the European Medicines Agency, [58] as
results from a clinical trial showed it had a small effect in preventing recurrence but was
associated with an increase in gastrointestinal side effects, leading to dose reductions
and treatment discontinuation in many patients. [59]
Sapatinib is not currently indicated for treatment of HER2-positive breast cancer.
Despite phase I studies indicating that sapatinib was well tolerated, [60,61] phase II
studies failed to show an advantage of sapatinib in combination with paclitaxel compared
with paclitaxel alone in patients with gastric cancer. [62] This is despite preclinical data
showing good bioavailability and target inhibition. [36,63]
Recent guidance from NICE supports reassessment of hormone receptor and HER2
status after progression to guide further treatment options. [50] Prior to 2017, retesting
was not indicated after progression. Loss of HER2 amplification at the primary site
following neoadjuvant or chemotherapy has been shown to confer worse recurrence-free
survival compared with those patients who maintain HER2-positivity. [64,65] Studies
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Figure 1.3. Schematic representation of known resistance mechanisms to HER2-
targeted agents. (A) Epitope masking has been evidenced as a resistance mechanism
against trastuzumab and pertuzumab. This may be by upregulating molecules with large
extracellular domains or cleavage of the extracellular domain, resulting in p95 huamn epidermal
growth factor receptor 2 (HER2). (B) Mutations within the regions bound by drugs can result
in resistance and lack of inhibition. (C) Additionally, upregulation of other receptor tyrosine
kinases (RTKs) can bypass HER2 inhibition, resulting in the same downstream pathways being
activated.
have indicated that between 20–35% of patients with metastatic breast cancer have
discordance between primary and metastatic sites, [66–68] but the effect this may have on
survival times is not clear. [66,67]
1.4 Resistance mechanisms
Between 45–62% of patients present with de novo resistance to trastuzumab in the
neoadjuvant setting. [69,70] Of those that initially respond to HER2-targeted therapies,
up to 70% will develop acquired resistance to trastuzumab within two years of treatment
commencing. [71] Depending on the mechanism of resistance, it may be possible to treat
with other HER2-targeting therapies, such as lapatinib. [72] However, some patients with
trastuzumab resistance are also lapatinib resistant. [73]
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1.4.1 Epitope masking and lineage changes
Up to 50% of HER2-positive breast cancers have been shown to express the truncated
form of HER2, p95. [74,75] High expression of this form of HER2 is an independent
predictor of reduced disease-free survival (DFS), compared with patients with high
expression of the full-length form of HER2. [74]
This isoform results from the cleavage of the extracellular domain of HER2. As a result
of this, therapies targeting the extracellular domain (fig 1.3 A) are no longer able to
bind to HER2. [74,75] Despite lacking the extracellular domain, p95 HER2 can dimerise
with other HER family members and is constitutively active. [76] However, p95 HER2 has
been shown to be sensitive to lapatinib, which targets the intracellular tyrosine kinase
domain. [74,76]
Other mechanisms of epitope masking include the expression of proteins with large
extracellular domains, such as mucin 4 (MUC4) or cluster of differentiation 44 (CD44).
MUC4 is a large, O-glycosylated membrane-associated glycoprotein. In the JIMT-1
cell line, derived from a patient with HER2-positive, hormone receptor-negative breast
cancer which was resistant to trastuzumab, [77] expression of MUC4 was associated with
a reduction in the ability of trastuzumab to bind to HER2. Additionally, knockdown of
MUC4 restored sensitivity to trastuzumab. [73]
JIMT-1 cells also have increased expression of CD44, a transmembrane receptor for
hyaluron. When bound to CD44, hyaluron results in activation of RAS and PI3K
pathways, [78] and decreases the binding capacity of trastuzumab for HER2 by blocking
its epitope. [79]
CD44 is associated with increased stemness and a mesenchymal phenotype, which
in turn is associated with increased expression of matrix metalloproteinases (MMPs).
Expression of matrix metalloproteinases (MMPs) has been shown to result in cleavage
of full-length HER2, giving rise to p95 HER2. [80] Moreover, expression of MMPs can
initiate epithelial-to-mesenchymal transition (EMT). [81]
EMT is associated with increased invasion, metastasis and resistance to apoptosis. [82]
In response to extracellular signals, EMT-related transcription factors, SLUG, SNAIL,
11
TWIST, zinc finger E-box binding homeobox 1 and 2 (ZEB1 and 2) orchestrate a switch
to a mesenchymal phenotype. [83]
Although the canonical role of EMT is invasion and metastasis, several studies have
shown that switching from an epithelial to a mesenchymal phenotype is associated with
resistance to chemotherapy and targeted therapies. [84–91] Data from our own lab have
linked EMT to loss of HER2 in a mouse model of HER2-positive breast cancer, [84]
whilst Liu et al. [80] linked EMT to increased MMPs and cleavage of full-length HER2,
as previously mentioned.
To overcome epitope masking of the extracellular domain, the small molecule tyrosine
kinase inhibitors can be used, as cells remain sensitive to them. [74,76] However, JIMT-1
cells are resistant to both trastuzumab and lapatinib, which is likely due to their increased
expression of CD44 leading to a mesenchymal phenotype. ZEB1 has been implicated
in maintaining EMT and hence resistance to targeted therapies; [85,89] inhibiting ZEB1
in vitro and in vivo leads to cells being resensitised to targeted therapies. [85,89] Due to
the range of mechanisms of resistance present in JIMT-1 cells, it is unclear if CD44
expression or EMT drives the resistance to lapatinib.
Some therapies targeting EMT have shown promising results in clinical trials. A novel
liposomal miR-34a mimic, MRX34, has been shown to target 30 oncogenes across many
pathways, including SNAIL-induced EMT and Notch signalling. [92] In a phase I study in
advanced solid tumours, MRX34 showed good tolerability, although only 15% of patients
had partial response or stable disease, [93] which is likely due to patients’ EMT status
not being assessed prior to therapy commencing.
Additionally, in EGFR overexpressing non-small cell lung cancer (NSCLC), resistance to
targeted therapies erlotinib and gefitinib is often associated with EMT and driven by
AXL. By inhibiting AXL, cells were resensitised to tyrosine kinase inhibitors and partial
reversal of EMT was seen. [94,95] Clinical trials investigating several AXL inhibitors
are currently ongoing. [96] However, EMT is a process that has inherent plasticity, [82]
thus targeting EMT through one pathway may result in EMT maintenance through an
unrelated signalling pathway.
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1.4.2 Mutations in HER2
Several mutations have been identified in HER2 which result in it no longer being
responsive to targeted therapies (fig 1.3 B). Most mutations affecting HER2 are point
mutations, but insertion and deletion mutations have been identified in the extracellular
domain (exon 16) and around the transmembrane domain (exon 20) (fig 1.4). These
mutations can be broadly classified by the domain affected.
Fewer mutations affect the extracellular region of HER2, although two activating
mutations have been identified in the second domain which is involved in receptor
dimerisation. [97] D227G/H/V/Y (D227X) and S310F/Y (S310X) have been found
in bladder and breast cancer, amongst others. [98,99] Both have been associated with
resistance to lapatinib, but D227X does not induce resistance on its own. Rather, when
combined with S310X it has been shown to enhance activation of HER2. [98] Conversely,
S310X alone can induce resistance to lapatinib, neratinib and trastuzumab. [98,99]
Deletion of exon 16, named ∆16, results in the constitutive activation of HER2. This
mutation is found to be expressed in up to 39% of patients tumours. [100] Despite
promoting the formation of disulfide bonds and stabilising HER2 dimerisation, ∆16 does
not prevent trastuzumab binding; in fact, patients with this mutation are more likely to
respond to treatment and have decreased probability of tumour recurrence. [101]
Transmembrane domain mutations affecting HER2 have been found in NSCLC. These
mutations are primarily insertions and deletions within exon 20. The transmembrane
domain has been shown to promote receptor activation and autophosphorylation through
a conformational change. [102] However, mutations in this region have been shown to
remain sensitive to lapatinib, neratinib and trastuzumab. [103–106]
Of all HER2 mutations, 65% are in the catalytic tyrosine kinase domain. [107] Mutations
in this region are associated with increased kinase activity and constitutive activation of
HER2. As a result, these mutations are frequently associated with resistance to HER2-
targeted therapies. However, some mutations are still sensitive to dual inhibition with
trastuzumab and neratinib. [108] If mutations render HER2 resistant to targeted therapies,
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Figure 1.4. Mutations identified within ERBB2. Schematic representation of ERBB2, the
gene encoding human epidermal growth factor receptor 2. Mutations identified from patient
tumours and in vitro studies are included. LR: Receptor L domain; CR: Cysteine-rich region;
TM: transmembrane; TK: tyrosine kinase; ins/del: insertion/deletion.
targeting downstream effectors or using non-targeted chemotherapy and radiotherapy
may be used to treat patients. [108]
1.4.3 Downstream pathway mutations
Mutations in the PI3K and ERK pathways have consistently been shown to predict
poor response to targeted therapies and worse PFS and OS. [22,109–113] Mutations in
all of these pathways are able to overcome resistance to HER2-targeted therapies
(fig 1.5). [109–111,113–115]
1.4.3.1 PI3K pathway
The most common mutation in HER2-positive breast cancer is PIK3CA. This gene
encodes the p110α catalytic subunit of PI3K. [114] In patient samples, 22% have mutations
within PIK3CA. [107] These mutations are found within exons 9 and 20; mutations in
exon 9 alter the ability of p85 to bind and inhibit the action of p110α, whereas those
in exon 20 alter the kinase domain, leading to constitutive activation and downstream
signalling. [114] Additionally, amplification of PIK3CA has been found in 8.78% of breast
cancers. [107]
Although mutations in the genes encoding AKT1-3 are rare, they are amplified in
6-8% of breast cancers, with amplification of AKT3 the most common. [107,116] Increased
expression of AKT is associated with worse survival outcomes in breast cancer, but the
mechanism for this without other pathway abberations is unclear. [110,116]
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Figure 1.5. Schematic representation of mutations downstream of HER2 found in breast
cancer. Proteins involved in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)
and mitogen-activated protein kinase (MAPK) pathways are commonly mutated in in cancers.
Activating mutations in PI3K, AKT, RAS and RAF result in downstream activation despite inhibition
of HER2. Mutations in phosphatase and tensin homolog (PTEN) stop the dephosphorylation of
phosphatidylinositol 3,4,5-triphosphate (PIP3) to phosphatidylinositol 4,5-biphosphate (PIP2).
Common mutations depicted with red asterisk.
PTEN mutations have been reported in up to 55% of patients. The majority of these
are monoallelic (40–50%), whereas 5% are biallelic. [117] An additional 5% of patients
present with complete loss of PTEN at diagnosis, [109,115] which has been shown to
independently predict survival outcomes and response to trastuzumab in HER2-positive
breast cancers. [109,111,115] A reduction or loss of PTEN results in increased activation of
the PI3K/AKT pathway through a lack of inhibition. [19,115]
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1.4.3.2 MAPK pathway
Mutations in the ERK pathway are less common in breast cancers than those in the
PI3K pathway. However, the three RAS isoforms (NRAS, KRAS, HRAS ) are found
mutated in 6% and amplified in 17.67% of breast cancers. [107] All identified mutations
within the RAS isoforms alter the GTPase-activating-protein-stimulated GTP hydrolysis
activity, resulting in constitutive activation and downstream signalling. [112]
While ARAF and BRAF are found amplified in 5.89% and 6.79% of breast cancers
respectively, only BRAF is found mutated in 2.5% of breast cancers. [107] Most BRAF
mutations result in the inactive confirmation of the protein being destabilised. This
results in the protein being in its active formation and further activation downstream of
RAF. [113]
1.4.3.3 Downstream pathway inhibition
Inhibitors targeting components of PI3K/AKT or MAPK pathways result in increased
activation of the untargeted pathway, for example when co-treated with EGFR inhibitor
gefitinib and a MEK inhibitor, breast cancer cells became more reliant on AKT activation
for survival. [118] This finding translates to treatment of HER2-overexpressing lines:
inhibition of PI3K in HER2-overexpressing breast cancer cells resulted in increased
activation of MAPK signalling. [119] However, in some cases combining targeted therapies
with MAPK inhibition can overcome resistance mechanisms. [120]
Vemurafenib, a tyrosine kinase inhibitor specifically targeting the BRAFV 600E mutation,
shows good efficacy initially. [121] However, within 12 months of treatment initiation,
MAPK pathway inhibition is relieved by new activating mutations or expression of
receptor tyrosine kinases (RTKs) to increase signalling via MAPK or PI3K/AKT
pathways. [121] Thus, although downstream inhibition initially results in good responses,
over time resistance to these new inhibitors can develop.
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1.4.4 Bypass of HER2 inhibition
Upon inhibition of HER2, activation of downstream signalling pathways is halted. This
results in a lack of proliferation, protein synthesis and decreased survival. [22] To overcome
this, cells upregulate unrelated RTKs to maintain signalling through the PI3K/AKT
and MAPK pathways (fig 1.3 C). [122–124]
In vitro studies utilising trastuzumab have shown increased expression of insulin-
like growth factor 1 receptor (IGF1R), AXL and fibroblast growth factor receptor
(FGFR). [122,124] This subset of RTKs were capable of maintaining downstream pathway
activation, whereas other RTKs frequently implicated as bypass RTKs were unable to,
despite being able to signal through these pathways. [122–124] This indicates that the
ligands for these RTKs must be sufficiently available within the tumour microenvironment
(TME) to maintain signal transduction.
Despite many RTKs being implicated in bypass of HER2 inhibition, activation of
SRC has also been implicated in resistance. SRC is a non-receptor tyrosine kinase that
interacts with many signalling pathways, including the PI3K/AKT and MAPK pathways.
Activation of SRC has been shown to be a common node; downstream of several resistance
pathways in response to trastuzumab and other targeted therapies. [120,125] However,
targeting of SRC has proved ineffective, as resistance is quickly developed. [120,126,127]
Targeting RTKs that are overexpressed can be a valid treatment option in vitro. However,
identifying overexpressed RTKs and their activation in patients is currently reliant on
clinical remission after administration of additional targeted therapies. It is important to
note that different patients may upregulate different RTKs, so a combination approach
targeting several RTKs may be beneficial, but comes with increased side effects through
the administration of several drugs. [22]
Cabozantinib, an RTK inhibitor, has been shown to be active against many RTKs
which have been implicated in resistance and tumour biology. Its targets include MET,
AXL, vascular endothelial growth factor receptor 2 (VEGFR2), RET, KIT and fms-like
tyrosine kinase 3 (FLT3). [128] Carbozanitib has been approved for use in renal cell
carcinoma and medullary thyroid cancer, with clinical trials showing improvements in
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OS, PFS and ORR. [129,130] Treatment with cabozantinib has not been investigated in
treatment-resistant HER2 breast cancer to date.
HSP90 inhibitors have shown great promise in vitro and in clinical trials. [131] As they
are involved in the folding and stabilising of many tyrosine kinases, inhibition can result
in the increased degradation of a range of pathways and RTKs that cells are reliant on
for continued proliferation and survival. [14] In patients with progressive HER2-positive
breast cancer treated with trastuzumab, HSP90 inhibitor 17-AAG resulted in a 24%
ORR, with 57% of patients deriving clinical benefit, including disease stabilisation. [132]
Despite showing promising results, further development was halted. To date, no HSP90
inhibitors have been approved by the FDA.
1.4.5 Altered iron homeostasis
Iron is involved in many biochemical pathways related to DNA synthesis and mitochondrial
function. [133] An overview of the key proteins and pathways involved in cellular iron
homeostasis can be seen in figure 1.6. Alterations in iron homeostasis have previously
been linked to resistance to radiotherapy and chemotherapy in many cancer types and
has been shown to have differing effects in treatment-resistant cancer models. The
key signalling axis in iron homeostasis is the hepcidin-ferroportin axis, responsible for
transporting ferric iron out of the cell. [134,135]
Several groups have reported that treatment with iron chelation regimens reversed
resistance to targeted therapies and chemotherapy. [136–138] Furthermore, disruption
of ferritin expression reversed resistance to radiotherapy and chemotherapy. [139,140]
Conversely, many groups have reported increased iron storage, ferritin expression and
reduced labile iron pools (LIPs) associated with resistance. [139,140,199] From the literature,
it is evident that iron plays a varied role in the development of resistance to many
therapies and may be cancer and model specific.
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Figure 1.6. Cellular iron homeostasis pathways. Free ferric iron is reduced to ferrous iron
by ferrireductases six transmembrane epithelial antigen of prostate (STEAP), cytochrome b
reductase 1 (DYCTB) and ferric chelate reductase 1. Free ferrous iron can be transported
into the cell by divalent metal-ion transporter 1 (DMT1), Zrt- and Irt-like protein 14 and 8
(ZIP14 and ZIP8). Transferrin-bound iron can only be taken up by transferrin receptor 1 (TFR1)
endocytosis. Transferrin-bound iron is then released and reduced to ferric iron by DMT1.
CD163 is a scavenger receptor which endocytoses haptoglobin-bound haemoglobin. After
this, haemoglobin is degraded and haem transported into the cytoplasm. Pro-low-density
lipoprotein receptor-related protein 1 (LRP1) can transport systemic haem complexed with
haemopexin into the cytoplasm. Haem-responsive gene 1 protein homologue (HRG1) and
feline leukaemia virus subgroup C receptor-related protein 2 (FLVCR2) can transport haem
directly to be processed by heme oxygenase-1 (HO-1) to be released as ferrous iron. Ferritin,
consisting of heavy and light chains, is broken down by scavenger receptor class A member 5
(SCARA5) which releases the ferric iron into the cytoplasm. The labile iron pool (LIP) consists
of cytoplasmic ferrous iron which can be stored in ferritin or used in biochemical processes and
enzymes. Expression of TFR1, DMT1, ferritin and ferroportin (FPN) is controlled by the LIP, via
the post-transcriptional iron regulatory protein–iron-responsive element (IRP–IRE) regulatory
system. The transcription of TFR1 and DMT1 can also be controlled by the hypoxia-inducible
factor-hypoxia response element (HIF-HRE) regulatory system. In turn, prolyl-4-hydroxylase
(PHD) regulates HIF expression and degradation under high oxygen conditions. Mitoferrin
transfers iron to the mitochondria, where many of these processes take place. Mitochondrially
produced haem is exported from mitochondria by FLVCR1B. Ferrous iron can be exported by
ferroportin, then oxidised to ferric iron by ceruloplasmin or hephaestin. Intracellular haem can
be exported directly by FLVCR1A. Reprinted by permission from RightsLink: Nature publishing
group, Nature Reviews Drug Discovery, Crielaard et al. 134 , 2017.
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1.5 Mouse models of HER2-positive breast cancer
Mouse models are commonly used in preclinical drug development to provide information
on the pharmacokinetics and pharmacodynamics of drugs in vivo. Use of mouse models
also allows validation that drugs are able to hit the correct target, monitor potential
side effects that may occur in humans, and assess appropriate concentrations relevant to
disease treatment. The most commonly used mouse models of breast cancer are cell- or
patient-derived xenografts, syngeneic mouse models and conventional, or conditional,
genetically engineered mouse models (GEMMs).
1.5.1 Transplantation models
Ectopic cell-derived xenografts use cell lines implanted subcutaneously. Although this is a
fast method which is not technically difficult, [141] the host must be immunocompromised
and will only model advanced disease. [142]
Orthotopic cell-derived xenografts are more technically difficult, as cells must be injected
into the mammary gland or fat pad. However, they offer benefits over ectopic xenografts
as the cells are surrounded by the appropriate microenvironment. [143] Despite this, they
only model advanced disease, as such, early events in tumourigenesis or the development
of resistant phenotypes may not be studied as easily as in other models. [142]
Patient-derived xenografts are preferable over cell-derived xenografts, as the histological
features and genetic profile of the original patient tumour can be maintained. [144]
This model does have several disadvantages — it favours aggressive subtypes of breast
cancer, has high costs associated with maintenance and requires access to fresh patient
material. [142]
Allografts taken from a strain-matched host have advantages over xenografts, as both
the tumour and microenvironment are derived from the same species, allowing the use of
immunocompetent mice. [145] Using allografts requires advanced tumours for transplant,
which is unsuitable for studing early events in tumourigenesis. [142] However, allografts
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have been shown to recapitulate the histological features of human cancer more faithfully
than cell-derived xenografts. [145,146]
1.5.2 Genetically engineered mouse models
Conventional GEMMs allow study of both early and late tumour progression, with a
natural tumour microenvironment and immunocompetent mice. Expression of genes of
interest under the control of mouse mammary tumour virus (MMTV) allows expression
of transgenes to be confined to mammary tissues. [147] However, the genetics of these
tumours are not truly representative of human disease states, with transgenes being
expressed at higher levels than would be seen in patient tumours.
Conditional GEMMs share many advantages with conventional GEMMs, but are better
able to represent genetic heterogeneity within tumours. Additionally, tumour initiation
can be controlled, giving better spatial and temporal activation of oncogenes. [142,147,148]
1.5.3 MMTV-NIC mice
The MMTV-Neu model was first derived by Muller et al. [147], placing the activated
rat Neu gene, encoding HER2 with a 16 amino acid in-frame deletion adjacent to
the transmembrane domain, under the control of MMTV to ensure expression in the
mammary tissues only. [147] These mice develop rapidly growing, invasive mammary
tumours with a mean latency of 197 days. [147] To allow expression of two transgenes
from the same bicistronic transcript, this model was altered to include an internal
ribosome entry site (IRES) between Neu and a Cre recombinase under the expression of
MMTV. [148] This gave rise to the MMTV-Neu-IRES-Cre (MMTV-NIC) model.
Disruption of Pten by flanking with loxP recombination sites (flox), ensuring expression
of HER2 and PTEN deletion occurred simultaneously, accelerated tumour onset, from
197 days in MMTV-Neu mice to 43 days in MMTV-NIC-PTENflox/flox mice. [149]
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In Creedon et al. [84], MMTV-NIC-PTEN+/- mice were used, which have deletion of one
Pten allele, giving rise to loss of heterozygosity to replicate human disease. [149] These
mice develop tumours with a mean latency of 81 days. [84]
1.5.4 MMTV-NIC-PTEN+/- mice
Two derivatives of the MMTV-NIC-PTEN+/- model were used as part of this thesis.
The MMTV-NIC-PTEN+/- model spontaneously develops up to 10 mammary tumours
simultaneously and tumour growth has been characterised in Creedon et al. [150] Once
tumours reached 0.1 cm3, treatment with vehicle or sapatinib began. Treatment was
continuous and mice sacrificed once any tumour reached 15 mm in any dimension. More
in-depth analysis of resistance mechanisms within this model has not been investigated
yet, but will be as part of this thesis.
To allow the development of acquired resistance to be studied in more detail, untreated
tumours from MMTV-NIC-PTEN+/- mice were fragmented and implanted into the
fourth mammary fat pad of FVB/N mice. Once tumours reached 0.1 cm3, treatment with
vehicle or sapatinib began. If tumours regressed below this, treatment was halted until
tumours had reached 0.1 cm3 again. This cyclical treatment continued until tumours no
longer responded to treatment. Mice were sacrificed once the tumour reached 15 mm in
any dimension. Initial characterisation of the tumours developed in this model has been
previously described, [84,150] and will be followed up in this thesis.
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1.6 Aims
Resistance to targeted therapies is a problem which occurs in all cancers. Despite
advances in targeted and combination therapies, patients still develop resistance and
their disease ultimately progresses. Targeting the resistance mechanisms currently
identified has not resulted in many, if any, viable alternatives to prevent resistance
developing in these patients. This thesis has focused on identifying novel mechanisms
of resistance to HER2-targeted therapies and investigating how the development of
resistance could be manipulated to prevent its occurrence.
The aims of this study were to:
• Understand the link between EMT and resistance to HER2-targeted therapy
previously identified in the Brunton lab. [84]
• Use a mouse model of HER2-driven mammary cancer to identify novel mechanisms







The composition of all buffers and solutions used are listed below. Where water is used
as a solvent, this was distilled. All chemicals were obtained from Sigma Aldrich (MO,
USA), unless otherwise stated.
Table 2.1. List of buffers used
Buffer Composition
0.1 M citric acid 10.5 g C6H8O7.H2O, 500 ml water
0.1 M sodium citrate 14.7 g C6H5Na3O7.2H2O, 500 ml water
10 mM sodium citrate,
pH 6
11.5 ml 0.1 M citric acid, 88.5 ml 0.1 M sodium citrate
1 M NaCl 29.22 g NaCl, 500 ml water
1 M Tris HCl pH 8 60.57 g TRIS, 500 ml water and pH to 8 using 1 M HCl
6X Laemmli sample
buffer
416 mM SDS, 47% (v/v) glycerol, 6 mM Tris (pH 6.8),




1.1% (w/v) bovine serum albumin (BSA), 0.2% (v/v)
Triton X-100 in PBS
Blocking buffer -
Western blotting











1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast
extract, 171 mM NaCl in water
Lysis buffer 1.25 µM PMSF, 0.5 M NaF, 0.1 M Na3VO4, 0.1% (v/v)
aprotinin in RIPA
Lysis buffer - Reverse
Phase Protein Array
(RPPA)
1% (v/v) Triton X-100, 50 mM HEPES (pH 7.4) 150
mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF,
10 mM Na4P2O7, 1 mM Na3VO4, 10% (v/v) glycerol,
cOmpleteTM, EDTA-free Protease Inhibitor Cocktail and
PhosSTOPTM (Roche).
Continued on the next page
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Continued from previous page
Buffer Composition
PEM Buffer 0.1 M PIPES, 50 mM EGTA, 1 mM MgCl2, 0.2% (v/v)
Triton-X 100, 4% (v/v) paraformaldehyde in water
Phosphate buffered
saline (PBS)
136 mM NaCl, 2.6 mM KCl, 12 mM Na2HPO4, 1.76 mM
KH2PO4 (pH 7.4) in water
RIPA 50 mM Tris HCl (pH 8), 150 mM NaCl, 1% NP40, 0.5%
C24H39NaO4, 0.1% SDS in water
Scott’s tap water 41 mM NaHCO3, 210 mM MgSO4 in water
Tris buffered saline
(TBS)
50 mM Tris, 150 mM NaCl, 2 mM DTT in water
Tris Glycine SDS
(TGS) buffer
25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3
in water
Trypsin 1 mM EDTA, 0.25% (v/v) trypsin (Gibco, Thermo Fisher
Scientific, MA, USA) in PBS
Urea Lysis Buffer 50 mM NH4HCO3, pH 7.4, 8 M urea, 100 mM NaF,
10 mM Na4P2O7, 1 mM Na3VO4 in mass spectrometry
grade water
2.1.2 Antibodies
The antibodies used are listed in the table below, with typical dilutions for western
blotting (WB), immunohistochemistry (IHC). All antibodies were diluted in the appropriate
buffer for the purpose, i.e, for western blots, antibodies were diluted in western blotting
blocking buffer. For immunofluorescence, all antibodies were used at 1/200 dilution.
Primary Antibodies
Table 2.2. List of primary antibodies used
Antibody Host Catalog No Company WB IHC
β-actin Rabbit 8457 CST 1/1000 -
β-catenin Mouse 610154 BD
Biosciences
- 1/800
CD31 Rabbit ab28364 Abcam - 1/400
Ceruloplasmin Rabbit ab48614 Abcam - 1/50
Cleaved caspase-3 Rabbit 9664 CST - 1/200
Continued on the next page
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Antibody Host Catalog No Company WB IHC
COX2 Rabbit 12282 CST - 1/600
DMT-1 Mouse ab55735 Abcam - 1/100
E-Cadherin Mouse M3612 Dako - 1/50
EGFR Rabbit 4405 CST 1/1000 -
Ferritin Heavy
Chain
Rabbit ab183781 Abcam 1/1000 1/400
Ferritin Light
Chain
Rabbit ab69090 Abcam 1/1000 1/400
Ferroportin Rabbit ab78066 Abcam - 1/50
Heme oxygenase-
1
Mouse ab13248 Abcam 1/1000 1/250
GPX4 Rabbit ab125066 Abcam - 1/100
HER2 Rabbit 2165 CST 1/1000 1/400











NRF2 Rabbit ab31163 Abcam - 1/100






Rabbit 4060 CST - 1/50
Phospho EGFR
(Tyr1068)
Rabbit 3777 CST 1/1000 -
Phospho HER2
(Tyr1221/1222)
Rabbit 2243 CST 1/1000 -
Phospho HER3
(Tyr1289)




Rabbit 4370 CST - 1/250
Continued on the next page
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Antibody Host Catalog No Company WB IHC
Phospho
SMAD1/5






PTEN Rabbit 9188 CST - 1/200
SLUG Rabbit ab27568 Abcam - 1/500
SMAD1 Rabbit 6944 CST 1/1000 -
SMAD5 Rabbit 12534 CST 1/1000 -
SNAIL Rabbit ab180714 Abcam - 1/5000
Transferrin
receptor




ZEB1 Mouse ab180905 Abcam - 1/150
ZEB2 Rabbit HPA003456 Atlas - 1/250
CST: Cell Signaling Technologies; SCB: Santa Cruz Biotechnologies; MP: Molecular Probes
Table 2.3. List of primary antibodies used for fluorescence
Antibody Host Catalog No Company FACS IF
HER2-APC Mouse 324407 BioLegend 1/200 -
Vimentin Rabbit 5741 CST - 1/200
Secondary Antibodies
Table 2.4. List of secondary antibodies used
Antibody Host Catalog No Company WB IF
Anti-Mouse Horse 7076 CST 1/5000 -
Anti-Rabbit Goat 7074 CST 1/5000 -
Anti-Mouse 546 Goat A-11003 MP - 1/400
Anti-Rabbit 488 Chicken A-21441 MP - 1/400
Phalloidin 594 - A12381 Invitrogen - 1/250
CST: Cell Signaling Technologies; MP: Molecular Probes
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2.1.3 Primers
Primers were designed using NCBI Primer Blast, [151] and made by Integrated DNA
Technologies (IA, USA).
Table 2.5. List of primers used












































Short hairpin RNA (shRNA) and overexpression plasmids were obtained from S. Brabletz
(University of Erlangen-Nuernberg, Germany), or purchased commercially.
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Table 2.6. List of plasmids used
Insert Backbone Reporter Source
Empty Vector pCI-Neo None -
Empty Vector pCMV6 GFP -
Empty Vector SMARTvector TurboGFP Dharmacon
HO-1 pCMV6 GFP Origene
shERBB2 SMARTvector TurboGFP Dharmacon
ZEB1 pCI-Neo None S. Brabletz
GFP: Green fluorescent protein
Releasing Open Reading Frame
To obtain empty vectors, plasmids containing open reading frames were digested in the conditions
listed in table 2.7.
Table 2.7. Conditions for plasmid digestion
Plasmid Restriction Enzyme Temperature Time
HO-1 Acc65I/BsiWI 37°C/ 55°C 60 mins/ 60 mins
ZEB1 XbaI 37°C 60 mins
Digested plasmids were then ligated with T4 DNA ligase (New England Biolabs, MA, USA) for
2 hours at room temperature (RT). Following ligation, OneShot TOP10 chemically competent
E. coli were transformed and plasmids purified as stated in section 2.2.5.
2.2 Methods
2.2.1 Animal Models & Analysis
Animal husbandry and breeding were carried out by the staff of the Institute of Genetics and
Molecular Medicine, University of Edinburgh. Genotyping was performed by Transnetyx (TN,
USA) with the use of ear notch tissue from at least 14-day old mice. All animal experiments
were carried out in compliance with UK Home Office guidelines by Morwenna Muir unless
otherwise indicated.
Mice were housed in conventional Techniplast 1144 cages with shavings, Kleenex® tissues for
nest material, cardboard tubes and aspen chew sticks. The light cycle was 12 hours on, 12
hours off (7:00–19:00). Mice were given Rat and Mouse No. 1 Maintenance diet (159 ppm
Fe; Special Diet Services, Essex, UK), unless otherwise indicated. Mice were sacrificed using
cervical dislocation and tissues were collected. Tissue was fixed overnight in neutral-buffered
10% formaldehyde (Surgipath, Europe), for later histological analysis, or flash frozen in liquid
nitrogen and stored at -80°C until required.
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Figure 2.1. Diagram of animal experiments. (A) Tumours from MMTV-NIC-PTEN mice were
removed and fragmented, then inserted into the fourth mammary fat pad of FVB/N mice. These
mice were randomised to recieve vehicle or sapatinib and treated cyclically until tumours reached
≥15 mm in any direction. (B) MMTV-NIC-PTEN mice were allowed to develop tumours, with
vehicle or sapatinib treatment beginning once tumours reached 0.1 cm3 for spontaneous tumour
experiments, or 0.33 for three day treatment experiments. For spontaneous tumour experiments,
mice were sacrificed once tumours reached ≥15 mm in any direction. For three day treatment
experiments, mice were sacrificed two hours after the third dose. (C) MMTV-NIC-PTEN mice
were allowed to develop tumours. Once a tumour was palpable, mice were randomised to
receive a control, iron-low diet or an iron-deficient diet. After four days on diet, mice were
randomised to receive vehicle or sapatinib treatment. Mice were sacrificed once any tumour
reached ≥15 mm in any direction.
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Fragment-Derived Tumour Experiment
This experiment was carried out by Dr Helen Creedon. Tumours were collected from MMTV-
NIC-PTEN+/- mice, washed in ice-cold PBS and cut into 1 mm3 sections. These were centrifuged
at 450 g and the supernatant removed prior to storage at -80°C. Fragments were defrosted at
RT and inserted into the fourth mammary fat pad of FVB/N mice. Mice were dosed weekly
with vehicle (1% Tween 80 in PBS) or sapatinib (100 mg/kg with 1% Tween 80 in PBS) by oral
gavage. To generate resistant tumours, an intermittent drug schedule was performed. Tumours
were allowed to grow to ≥0.1 cm3 before starting treatment. Once tumours had regressed to
≤0.1 cm3, treatment was stopped. Mice were sacrificed when tumours reached ≥15 mm in any
direction. Summarised in fig 2.1 A.
Spontaneous Tumour Experiment
Tumour measurements were carried out by Dr Helen Creedon. MMTV-NIC-PTEN+/- mice on
an FVB/N background [148] were randomised to receive treatment with vehicle (1% Tween 80 in
PBS) or sapatinib (100 mg/kg with 1% Tween 80 in PBS) by oral gavage. Mice were monitored
twice weekly for palpable tumour development. Once tumours were ≥0.1 cm3, treatment
commenced. When tumours were ≥15 mm in any direction, mice were sacrificed. Summarised
in fig 2.1 B.
3 Day Spontaneous Tumour Treatments
This experiment was carried out by Dr Helen Creedon. MMTV-NIC-PTEN+/- mice were
randomised to receive treatment with vehicle (1% Tween 80 in PBS) or sapatinib (100 mg/kg
with 1% Tween 80 in PBS) by oral gavage. Mice were monitored twice weekly for palpable
tumour development. Once tumours were ≥0.3 cm3, treatment commenced. Mice were sacrificed
two hours after the third dose. Summarised in fig 2.1 B.
Iron-Deficient Diet Spontaneous Tumour Experiment
MMTV-NIC-PTEN+/- mice were monitored twice weekly for palpable tumour development.
Once a palpable tumour was detected, mice were randomised to receive a iron-low control diet
(TD.80394, 49 ppm Fe; Envigo, NJ, USA), or an iron deficient diet (TD.80396, 2 ppm Fe; Envigo,
NJ, USA). Four days after diet commenced, mice were randomised to receive vehicle (1% Tween
80 in PBS) or sapatinib (100 mg/kg with 1% Tween 80 in PBS) by oral gavage. When tumours
were ≥15 mm in any direction, mice were sacrificed. Summarised in fig 2.1 C.
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Immunohistochemistry
Sections of tumours were cut, 4 µm thick, using a microtome. These were placed on slides
and dried on a hot plate at 55°C. Paraffin was removed by immersing slides in xylene for 5
minutes, followed by decreasing ethanol washes (100%, 100%, 80% and 50%) for 5 minutes
each. Slides were rinsed in water, then heat-mediated antigen retrieval was performed in pH 6
citrate buffer. Following this, slides were left to cool, rinsed with water and washed in TBST
(0.0025%) for 5 minutes. Slides were stained using Dako Envision DAB+ kit (Dako, Denmark)
and counterstained with haemotoxylin for 2 minutes. Slides were dehydrated in increasing
alcohol washes (50%, 80%, 100%, 100%) and cleared with xylene.
Immunohistochemical Analysis
Slides were imaged using a Nanozoomer (Hamamatsu, Japan). Once images were obtained,
Definiens Architect Tissue Studio software (Definiens, Germany) was used to score the antibody
staining. Analysis parameters were altered for each antibody depending on the intensity of
staining. Region of interest (ROI) detection was performed to exclude non-tumour tissue and
areas of necrosis from the analysis. Statistical analysis was performed on the scoring as described
below (section 2.2.8).
Perls’ Prussian Blue
Sections were prepared and rehydrated as described above (section 2.2.1). Slides were rinsed in
water, then placed in 1% (w/v) potassium ferrocyanide (Perls’ Prussian Blue) and incubated for
3 minutes at RT. Slides were rinsed in distilled water and then stained for 5 minutes in nuclear




Total iron, Fe2+ and Fe3+ concentration was determined using an Iron Assay Kit (Abcam,
Cambridge, UK). Samples were measured in duplicate and normalised to protein concentration,
determined as stated in section 2.2.6.
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Glucose 6 Phosphase Dehydrogenase Assay
Glucose 6 Phosphate Dehydrogenase activity was determined using a G6PD activity assay kit
(Abcam, Cambridge, UK). Samples were measured in duplicate.
Glutathione Assay
Reduced and oxidised glutathione concentration was determined using a GSH/GSSG ratio
detection assay kit (Abcam, Cambridge, UK). Samples were measured in duplicate.
Active caspase 3/7 Assay
Levels of active caspase 3 and 7 were determined using a Caspase-Glo 3/7 Assay (Promega, WI,
USA). Samples were normalised to DMSO control.
2.2.3 Cell Culture Methods
Cell Culture
Human breast cancer cell line SKBR3 (American Type Culture Collection, VA, USA) was grown
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM L-glutamine and
10% foetal bovine serum (FBS; all Thermo Fisher Scientific, MA, USA). Cells were maintained at
37°C in a humidified atmosphere containing 5% CO2. Sapatinib was obtained from AstraZeneca
(Cambridge, UK), lapatinib from GlaxoSmithKline (Brentford, UK).
Generation of Resistant Lines
SKBR3 cells were exposed to increasing concentrations of sapatinib or lapatinib. The concentration
was increased after two passages. Cells were classed as resistant when they grew in the highest
concentration of drug used. Sapatinib resistant cells were maintained in 0.67 µM sapatinib.
Lapatinib resistant cells were maintained in 5 µM lapatinib.
Generation of shRNA cell lines
HEK293T cells were seeded in a 6 well plate at a density of 2.5x105. The following day, cells
were transfected with 1 µg construct, 0.2 µg psPAX2 and 0.3 µg pMD2.G using lipofectamine
2000 (Thermo Fisher Scientific, MA, USA) to produce virus. From this point, cells were handled
in Category 2 confinement.
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Table 2.8. Drug concentrations used over 48 hour period to determine cell death.
Drug Concentration Supplier
3-Methyladenine 5 mM Sigma Aldrich
Bafilomycin A1 5 nM Sigma Aldrich
Deferoxamine 100 µM Sigma Aldrich
Erastin 10 µM Sigma Aldrich
Ferrostatin 5 µM Sigma Aldrich
Lapatinib 5 µM GlaxoSmithKline
Sapatinib 0.67 µM AstraZeneca
Z-VAD-FMK 20 µM Abcam
Z-VAD-FMK: benzyloxycarbonyl-phenylalanyl-alanyl-fluoromethyl ketone
One day after transfection, HEK293T cells were washed and medium replaced. On day 2,
medium was collected from HEK293T cells, supplemented with an additional 10% FBS and
filtered then added to target cells. Target cells were kept in Category 2 for 2 passages, then




Cells were seeded on day -1. On day 0, one plate was taken as a day 0 measurement. A
1/10 concentration of Alamar Blue reagent (Invitrogen, CA, USA) was added to each well and
incubated at 37°C for 2 hours and the plate read at 590 nm. Drugs were added to the remaining
plates, which were incubated for 3 days to allow growth. After 3 days, Alamar Blue was added
to each well and plates incubated for 2 hours at 37°C prior to reading at 590 nm. Data were
normalised to DMSO controls.
Cell Death Assay
Cells were seeded on day -1. On day 0, drugs were added into each well. Cells were incubated
with drug (table 2.8) for 48 hours. After this time, cells were stained with 1 µg/ml propidium
iodide (PI) and cell death assessed using a Tali Image-Based Cytometer (Invitrogen, CA, USA).
Fluorescence Activated Cell Sorting (FACS)
Cells were washed with PBS and cell dissociation solution (Thermo Fisher Scientific, MA, USA)
added for 5 minutes at 37°C. Cells were filtered through a 70 µm cell strainer, centrifuged at 500
g for 5 minutes at 4°C, resuspended in PBS, transferred to a 96 well plate and centrifuged again.
Cells were resuspended in 1 µg/ml PI and incubated for 30 minutes at 4°C, then centrifuged
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again. Cells were resuspended in FC block (BD Biosciences, NJ, USA) in FACS buffer for 15
minutes minutes at RT. Target antibody was added, final concentration 1/400 in FACS buffer
and incubated for 30 minutes at RT. Cells were centrifuged and washed three times with FACS
buffer, then resuspended for analysis on the LSR Fortessa (BD Biosciences, NJ, USA).
For C11 BODIPY staining, cells were incubated with 2 µM C11 BODIPY for 30 minutes at
37°C, then washed twice and analysed on the LSR Fortessa (BD Biosciences, NJ, USA).
Immunofluorescence
Cells were cultured on sterile glass coverslips in 6 well plates. Cells were fixed in PEM buffer
containing 4% paraformaldehyde (PFA) for 15 minutes at RT, then washed thrice in PBS.
Blocking buffer was added for 1 hour at RT. After this, primary antibodies were added and
incubated overnight at 4°C. Cover slips were washed thrice with TBST (0.1%) and incubated
for 1 hour at RT with secondary antibodies and phalloidin. Cover slips were washed thrice in
TBST (0.1%) then mounted on glass slides using VectaShield with DAPI (Vector Laboratories,
CA, USA). Slides were then stored at -20°C until imaged.
2.2.4 Microscopy
Phase Contrast
Cells were imaged using a 10x objective on a Leica DMIL LED microscope (Leica, Germany)
attached to a Retiga EXi FAST1394 camera (Q Imaging, BC, Canada).
Proliferation & Wound Healing Assays
Cells were seeded in a 96 well plate (Greiner Bio-One, Austria) then imaged in the IncuCyte
ZOOM (Essen Bioscience, MI, USA) at 10x, every 3 hours. For wound healing assays, once cells
were seeded, they were returned to 37°C incubator overnight then a wound was created using
an IncuCyte WoundMaker (Essen Bioscience, MI, USA). After creation of a wound, cells were
imaged in the IncuCyte ZOOM for 96 hours.
Confocal Microscopy
Cells fixed on glass coverslips were imaged using a 63x HCX PL Apo 1.4 NA Iris oil immersion
objective on a Leica SP5 confocal microscope (Leica, Germany). Z stacks were taken for all
images. Images shown are maximum intensity projection compressed Z stacks.
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2.2.5 Nucleic Acid Methods
RNA Extraction
Cells
Cells were pelleted and lysed in Buffer RLT containing β-mercaptoethanol. The RNeasy Mini
Kit (Qiagen, Germany) was used according to the manufacturers instructions.
Tissue
Tissue was homogenised using a pestle and mortar, then Buffer RLT containing β-mercaptoethanol
was added. The RNeasy Mini Kit (Qiagen, Germany) was used according to the manufacturers
instructions.
cDNA Synthesis
For each cell line or tissue, 1 µg of RNA was used to generate complementary deoxyribonucleic
acid (cDNA). QuantiNova Reverse Transcription kit (Qiagen, Germany) was used, according to
the manufacturers instructions.
Real Time PCR
For each reaction, 5 ng of cDNA was added. Each reaction was performed in triplicate. SYBR
Select Master Mix (Applied Biosystems, CA, USA) was used according to the manufacturers
instructions. Each PCR reaction included a H2O control to check for primer specificity. Primers
were used at a final concentration of 200 nM. The following cycling conditions were used:
• Pre-incubation at 95°C/3 minutes
• 40 cycles of:
– 95°C 5 seconds
– 60°C 10 seconds
– 72°C 10 seconds
• One dissociation cycle:
– 95°C 15 seconds
– 60°C 60 seconds
– Increasing 0.3°C every 15 seconds, until 95°C is reached
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Cycle threshold (CT) was determined by StepOne Real-Time PCR System software (Applied
Biosystems, CA, USA).
Cloning
One Shot TOP10 Chemically Competent E. coli (Invitrogen, CA, USA) were used according
to the manufacturers instructions. Transformed colonies were selected on plates containing
appropriate antibiotic (Invitrogen, CA, USA). One colony from each plate was selected and
transferred into 2 ml of LB broth containing 100 µg/ml antibiotic. After 2 hours shaking at
37°C, cultures were transferred to 200 ml LB broth containing 100 µg/ml ampicillin and left
overnight at 37°C, while shaking.
Plasmid Purification
Cultures were centrifuged at 10000 g for 15 minutes at 4°C to obtain a pellet. Following this,




Cells were grown in 15 cm dishes until 70% confluence was reached. Dishes were transferred to
ice, medium removed and cells washed twice with ice cold PBS. Cells were lysed in lysis buffer
then incubated on ice for 20 minutes, with occasional agitation. Lysates were centrifuged at
210000 g for 15 minutes at 4°C and the supernatant transferred to a new microcentrifuge tube.
Lysates were stored at -20°C.
For RPPA, RPPA lysis buffer was used in place of lysis buffer and the remainder of the procedure
was the same.
For tumours, a fragment was cut from fresh frozen tumour and homogenised using the FastPrep-
24 homogeniser in pre-cooled Lysing matrix-D tubes (MP Biomedicals, CA, USA). RPPA lysis
buffer was added immediately after homogenisation and vials placed on ice for 30 minutes.




Protein concentration of lysates was determined using a bicinchoninic acid assay (BCA assay).
Micro BCA Protein Assay Kit (Thermo Fisher Scientific, MA, USA) was used according to
manual. Plates were read on a plate reader at 540 nm wavelength, each lysate was measured in
triplicate.
For use in the Iron Determination Assay, protein concentration of lysates was determined
using the Coomassie Plus Protein Assay (Thermo Fisher Scientific, MA, USA), according to
manufacturers instructions. Plates were read on a plate reader at 595 nm wavelength, samples
were measured in duplicate.
Western Blotting
After determination of protein concentration as described above (section 2.2.6), 20 µg of cell
lysate was added to 6X Laemmli buffer and denatured for 5 minutes at 95°C. Denatured proteins
were loaded into 4-15% Mini-PROTEAN TGX precast gels (BioRad, Germany) and ran in a
BioRad Mini-PROTEAN 3 gel chamber in TGS buffer at 180 V for 40 minutes.
Proteins were transferred to Trans-Blot Turbo Midi Nitrocellulose membranes (BioRad, Germany)
by semi-dry blotting, using a Trans-Blot Turbo Transfer System (BioRad, Germany) at 25 V,
2.5 A for 7 minutes. Membranes were blocked in blocking buffer for 1 hour at RT before addition
of primary antibody. Membranes were incubated with primary antibody overnight at 4°C before
being washed with TBST (0.1%). Secondary antibodies were incubated with the membrane for
1 hour at RT, before washing a minimum of three times in TBST (0.1%). Bound antibodies
were detected by chemiluminescence using Clarity ECL Substrate (BioRad, Germany) on the
BioRad Gel Doc XR+, or by near-infrared fluorescence on the LI-COR Odyssey Sa Infrared
Imaging System (LI-COR, NE, USA).
Reverse Phase Protein Array
Cell and tumour lysates were prepared as described above (section 2.2.6). Lysates were serially
diluted to produce a dilution series comprising four serial two-fold dilutions of each sample
and spotted onto nitrocellulose-coated slides (Grace Bio-Labs, OR, USA) in triplicate under
conditions of constant 70% humidity using the Aushon 2470 array platform (Aushon Biosystems,
MA, USA). Slides were hydrated in blocking buffer (Thermo Fisher Scientific, MA, USA) and
then incubated with validated primary antibodies (all 1/250). Bound antibodies were detected
by incubation with anti-rabbit DyLight 800-conjugated secondary antibody (New England
BioLabs, MA, USA).
An InnoScan 710-IR scanner (Innopsys, France) was used to read the slides and images
were acquired at the highest gain without saturation of the fluorescence signal. The relative
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fluorescence intensity (RFI) of each sample spot was quantified using Mapix software (Innopsys,
France). The linear fit of the dilution series of each sample was determined for each primary




A fragment was cut from fresh frozen tumour and homogenised in 300 µl of urea lysis buffer.
Lysates were then sonicated and clarified by centrifugation at 20000 g for 15 minutes at 4°C.
Supernatant was transferred into low-bind microcentrifuge tubes (Eppendorf, Germany). Protein
concentration determination was performed as above (section 2.2.6).
Samples were denatured with 8 mM dithiothreitol for 10 minutes at 50°C and alkylated with
16 mM iodoacetamide for 10 minutes at 37°C. Urea concentration was reduced to 2 M using
50 mM NH4HCO3 and samples digested with trypsin (1:200 enzyme:protein; Thermo Fisher
Scientific, MA, USA) at 37°C overnight. Samples were clarified by centrifugation at 2500 g for 5
minutes and acidified with 10% trifluoroacetic acid (TFA).
Stage tips [152] were prepared by inserting a plug of C18 material (Thermo Fisher Scientific, MA,
USA) into a Greiner BioOne 200 µl capacity pipette tip. Stage Tips were activated with 30 µl
MeOH and equilibrated with 50 µl 0.1% TFA. 10 µg of sample was added and incubated at RT
for 30 seconds, then aspirated and washed twice with 50 µl 0.1% TFA. Stage Tips were stored
at -20°C until analysis. Peptides were eluted with 80% acetonitrile, 0.1% TFA into a clean PCR
plate, then dried in a vacuum concentrator. After this, samples were made up to 15 µl and
analysis performed.
Analysis of samples was performed using a Q Exactive Plus instrument (Thermo Fisher Scientific,
MA, USA) controlled by Xcalibur (Thermo Fisher Scientific, MA, USA). Peak lists were
generated using MaxQuant. [153,154] MS data were searched against SwissProt, UniProt KB [155]
using MaxQuant. LFQ ratio and p values, generated using Wilcoxon-Mann-Whitney test, were
calculated by MaxQuant.
Lipidomics
A fragment was cut from fresh frozen tumour and homogenised using a Dounce homogeniser.
After this, 375 µl chloroform/methanol (1:2) solution was added and vortexed. Tubes were
agitated vigorously for 40 minutes at 4°C. Chloroform and water (125 µl) were added sequentially
and tubes vortexed after each addition. Tubes were centrifuged at 200 g for 5 minutes at RT
and the lower phase transferred into a flat-bottomed 2 ml glass vial (Sigma Aldrich, MO, USA)
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using a glass Pasteur pipette. This was dried under nitrogen and stored at 4°C. To prepare
samples for LC-MS/MS, lipidomic reconstitution buffer was used.
Once reconstituted, lipid extracts were separated on a Kinetex 1.7 u C18 100 Å column
(Phenomenex, CA, USA) using a Thermo Ultimate BioRS HPLC maintained at 45°C. Separated
lipids were eluted into a Q Exactive Plus instrument (Thermo Fisher Scientific, MA, USA) and
acquired in positive-ion mode. Lipid identification was carried out as in Wills et al. [156]
2.2.8 Statistical Analysis
Statistical analyses were performed using GraphPad Prism (GraphPad Software, CA, USA).
Data were assumed to have a non-normal distribution and tested accordingly. For statistical
analysis of IHC, the percentage of positively stained cells was taken and the appropriate analysis
performed on these data. For determination of growth inhibition 50% (GI50) values, data
obtained from alamar blue assays were log transformed, normalised to DMSO controls and a
curve fitted to the data points.
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Chapter 3
Resistance to sapatinib is
associated with a loss of HER2
and EMT in vivo
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Loss of HER2 after neoadjuvant or chemotherapy has consistently been shown to
correlate with a worse prognosis in patients with HER2-positive breast cancer. [64,65] In
vitro studies of resistance to HER2-targeted therapies show that loss of HER2 is the
result of cancer cells losing their reliance on HER2, instead becoming reliant on other
RTKs. [122–124] Understanding the mechanism behind loss of HER2 and reversing it could
enable tumours to become resensitised to HER2-targeted therapies.
Several studies have shown that loss of HER2 is associated with EMT in trastuzumab-
resistant models in vitro. [90,157] These groups, and others, have evidenced a link between
EMT and resistance to targeted therapies. [84,89–91,157–159] Furthermore, reversal of EMT
restored the epithelial phenotype and sensitivity to targeted therapies. [89,91,158]
Previous research by the Brunton lab [84] showed concurrent loss of HER2 and induction
of EMT as a result of the development of acquired resistance to sapatinib. Using
tumour fragments derived from MMTV-NIC-PTEN+/-, matched vehicle-treated and
sapatinib-resistant fragment-derived tumours were developed in FVB/N mice. Half
of the fragment-derived tumours made resistant to sapatinib displayed an epithelial
phenotype and were phenotypically indistinguishable from vehicle-treated tumours. The
remaining resistant fragment-derived tumours displayed a mesenchymal phenotype with
loss of HER2.
It is currently unknown if the primary mechanism of resistance was loss of HER2 or
EMT induction. Understanding of the mechanism of resistance would allow further
research into resensitising tumours and overcoming resistance. Initial comparison and
characterisation of sapatinib-resistant tumours can be seen in Creedon et al. [84]
This chapter will therefore explore the following aims:
• Identify the transcriptional regulation of EMT in sapatinib-resistant fragment-
derived tumours.
• Clarify if the HER2 loss seen is at the transcriptional or protein level.
• Establish whether HER2 levels are altered by increased EMT.
• Assess if loss of HER2 induces a program of EMT.
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3.1 Sapatinib-resistant fragment-derived tumours have
undergone EMT and lost HER2
Detailed results for this chapter can be found in tables A.1–A.4.
EMT has been demonstrated to confer primary resistance to targeted therapies in HER2-
positive breast cancer [158] and EGFR-positive NSCLC, [89] as well as chemoresistance in
pancreatic cancer. [160]
Fragment-derived tumours made resistant to sapatinib showed two distinct phenotypes.
Half of all sapatinib-resistant fragment-derived tumours had an epithelial morphology
also seen in vehicle-treated fragment-derived tumours (fig 3.1 A and B) and had no
expression of vimentin (fig 3.1 D and E; staining performed by Dr Helen Creedon),
E-cadherin (fig 3.1 G and H; staining performed by Dr Helen Creedon) and HER2
(fig 3.5 A and B; staining performed by Dr Helen Creedon) similar to vehicle-treated
fragment-derived tumours. The remaining tumours exhibited a spindle cell morphology
associated with a mesenchymal phenotype (fig 3.1 C), [82] gained expression of vimentin
(fig 3.1 F) and lost expression of E-cadherin (fig 3.1 I) and HER2 (fig 3.5 C).
3.1.1 EMT is maintained by ZEB1 and ZEB2 in vivo
To understand the mechanisms driving EMT at the transcriptional level, five EMT-
related transcription factors were assessed by IHC. SLUG, SNAIL, TWIST, ZEB1
and ZEB2 are all known to play different roles in the induction and maintenance of
EMT, with both distinct and overlapping functions. IHC analysis of these transcription
factors revealed significantly increased levels of ZEB1 and ZEB2 in sapatinib-resistant
EMT tumours, compared with vehicle-treated and sapatinib-resistant tumours with an
epithelial phenotype (fig 3.2 A–H). No difference can be seen in levels of SLUG, SNAIL
and TWIST, which were not broadly expressed in any of the tumours (fig 3.2 I–T).
As both ZEB1 and ZEB2 were upregulated in sapatinib-resistant fragment-derived
tumours, KM-plotter [161] was interrogated for patients with HER2-positive breast cancer
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Figure 3.1. Resistance to sapatinib is associated with epithelial-to-mesenchymal
transition (EMT) in fragment-derived tumours. (A–C) Representative haematoxylin and
eosin (H&E) staining of tumours performed on MMTV-NIC-PTEN+/- fragment-derived tumours
that had been inserted into the fourth mammary fat pad of FVB/N mice (vehicle: n=9; sapatinib:
n=3; sapatinib EMT: n=4). Representative immunohistochemical (IHC) staining of (D–F) vimentin
and (G–I) E-cadherin. Scale bar: 50 µm. Staining by Dr Helen Creedon.
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Figure 3.2. Maintenance of the mesenchymal phenotype is a result of ZEB1 and ZEB2
expression. Immunohistochemistry (IHC) was performed on sections of MMTV-NIC-PTEN+/-
fragment-derived tumours that had been inserted into the fourth mammary fat pad of FVB/N
mice. Representative IHC staining of (A–C) zinc finger E-box binding homeobox 1 (ZEB1;
vehicle: n=8; sapatinib: n=3; sapatinib EMT: n=4), (E–G) zinc finger E-box binding homeobox 2
(ZEB2; vehicle: n=6; sapatinib: n=3; sapatinib EMT: n=2), (I–L) SLUG (vehicle: n=7; sapatinib:
n=3; sapatinib EMT: n=3), (M–O) SNAIL (vehicle: n=8; sapatinib: n=3; sapatinib EMT: n=2) and
(Q–S) TWIST (vehicle: n=5; sapatinib: n=3; sapatinib EMT: n=2). Scale bar: 50 µm. (D, H, L,
P and T) Quantification of IHC staining by Definiens Architect. Vehicle was compared with both
sapatnib phenotypes. Results presented as mean ± standard deviation. Kruskal-Wallis, Dunn’s
post-hoc test, not significant = NS, p<0.05=*. Detailed results can be found in table A.1.
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Figure 3.3. Patients with high expression of ZEB1 have worse recurrence-free survival.
Survival analysis based on high or low gene expression of (A) zinc finger E-box binding
homeobox 1 (ZEB1) and (B) zinc finger E-box binding homeobox 2 (ZEB2) in all patients for
whom these data were available with human epidermal growth factor receptor 2 (HER2)-positive
breast cancer (n=150). Generated using www.kmplot.com. [161]
with high or low ZEB1 or ZEB2 expression levels, to ascertain the relevance to human
disease.
This showed that patients with high expression of ZEB1 had worse recurrence-free
survival (RFS) than those with low expression (fig 3.3 A; median RFS: low: 44 months;
high: 27.4 months; hazard ratio (HR): 1.8; p=0.036). However, no significant difference
could be seen between patients with high and low expression of ZEB2 (fig 3.3 B; median
RFS: low: 37 months; high: 39 months; HR: 1.19; p=0.87).
To establish whether the results from sapatinib-resistant EMT tumours were consistent
regarding EMT-related transcription factors and their impact on human disease, KM-
plotter was also interrogated for expression levels of SLUG, SNAIL and TWIST from
patients with HER2-positive breast cancer. This showed that patients with high levels
of SLUG, SNAIL or TWIST had no survival disadvantage when compared with patients
with low expression levels of these three genes (fig 3.4 A–C; SLUG median RFS: low:
44.17 months; high: 37 months; HR: 1.3; p=0.25; SNAIL median RFS: low: 40.56
months; high: 39 months; HR: 1.14; p=0.57; TWIST median RFS: low: 41.69 months;
high: 39 months; HR: 1.28; p=0.27).
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Figure 3.4. Patients with high expression of SLUG, SNAIL and TWIST have no survival
disadvantage. Survival analysis based on high or low gene expression of (A) SLUG, (B) SNAIL
or (C) TWIST in all patients for whom these data were available with human epidermal growth
factor receptor 2 (HER2)-positive breast cancer (n=252). Generated using www.kmplot.com. [161]
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3.1.2 Sapatinib-resistant fragment-derived tumours with EMT have no
detectable HER2 protein
HER2 was assessed by western blotting and quantitative PCR (qPCR) to look for
differences at the protein and transcript level, in order to better understand and confirm
the loss of HER2 in half of the sapatinib-resistant fragment-derived tumours. This
confirmed the loss of HER2 at the protein level, with no band detected in sapatinib-
resistant EMT tumours, despite detection of HER2 in both the vehicle-treated and
sapatinib-resistant epithelial fragment-derived tumours (fig 3.5 D).
QPCR analysis of mRNA from fragment-derived tumours showed significantly less
Erbb2 expression in sapatinib-resistant fragment-derived tumours which had undergone
EMT, compared with vehicle-treated fragment-derived tumours. Sapatinib-resistant
fragment-derived tumours with an epithelial morphology did not have a significant
reduction in transcript levels, but there was a trend towards lower expression which was
not significantly different from vehicle-treated fragment-derived tumours (fig 3.5 E).
3.2 Resistance in vitro is not associated with loss of HER2
or induction of EMT
To understand the relationship between HER2 loss and EMT, an in vitro model of
resistance was developed. SKBR3 HER2-positive breast cancer cells were exposed
to escalating doses of sapatinib or lapatinib. Once cells began to grow through the
maximum drug concentration, they were classed as resistant. This was repeated, giving
rise to two resistant cell lines per drug.
3.2.1 SKBR3 cells treated with escalating doses of sapatinib or
lapatinib are resistant
To confirm resistance to sapatinib and lapatinib, the GI50 values of the cell lines
maintained in each drug were determined (table 3.1). Resistant cell lines had higher
49
Figure 3.5. Resistance to sapatinib is associated with EMT and loss of HER2 in fragment-
derived tumours. Representative immunohistochemical (IHC) staining of (A–C) human
epidermal growth factor receptor 2 (HER2) performed on MMTV-NIC-PTEN+/- fragment-derived
tumours that had been inserted into the fourth mammary fat pad of FVB/N mice. Scale bar: 50
µm. Staining by Dr Helen Creedon. (D) Representative western blot analysis of HER2 from
two biological repeats. B-actin was used as a loading control. (E) Quantitative PCR analysis of
the gene encoding HER2, erythroblastic oncogene B (Erbb2) mRNA transcript levels (vehicle:
n=2; sapatinib: n=2; sapatinib EMT: n=2). Two primers targeting different regions of Erbb2 were
used and the results pooled. Results from the same tumour are grouped by symbol. Results
presented as mean + standard deviation. Kruskal-Wallis test, Dunn’s post-hoc test, p<0.05=*.
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Table 3.1. GI50 values to sapatinib and lapatinib of parental SKBR3 cells and SKBR3 cells
made resistant to sapatinib or lapatinib
Drug
Cell Line Sapatinib (M) Lapatinib (M)
SKBR3 5.83x10-12 1.12x10-12
SKBR3 SapR-A >3x10-4 >3x10-6
SKBR3 SapR-B >3x10-4 >3x10-6
SKBR3 LapR-A >3x10-4 >3x10-6
SKBR3 LapR-B >3x10-4 >3x10-6
GI50 values than parental SKBR3 cells; in all cases their GI50 values could not be
accurately calculated as they were greater than the highest assay concentration.
SKBR3 sapatinib-resistant and lapatinib-resistant cell lines are at least 10,000,000 times
and 3,000,000 times more resistant to sapatinib and lapatinib, respectively, compared
with parental SKBR3 cells. All cell lines are cross-resistant to sapatinib and lapatinib,
to the same extent as cells made resistant to each drug (table 3.1). This indicates that
all resistant cell lines have a mechanism of resistance that is not specific to sapatinib
and lapatinib and has the potential to be applicable across all HER2-targeted tyrosine
kinase inhibitors.
Resistant cell lines were maintained in either 0.67 µM sapatinib, or 5 µM lapatinib. These
concentrations are lower than plasma concentrations identified in phase I clinical trials for
sapatinib (240 mg oral dose: Cmax: 1.345 µM; Tjulandin et al. [61]) and similar to those
for lapatinib (1250 mg oral dose: Cmax: 3.804–4.371 µM; Burris et al. [162], Simonelli
et al. [163]).
Plasma concentrations of lapatinib are a poor indication of tumour concentrations,
which have been shown to be 6 to 9 times higher in tumours. [164] The concentrations
of sapatinib and lapatinib used have been shown to inhibit phospho-HER2 in SKBR3
cells, [165] as such they were deemed sufficient concentrations to class lines as resistant.
Moreover, relevant lapatinib concentrations were not reached as the drug precipitates in
vitro at higher concentrations.
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Figure 3.6. Resistant SKBR3 cells are morphologically similar to parental SKBR3 cells.
SKBR3 human epidermal growth factor receptor 2 (HER2)-positive breast cancer cell line was
exposed to increasing doses of sapatinib or lapatinib until cells were no longer inhibited. Cells
were cultured in drug. Representative phase contrast images of (A) parental SKBR3 cells, (B–C)
sapatinib-resistant (SapR-A/B) cells and (D–E) lapatinib-resistant (LapR-A/B) cells. Scale bar:
50 µm.
3.2.2 Sapatinib-resistant and lapatinib-resistant SKBR3 cells have no
EMT phenotype
To assess if any morphological changes had taken place in response to exposure to
sapatinib or lapatinib, phase contrast images of the cells were taken and compared
(fig 3.6 A-E). All resistant cell lines maintained their epithelial morphology and no
evidence of a spindle cell morphology, expected if EMT had occurred, could be seen.
EMT is characterised by increased levels of ZEB1, ZEB2, SLUG and SNAIL driving a
program of transcriptional regulation, alone or in concert with each other. [82] Because of
this, the transcript level of these genes was assessed by qPCR. No transcript could be
detected for any of the four genes in parental SKBR3 or the four resistant lines (fig 3.7
A).
Increased proliferation and motility are key characteristics of EMT. [82] To determine
whether the resistant lines had acquired these characteristics, proliferation and migration
assays were carried out. Sapatinib-resistant and lapatinib-resistant cell lines showed
significantly decreased proliferation when compared with parental SKBR3 cells (fig 3.8
A). Only SKBR3 LapR-B showed no difference in proliferation compared with SKBR3
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Figure 3.7. Resistant SKBR3 cells have no detectable EMT-related transcription factors.
(A) Quantitative PCR analysis of parental and resistant SKBR3 cells of zinc finger E-box binding
homeobox 1 (ZEB1), zinc finger E-box binding homeobox 2 (ZEB2), SLUG and SNAIL from
three biological repeats. MDA-MB-231 cells were used as positive control. Results presented
as mean + standard deviation. Not detected = ND.
cells. Parental SKBR3 cells showed a similar migratory capability compared with SapR-
A, LapR-A and LapR-B cells. However, SapR-B cells had significantly greater migration
when compared with SKBR3 cells (fig 3.9 A). Cells from all lines migrated collectively,
rather than as single cells (fig 3.10 A–E).
A program of EMT results in decreased E-cadherin and increased vimentin. [82] SKBR3
cells have a homozygous deletion in the CHD1 gene which encodes E-cadherin, [166] as
such we were unable to look for changes in the expression of E-cadherin as a consequence
of EMT. Immunofluorescence was undertaken to look for expression of vimentin. No
expression of vimentin could be seen in the parental SKBR3 or resistant lines (fig 3.11
A and C–F), despite being detected in positive controls (fig 3.11 B).
3.2.3 Sapatinib-resistant and lapatinib-resistant SKBR3 cells have no
loss of HER2
Resistant cell lines were assessed for any loss of HER2, as seen in the sapatinib-resistant
fragment-derived tumours which had undergone EMT. No loss of HER2 could be seen
in any of the resistant cell lines, but SKBR3 SapR-A showed decreased levels of HER3
by western blotting (fig 3.12 A). Despite being cultured in the presence of sapatinib,
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Figure 3.8. Resistant SKBR3 cells do not have increased rates of proliferation. (A) Rate
of cell proliferation was measured in parental and resistant SKBR3 cells using the IncuCYTE
ZOOM over a 72-hour period. Results presented as mean ± standard deviation, from three
biological repeats. Friedman test, Dunn’s post-hoc test, p<0.05=*, p<0.0001=****. Detailed
results can be found in table A.2.
Figure 3.9. Resistant SKBR3 cells migrate at a similar rate as SKBR3 cells. (A) Rate of
wound closure of parental and resistant SKBR3 cells was measured using the IncuCYTE ZOOM
over a 24-hour period. Results presented as mean ± standard deviation, from three biological
repeats. Friedman test, Dunn’s post-hoc test, p<0.01=**. Detailed results can be found in
table A.2.
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Figure 3.10. Resistant SKBR3 cells migrate collectively. Representative images, from three
biological repeats, at 0 and 24 hours of (A) SKBR3, (B, D) SKBR3 sapatinib resistant (SapR-A
and SapR-B), (C, E) SKBR3 lapatinib-resistant (LapR-A and LapR-B) cells. Scale bar: 300 µm.
Red dashed lines represent the edge of the wound.
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Figure 3.11. Resistant SKBR3 cells have no expression of vimentin. Representative
images, from three biological repeats, of immunofluorescence staining of vimentin in (A) SKBR3
cells, (B) JIMT-1 positive-control cells, (C–D) sapatinib-resistant (SapR-A and SapR-B) and
(E–F) lapatinib-resistant (LapR-A and LapR-B) SKBR3 cells. Images displayed as maximum
intensity projection of Z stack. Scale bar: 10 µm.
HER2 and HER3 remained phosphorylated in both SKBR3 SapR-A and SapR-B, with
levels of phospho-HER3 similar in resistant lines to that seen in parental SKBR3 cells.
This was not seen in LapR-A or LapR-B cells, which both had undetectable phospho-
HER2 and phospho-HER3, despite lapatinib targeting only HER2 and EGFR. Total and
phospho-EGFR remained undetectable in all cell lines. QPCR of all cell lines revealed
no significant differences in the level of ERBB2 transcript between parental SKBR3 and
the resistant cell lines (fig 3.12 B).
Although HER2 protein levels were unaltered in the resistant cells when analysed by
western blot, HER2 and HER3 phosphorylation was unaffected in SapR-A and SapR-B
cells. To ascertain the cell surface expression of HER2 in the resistant cells, FACS was
performed using an antibody targeting an extracellular epitope of HER2.
Unstained cells showed similar peak distribution, although LapR-A and LapR-B had
higher levels of autofluorescence, caused by intracellular lapatinib. [167] Because of this,
lapatinib-resistant cells were gated differently than SKBR3 and sapatinib-resistant cells.
FACS of HER2-APC stained cells showed that parental SKBR3 cells had similar levels
56
Figure 3.12. Resistant SKBR3 cells show no loss of HER2. (A) Representative western
blots, from three biological repeats, of total and phospho-human epidermal growth factor receptor
2 (HER2), HER3 and epidermal growth factor receptor (EGFR). B-actin was used as a loading
control. (B) Quantitative PCR analysis of the gene encoding HER2, erythroblastic oncogene
B (ERBB2) transcript levels. Results presented as mean + standard deviation, from three
biological repeats. Kruskal-Wallis test, Dunn’s post-hoc test, not significant=NS. Detailed results
can be found in table A.2.
of cells negative for cell surface HER2 compared with resistant sapatinib and lapatinib
lines (fig 3.13 A–F).
3.3 Expression of ZEB1 does not reduce levels of HER2
As the program of EMT in vivo was maintained by ZEB1, SKBR3 cells were transiently
transfected with a plasmid containing an empty vector or ZEB1 to induce EMT, as
stable transfection is toxic (S Brabletz, January 2016, personal communication). Five
days after transfection, ZEB1 -overexpressing cells did not have a significantly different
morphology compared with empty vector cells (fig 3.14 A and B). Despite this, SKBR3
ZEB1 -overexpressing cells had a significant increase in levels of ZEB1 transcript, which
was undetectable in SKBR3 cells containing an empty vector (fig 3.14 C). No expression
of ZEB2, SLUG and SNAIL could be detected in either ZEB1 -overexpressing cells or
SKBR3 empty vector cells.
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Figure 3.13. Resistant SKBR3 cells have similar levels of cells negative for cell surface
HER2. Representative fluorescent activated cell sorting (FACS) plots of unstained and human
epidermal growth factor receptor 2 (HER2)-stained (A) SKBR3 (B and D) sapatinib-resistant
(SapR-A and SapR-B) cells and (C and E) lapatinib-resistant (LapR-A and LapR-B) cells.
(F) Quantification of HER2-negative cells in parental, sapatinib-resistant or lapatinib-resistant
SKBR3 cell lines. Results presented as mean ± standard deviation, from two biological repeats.
Kruskal-Wallis test, Dunn’s post-hoc test, not significant = NS. Detailed results can be found in
table A.2.
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Figure 3.14. SKBR3 cells overexpressing ZEB1 do not have a mesenchymal morphology.
Representative phase contrast images of (A) SKBR3 cells containing empty vector and (B)
SKBR3 zinc finger E-box binding homeobox 1 (ZEB1)-overexpressing cells. Scale bar: 50 µm.
(C) Quantitative PCR analysis, from three biological repeats, of ZEB1, ZEB2, SLUG and SNAIL
in SKBR3 cells containing empty vector or overexpressing ZEB1. MDA-MB-231 cells were
used as positive control. Results presented as mean + standard deviation. Multiple t-tests,
Sidak-Bonferroni correction, not detected = ND, p<0.0001=****.
To see if levels of HER2 were affected by the increase in ZEB1, cells were assessed by qPCR
and western blot for HER2 and phospho-HER2. QPCR revealed no significant difference
in levels of ERBB2 transcript between empty vector cells and ZEB1 -overexpressing cells
(fig 3.15 A). Furthermore, no significant reduction could be seen in levels of HER2, or
phospho-HER2 by western blot in ZEB1 -overexpressing cells (fig 3.15 B-D).
3.4 Loss of HER2 does not induce a full program of EMT
As no loss of HER2 was observed in resistant SKBR3 lines and expression of ZEB1 did
not result in loss of HER2, we then asked if loss of HER2 was sufficient to induce EMT.
SKBR3 cells were stably transfected with either non-target or ERBB2 shRNA.
To see if loss of HER2 had any morphological effect on the cells, phase contrast images
were taken and compared. These images showed that cells containing ERBB2 shRNA
did not have a cobblestone morphology as distinct as non-target shRNA cells (fig 3.16 A
and B). However, they did still form cell-cell contacts and did not have an overt spindle
cell morphology.
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Figure 3.15. SKBR3 cells overexpressing ZEB1 do not have a reduction in HER2 or
phospho-HER2 levels. (A) Quantitative PCR analysis, from three biological repeats, of the
gene encoding HER2, erythroblastic oncogene B (ERBB2) in SKBR3 cells containing empty
vector or overexpressing zinc finger E-box binding homeobox 1 (ZEB1). Results presented as
mean ± standard deviation (SD). Mann-Whitney test, not significant= NS. (B) Representative
western blot analysis, from three biological repeats, of HER2 and phospho-HER2. B-actin was
used as a loading control. (C) Quantification of HER2 protein expression (arbitrary unit: A.U),
normalised to β-actin. Results presented as mean ± SD. Mann-Whitey test, not significant = NS.
(D) Quantification of phospho-HER2:HER2 ratio, normalised to β-actin. Results presented as
mean ± SD. Mann-Whitney test, not significant = NS. Detailed results can be found in table A.3.
To confirm successful gene silencing, levels of HER2 were assessed by western blotting
and qPCR. Other HER family members were also assessed to see if there had been a
switch to utilising other RTKs in the same family. Assessment of HER family members by
western blot revealed no detectable HER2 or phospho-HER2 in ERBB2 shRNA treated
cells (fig 3.16 C). Analysis by qPCR showed a significant reduction in the transcript
level of ERBB2 (fig 3.16 D).
As a concurrent loss of HER3 and phospho-HER3 could be seen in ERBB2 shRNA cells
by western blotting (fig 3.16 C), qPCR was performed to check if the ERBB2 -targeted
shRNA was having off-target effects on ERBB3. This showed no reduction in ERBB3
transcript levels (fig 3.16 D).
To determine if loss of HER2 resulted in a program of EMT, SKBR3 cells treated with
non-target or ERBB2 shRNA were analysed by qPCR for EMT-related transcription
factors. Both non-target and ERBB2 shRNA cells showed similar levels of ZEB2 and
SNAIL (fig 3.17 A). However, ERBB2 shRNA-treated cells had significantly increased
ZEB1 and SLUG transcript levels (fig 3.17 A). These results indicate that loss of HER2
has had some effect in increasing mesenchymal properties in SKBR3 cells.
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Figure 3.16. Loss of HER2 does not change cell morphology, or reliance on other HER
family members. Representative phase contrast images of (A) non-target shRNA and (B)
ERBB2 shRNA treated cells. Scale bar: 50 µm. (C) Representative western blot analysis,
from three biological repeats, of total and phospho-human epidermal growth factor receptor
2 (HER2), HER3 and epidermal growth factor receptor (EGFR) in SKBR3 cells treated with
non-target shRNA, ERBB2 shRNA or untreated. B-actin was used as a loading control. (D)
Representative qPCR analysis, from three biological repeats, of ERBB2 and ERBB3 levels in
SKBR3 cells treated with non-target shRNA or ERBB2 shRNA. Results presented as mean ±
standard deviation. Multiple two-tailed t-tests, Sidak-Bonferroni correction, not significant = NS,
p<0.0001=****. Detailed results can be found in table A.4.
Cells that have undergone EMT are more proliferative, migratory and invasive. [82] To
see whether ERBB2 shRNA cells have these characteristics, proliferation and migration
assays were used. This revealed that ERBB2 shRNA cells proliferated significantly
less than non-target shRNA cells (fig 3.18 A). However, ERBB2 shRNA cells were
significantly more migratory than non-target shRNA cells (fig 3.19 A). Both non-target
and ERBB2 shRNA cells moved collectively to close the wound (fig 3.19 B).
Vimentin is the main cytoskeletal protein in mesenchymal cells and is used as a marker of
cells that have undergone EMT. [82] To identify any increase in cells expressing vimentin,
immunofluorescence was used. Non-target and ERBB2 shRNA cells had similar levels of
vimentin (fig 3.20 A and B) when assessed by immunofluorescence. However, previous
analysis of parental SKBR3 cells and resistant lines showed no expression of vimentin
(fig 3.11). As vimentin is present in non-target and ERBB2 shRNA lines, it may be due
to the transfection process.
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Figure 3.17. Loss of HER2 alters expression of some EMT-related transcription factors.
(A) Quantitative PCR analysis, from three biological repeats, of zinc finger E-box binding
homeobox 1 (ZEB1), ZEB2, SLUG and SNAIL in SKBR3 cells treated with ERBB2 or non-target
shRNA. Results presented as mean + standard deviation. Multiple two-tailed t-tests, Sidak-
Bonferroni correction, not significant = NS, p<0.01=**, p<0.0001=****.Detailed results can be
found in table A.4.
Figure 3.18. Loss of HER2 reduces proliferation. (A) Rate of cell proliferation of SKBR3
cells treated with non-target shRNA or ERBB2 shRNA was measured using the IncuCyte ZOOM
over a 72-hour period, from three biological repeats. Results presented as mean ± standard
deviation. Two-tailed Wilcoxon matched-pairs signed-rank test, p<0.0001=****. Detailed results
can be found in table A.4.
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Figure 3.19. Loss of HER2 increases migratory capacity. SKBR3 human epidermal growth
factor receptor 2 (HER2)-positive breast cancer cell line was treated with shRNA targeting the
gene encoding HER2, erythroblastic oncogene B (ERBB2) or a non-target control shRNA. (A)
Rate of wound closure was measured using the IncuCYTE ZOOM over a 24-hour period, from
three biological repeats. Results presented as mean ± standard deviation. Two-tailed Wilcoxon
matched-pairs signed-rank test, p<0.01=**. (B) Representative images at 0, 12 and 24 hours
from non-target and ERBB2 shRNA. Scale bar: 300 µm. Red dashed lines represent the edge
of the wound. Detailed results can be found in table A.4.
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Figure 3.20. Loss of HER2 does not increase the level of vimentin or N-cadherin. SKBR3
human epidermal growth factor receptor 2 (HER2)-positive breast cancer cell line was treated
with shRNA targeting the gene encoding HER2, erythroblastic oncogene B (ERBB2) or a
non-target control shRNA. Representative immunofluorescence staining, from three biological
repeats, of vimentin in SKBR3 cells treated with (A) non-target shRNA or (B) ERBB2 shRNA.
Images displayed as maximum intensity projection of Z stack. Scale bar: 10 µm.
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3.5 Discussion
Previous work by Creedon et al. [84] evidenced a link between EMT and loss of HER2 in
a fragment-derived tumour mouse model in response to the development of sapatinib
resistance. This in vitro analysis evidences that short-term overexpression of ZEB1 alone
is not sufficient to result in a loss of HER2 and that loss of HER2 is not sufficient to
induce a full program of EMT, but was able to give rise to some mesenchymal properties.
3.5.1 ZEB1 and ZEB2 maintained the mesenchymal phenotype in
sapatinib-resistant fragment-derived tumours
Increased ZEB1 and ZEB2 can be seen in sapatinib-resistant tumours that had undergone
EMT while other EMT-associated transcription factors were unaltered (fig 3.2 A–H).
This indicates that ZEB1 and ZEB2 are required for EMT in these resistant tumours.
However, tumours were collected at the time of sacrifice, as such it is unclear if EMT
was initially driven and then maintained by ZEB1 and ZEB2, or whether other EMT
transcription factors played a role in the initiation of EMT.
Transcriptional regulation of EMT can be the result of many different cellular pathways.
In the MMTV-NIC mouse model, tumour-initiating, or stem, cells have increased TGF-β
signalling and EMT. [168] Increased signalling through the TGF-β pathway can result in
decreased expression of miR-200 family members and a loss of inhibition at the promoter
regions of ZEB1 and ZEB2 allowing them to be transcribed. [169,170] Thus, the increase
in ZEB1 and ZEB2 could be indicative of a higher proportion of tumour stem cells within
the sapatinib-resistant EMT tumours, compared with the epithelial sapatinib-resistant
tumours.
It is interesting to note that no significant difference could be seen in levels of nuclear
ZEB1 between vehicle-treated and sapatinib-resistant tumours with an epithelial or
mesenchymal phenotype, but a significant difference could be seen between the two
resistant tumour phenotypes (fig 3.2 A–D). Analysis of ZEB1 staining in vehicle-treated
tumours shows that the percentage of ZEB1-positive cells was between that seen in
sapatinib-resistant epithelial and mesenchymal tumours.
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The variation in ZEB1 expression in the vehicle-treated tumours could be indicative
of heterogeneity within the implanted fragments. If two populations (ZEB1high and
ZEB1low) are present in the implanted tumours, ZEB1high may give a selective advantage
in some circumstances, resulting in mesenchymal ZEB1high and epithelial ZEB1low
tumours. Secretion of pro- or anti-EMT factors (fig 3.21) by stromal cell populations in
different tumour regions may be driving the selection of the epithelial and mesenchymal
phenotypes seen in sapatinib-resistant tumours. [83]
ZEB1 expression has been shown to confer resistance to radio-, chemo-, and targeted
therapies. [85,171,172] This is consistent with our data which showed patients with high
gene expression of ZEB1 have worse RFS than patients with lower levels (fig 3.3 A). [161]
Published data [85,171,172] and the patient data presented here (fig 3.3 A) indicate that
ZEB1 is a key transcription factor controlling a mesenchymal phenotype and therapy
resistance, as seen in the sapatinib-resistant fragment-derived tumours which have
undergone EMT. However, the process leading to increased ZEB1 and ZEB2 in the
sapatinib-resistant tumours is not known, due to tumours being collected at sacrifice. If
increased ZEB1 is the primary mechanism of resistance, development of better in vitro
models will allow modulation of this for confirmation.
3.5.2 Linking EMT and HER2 loss
In Creedon et al. [84], concurrent loss of HER2 and EMT were seen (fig 3.1, 3.5).
Although induction of EMT in response to targeted therapies has been shown in the
literature, [80,85,87,89,91,122,173,174] EMT is not consistently induced in response to targeted
therapies. [123,175–177] Despite being highly resistant to both sapatinib and lapatinib, none
of the resistant lines replicated the mesenchymal phenotype seen in vivo (section 3.2).
In our models, overexpression of ZEB1 did not result in any loss of HER2 protein or
transcript (fig 3.15). However, these were short-term experiments; despite increased
ZEB1 transcript, other evidence supporting EMT was lacking. Studies evidencing
EMT in response to HER2-targeted therapies utilised trastuzumab, [80,91,122] whereas
our models of acquired resistance used the tyrosine kinase inhibitors sapatinib and
lapatinib. Although, other studies have evidenced ZEB1 as a driver of resistance using
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Figure 3.21. EMT can be induced by stimuli from the tumour microenvironment. The
tumour microenvironment (TME) consists of cells such as fibroblasts and immune cells that
are able to release cytokines which act on the tumour cells. Cellular pathways including
phospho-inositide-3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) can be
activated. This can lead to activation of transcription factors signal transducer and activator
of transcription 3 (STAT3), Yes-associated protein (YAP) and transcriptional co-activator with
PDZ-binding motif (TAZ). Genes downstream of these proteins include epithelial to mesenchymal
transition (EMT) transcription factors: SLUG, SNAIL, TWIST, zinc finger E-box binding homeobox
1 and 2 (ZEB1 and ZEB2). Cancer stem cell activity can be modulated by cytokines through
MET and its receptor, CD44v6, which amplifies hepatocyte growth factor (HGF) signalling and
transcription of EMT-associated genes. Cellular interaction with extracellular matrix (ECM)
through integrins and other cell-adhesion proteins can also affect this signalling pathway.
Conversely, bone morphogenetic proteins (BMPs) and AMP-activated protein kinase (AMPK)
prevent EMT gene transcription. Micro-RNAs (miRNAs) can inhibit or support EMT dependent
on their target genes. Abbreviations: BMPR: BMP receptor; Co-SMAD: common mediator
SMAD; EGF: epidermal growth factor; FAK: focal adhesion kinase; FGF: fibroblast growth factor;
HDAC: histone deacetylase; HIF-1α: hypoxia-inducible factor 1α; ID2: inhibitor of DNA binding
2; IL-6: interleukin-6; LOX: lysyl oxidase; NF-κB: nuclear factor-κB; PDGF: platelet-derived
growth factor; ROS: reactive oxygen species; R-SMAD: receptor-regulated SMAD; SMAD:
an acronym from the fusion of C. elegans Sma genes and the D. melanogaster mothers
against decapentaplegic; TGF-β: transforming growth factor-β. Reprinted by permission from
RightsLink: Nature publishing group, Nature Reviews Drug Discovery, Marcucci et al. [83], 2016.
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in vitro models of acquired resistance to tyrosine kinase inhibitors and chemotherapeutic
agents. [85,89] Thus, ZEB1 induction is not exclusive to resistance to targeted monoclonal
antibodies.
Trastuzumab has a different mechanism of action to sapatinib and lapatinib; by targeting
the extracellular domain of HER2, it inhibits downstream pathway signalling, induces
ADCC and triggers HER2 internalisation. [32,39,40] However, sapatinib and lapatinib only
inhibit phosphorylation of HER2, preventing downstream pathway activation. [34,36]
The additional actions of trastuzumab may encourage cells to undergo EMT in vitro
without further stimulation by pro-inflammatory cytokines. Development of trastuzumab-
resistant lines, or treatment of ZEB1 -overexpressing cells with trastuzumab, may provide
enough stimulus for cells to fully undergo EMT. However, as ZEB1 has been shown in
response to other small molecule inhibitors, the question remains as to why resistant
SKBR3 cells did not increase ZEB1, as seen in vivo.
Lapatinib has been shown to disrupt ERK and PI3K/AKT signalling through EGFR,
resulting in suppression of EMT in squamous cell carcinoma. [178] Conversely, research by
Kim et al. [173] evidenced that lapatinib resistance is associated with induction of EMT
via Testican-1 signalling in gastric cancer. However in this instance, levels of HER2 and
phospho-HER2 were maintained. From the conflicting results published, it is evident
that the induction of EMT in response to targeting of HER family members is context
specific and does not always correlate with downregulation of HER2 or EGFR.
Tumours with PTEN loss or PIK3CA mutations, leading to constitutive pathway
activation, [109–111,114,115] have been shown to express EMT-like properties and increase
expression of stem cell markers. [91,159] SKBR3 cells possess PTEN, whereas tumours
from MMTV-NIC-PTEN+/- have reduced PTEN activity. [165] As a result of the reduced
PTEN activity, PI3K/AKT signalling is increased in these tumours. [165,179] Therefore,
the lack of concurrence between the in vivo and in vitro data may be due to the differing
PTEN status of the models.
Increased expression of HER2 has been linked to EMT. [80,87,180] Liu et al. [80] found that
activation of MMPs led to shedding of the extracellular domain and loss of membranous
HER2, despite continued reliance on p95 HER2, which is evidenced by the sensitivity
68
of the cells to lapatinib. As HER2 overexpression can drive EMT and increase cancer
stemness, we used SKBR3 cells to model this. However, development of resistant lines
and overexpression of ZEB1 failed to recapitulate the EMT seen in vivo. [84]
The data are contradictory: loss of HER2 due to EMT has also been shown. [90,157]
Supporting the link between reduced HER2 expression and EMT, a recent meta-analysis
showed that although HER2-positive breast cancers were more likely to be associated with
decreased E-cadherin than luminal A or B subtypes, triple-negative breast cancers were
significantly more likely than HER2-positive cancers to have decreased E-cadherin. [181]
Loss of HER2 after initial diagnosis has also been shown in primary breast cancers. [64,65]
Both studies showed a loss of ERBB2 DNA amplification, rather than at the protein or
transcript level. The tumours analysed in Creedon et al. [84], and within this chapter,
are derived from a genetically engineered mouse model, with Erbb2 under the control
of the MMTV promoter; ensuring HER2 becomes expressed and drives tumourigenesis
only within mammary tissues. [147,148] We have confirmed that within this mouse model,
there is complete loss of HER2 at the protein level (fig 3.5 C and D) in half of the
sapatinib-resistant fragment-derived tumours. A significant decrease in Erbb2 at the
transcript level (fig 3.5 E) indicates that these tumours still possess the transgene, as
Erbb2 was detected in all tumours.
To explore loss of HER2 driving EMT, we knocked down ERBB2 in SKBR3 cells.
However loss of HER2 in SKBR3 cells did not result in a switch to an overt mesenchymal
phenotype (section 3.4). Although, ERBB2 shRNA cells had increased ZEB1 and
were more migratory, evidencing some mesenchymal properties (fig 3.17, 3.19). If the
mesenchymal phenotype seen in the sapatinib-resistant tumours is reliant on cell-extrinsic
factors, the full program of EMT would not occur despite loss of HER2.
3.5.3 Modelling resistance in vitro
As described above, in the MMTV-NIC-PTEN+/- model, resistance to sapatinib was
associated with EMT and concurrent loss of HER2. [84] However, this was not recapitulated
in vitro using the SKBR3 cell line (section 3.2). SKBR3 cells were chosen as they most
accurately represent the molecular signature of the tumours generated in MMTV-NIC-
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Table 3.2. HER2-positive cell lines
Cell line TR LR Additional Information
SKBR3 - - -
AU565 - - Derived from same patient as SKBR3
HCC1569 - + -
HCC1954 + - -
HCC202 - + -
JIMT-1 + + -
KPL-4 + - Inflammatory
MDA-MB-453 + + Misidentified cell line
OCUB-1F - - Non-adherent
SUM225 + - -
UACC-893 + - -
TR: trastuzumab resistant; LR: lapatinib resistant. References: Tanner
et al. [77], O’Brien et al. [182], Dai et al. [183], Ellison et al. [184], Jernström
et al. [185], Sawada et al. [186]
PTEN+/- mice, which are BRCA wild-type and oestrogen receptor and progesterone
receptor negative. [165] Other HER2-positive cell lines lacking oestrogen and progesterone
receptors have been derived but have been shown to be de novo resistant to trastuzumab
or lapatinib (table 3.2). [77,182–186] Due to this, they have limited utility in our experiments
as matched, responsive lines are not available for comparison.
Two cell lines, AU565 and OCUB-1F, are not resistant to trastuzumab or lapatinib.
However, AU565 and SKBR3 cells are derived from the same patient. [182] As such, they
have the same molecular signature and react to drug treatments in similar ways. [182]
Because of this, AU565 cells offer no advantage over SKBR3 cells. OCUB-1F cells are a
non-adherent cell line and there is little information available in the literature regarding
their sensitivity to targeted therapies, or their origin. [186] With this in mind, SKBR3 is
the best in vitro model to replicate MMTV-NIC-PTEN+/- tumours.
Previous work in the Brunton lab generated cell lines derived from MMTV-NIC-PTEN+/-
tumours. [187] However, these lines showed fluctuations in their expression of HER2 and no
longer expressed the MMTV-NIC transcript. Additionally, alterations in the expression
of cytokeratins and mesenchymal markers indicated that the cells were undergoing
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lineage changes, without the addition of sapatinib or lapatinib. [187] Thus, use of these
lines to study the relationship between HER2 loss and EMT in response to targeted
therapies was not tenable.
Studies linking EMT and resistance to targeted therapies have shown that this is reliant
on pro-inflammatory cytokines mediating a positive-feedback loop. [90,91,188] Increased
expression of interleukin-6 (IL-6) or IL-1α through NFκB and STAT3 signalling promote
chronic inflammation which is necessary to support EMT and enhanced stemness
(fig 3.21). [91,188] These cytokines can be produced by cancer cells themselves or, in in
vivo models, by immune cells. [83,90,91]
Without the influence of pro-inflammatory cytokines in vitro our models are lacking
the external signals which may be necessary for the induction of EMT. Co-culture
experiments would better replicate the impact of the immune system and other cell
types on cancer cells in vitro. [189,190] These systems better recapitulate the cross-talk
between different cell types within a tumour. Cells within the microenvironment can
exert a large influence on cell-fate decisions. [189] In particular, the release of cytokines
by immune cells and fibroblasts can activate the TGF-β pathway which can result in
increased expression of ZEB1 (fig 3.21). [83,90,91]
Signals from the extracellular matrix can also influence cells to undergo EMT (fig 3.21).
As the plastic used in 2D tissue culture is stiffer than the extracellular matrix, signalling
pathways can be altered. [191] In contrast, 3D tissue scaffolds can be made of a variety of
materials and have the ability to modulate substrate stiffness to better portray conditions
in vivo. [192]
By utilising a co-culture or 3D culture technique, it may be possible to better recapitulate
the EMT seen in vivo in response to sapatinib. As such, future research should employ
these techniques to ascertain the effect they may have on EMT and HER2 loss in vitro
in response to sapatinib.
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3.5.4 Summary
We have shown that the EMT phenotype seen in vivo is maintained by ZEB1 expression;
furthermore, patient data supports the translational relevance of the model. Additionally,
we have shown that loss of HER2 is not sufficient to induce EMT in SKBR3 cells, despite
bestowing some mesenchymal properties. Currently, it is still unclear how EMT and
loss of HER2 are linked in the MMTV-NIC-PTEN+/- fragment-derived tumour mouse
model.
Future studies should focus on the difference between the current in vitro and in vivo
models and further elucidate the effect that PTEN loss may have on the development of
HER2 loss and EMT in response to sapatinib treatment. Development of more relevant
in vitro models, using co-culture or 3D cultures, will allow pathway manipulation to







In the past decade, targeted therapies have resulted in major advances in the treatment of
HER2-positive breast cancers. Despite this, up to 70% of patients will develop resistance
to targeted therapies such as trastuzumab and lapatinib within two years. [71] Resistance
to these therapies means that patients’ disease will inevitably progress. If patients
do progress on targeted therapies, chemotherapy becomes the only alternative. By
uncovering pathways and mechanisms that resistant tumours are utilising to overcome
targeted therapies, it is possible that these can be targeted to render the tumours
sensitive to therapy once more.
To study resistance mechanisms within the primary tumour, a spontaneous mouse model
of HER2-positive breast cancer was used. The MMTV-NIC-PTEN+/- mouse model
develops multiple HER2-driven mammary tumours. [147,148] To understand resistance
mechanisms behind HER2-targeted therapies, MMTV-NIC-PTEN+/- mice were treated
with vehicle (1% Tween 80 in PBS; po, q.d.), or sapatinib (100 mg/kg, with 1% Tween
80 in PBS; po, q.d.) once a palpable tumour developed. Initial characterisation of
untreated tumours and tumours treated with sapatinib for three days from this model
has previously been undertaken and is detailed in Creedon et al. [84]
In this chapter, the following aims will be explored:
• Characterisation of a sapatinib-treated MMTV-NIC-PTEN+/- spontaneous tumour
mouse model.
• Identify pathways which are differentially regulated in sapatinib-treated tumours.
• Validation of identified pathways and proteins ex vivo.
• Assess the similarity of resistance mechanisms between the fragment-derived
tumour model and the spontaneous tumour model.
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4.1 Sapatinib-treated mice have longer survival times
despite similar tumour burden
Tumour development and measurements were performed by Dr Helen Creedon. Survival
data up to 40 days after the first palpable tumour were assessed by Dr Helen Creedon, [165]
and is included in Creedon et al. [84]. I performed all subsequent analysis presented in
this chapter. Detailed results for this chapter can be found in tables A.5–A.8.
MMTV-NIC-PTEN+/- mice were monitored twice weekly for the development of palpable
tumours. Vehicle-treated mice had a median survival time of 22 days after onset of
treatment, compared with 71 days for sapatinib-treated mice (fig 4.1 A; HR: 0.3099;
CI of ratio: 0.08970–1.070; p=0.0018). MMTV-NIC-PTEN+/- mice can develop up to
10 mammary tumours: mice treated with vehicle developed a median of six tumours
each, whereas mice on sapatinib treatment developed a median of five tumours each
(Mann-Whitney test; CI: (−3)–4; p=0.3175; NS).
Clinical disease progression is classified as a greater than 20% increase in tumour volume
from baseline, whereas responsive disease is classed as a greater than 30% decrease in
tumour volume. [193] Using these guidelines, 83% of all tumours from both treatment
arms combined were classed as progressive (fig 4.1 B; vehicle: n=25 [92.59%]; sapatinib:
n=17 [70.83%]). Two tumours were between 20% increase and 30% decrease in tumour
volume (fig 4.1 B; vehicle: n=0 [0%]; sapatinib: n=2 [8.34%]) and were thus classified as
stable. [193]
Several tumours that became palpable after treatment commenced showed pathological
complete response (pCR) to treatment, with no palpable tumour detected (fig 4.1 B;
vehicle: n=0 [0%]; sapatinib: n=5 [20.84%]). Two tumours had partial responses, greater
than 30% regression, but less than 100% regression (fig 4.1 B; vehicle: n=1 [3.70%];
sapatinib: n=1 [4.17%]). No significant difference was seen between treatment groups
when comparing the percentage volume change from baseline (Mann-Whitney test;
p=0.0682; NS).
The index tumour was defined as the largest tumour at the time of sacrifice. Growth
kinetics of the index tumours from each mouse (fig 4.1 C) showed that tumours from
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Figure 4.1. Sapatinib increases survival time in MMTV-NIC-PTEN+/- mice. (A) Kaplan-
Meier survival curve showing survival time from start of treatment in MMTV-NIC-PTEN+/- mice
treated with vehicle or sapatinib. Log-rank test, p=0.0018. (B) Waterfall plot showing volume
change from baseline (%) of all MMTV-NIC-PTEN+/- tumours from mice treated with vehicle
or sapatinib. Dotted blue lines represent 20% increase, 30% decrease and 100% decrease in
tumour volume from baseline, respectively. Mann-Whitney test, p=0.0682. (C) Graph showing
growth curves of index tumours in MMTV-NIC-PTEN+/- mice treated with vehicle or sapatinib
from the onset of the first palpable tumour.
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vehicle-treated mice grew rapidly after the initial tumour onset, whereas index tumours
from sapatinib-treated mice had a longer period of latency after treatment commenced
before rapid growth began. Subsequent analysis presented here has been performed on
tumours progressing on vehicle or sapatinib treatment.
4.2 Spontaneous tumours have a mechanism of resistance
distinct from that seen in fragment-derived tumours
that have undergone EMT
4.2.1 Tumours from sapatinib-treated mice are morphologically similar
to tumours from vehicle-treated mice
Previous data generated by the lab showed that 50% of the sapatinib-resistant tumours
derived following implantation of MMTV-NIC-PTEN+/- tumour fragments exhibited
a mesenchymal morphology, increased expression of mesenchymal markers and loss of
HER2 (see chapter 3; Creedon et al. 84). Haematoxylin and eosin staining shows resistant
tumours from sapatinib-treated mice have a similar cellular morphology and tumour
composition to those from vehicle-treated mice (fig 4.2 A–D, 4.2 E).
If tumours had undergone EMT a spindle cell morphology would be expected (fig 3.1
C; Creedon et al. 84), but these cells exhibited a rounded, epithelial-like morphology.
However, tumours from sapatinib-treated mice had a larger median cell area compared
with vehicle-treated and untreated tumours (fig 4.2 E). Sapatinib-treated tumours also
had a larger mean nuclear area (fig 4.2 F), compared with vehicle-treated tumours,
although no significant difference can be seen between untreated and sapatinib-treated
tumours.
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Figure 4.2. Tumours from sapatinib-treated MMTV-NIC-PTEN+/- mice are morphologically
similar to vehicle-treated mice. Representative haematoxylin and eosin (H&E) staining of
tumours from MMTV-NIC-PTEN+/- mice treated with vehicle (n=24) or sapatinib (n=11). (A–B)
Scale bar: 250 µm and (C–D) scale bar: 50 µm. (E) Determination of mean cell area by Definiens
Architect, compared with untreated tumours from MMTV-NIC-PTEN+/- mice (images not shown).
Results presented as scatter plot with median ± IQR. Kruskal-Wallis test, Dunn’s post-hoc
test p<0.05=*. (F) Determination of mean nuclear area by Definiens Architect, compared with
untreated tumours from MMTV-NIC-PTEN+/- mice (images not shown). Results presented
as scatter plot with median ± interquartile range. Kruskal-Wallis test, Dunn’s post-hoc test
p<0.01=**. Detailed results can be found in table A.5.
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Figure 4.3. Sapatinib-treated tumours from MMTV-NIC-PTEN+/- mice have no loss of
HER2, or mesenchymal phenotype. Immunohistochemistry (IHC) was performed on tumours
from MMTV-NIC-PTEN+/- mice treated with vehicle or sapatinib. Representative IHC staining
of (A–B) human epidermal growth factor receptor 2 (HER2) (vehicle: n=25; sapatinib: n=12),
(C–D) vimentin (vehicle: n=23; sapatinib: n=11) and (E–F) β-catenin (vehicle: n=22; sapatinib:
n=10). Scale bar: 50 µm. Quantification of (G) HER2, (H) vimentin and (I) β-catenin staining by
Definiens Architect. Results presented as mean ± standard deviation. Two-tailed Mann-Whitney
test, not significant = NS, p<0.001=***. Detailed results can be found in table A.5.
4.2.2 Sapatinib-treated tumours have no loss of HER2 or EMT
associated protein expression
To further ascertain whether sapatinib-treated spontaneous tumours exhibit similar
changes to sapatinib-resistant fragment-derived tumours that had developed acquired
resistance (fig 3.1, 3.5), IHC was performed for HER2, vimentin and β-catenin. Unlike
the sapatinib-treated fragment-derived tumours, sapatinib-treated spontaneous tumours
showed similar numbers of HER2-positive cells as vehicle-treated spontaneous tumours
(fig 4.3 A, B and G). Additionally, no increase in the number of vimentin positive cells,
associated with a mesenchymal phenotype, was seen (fig 4.3 C and D). Sapatinib-treated
tumours also showed increased numbers of β-catenin positive cells, associated with an
epithelial phenotype, compared with vehicle-treated tumours (fig 4.3 E, F and H).
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4.3 Alterations in key signalling axes indicate that
sapatinib-treated tumours are utilising alternative
pathways
4.3.1 Sapatinib-treated tumours have greater proliferation compared
with vehicle-treated tumours
To assess if sapatinib-treated tumours had similar numbers of actively proliferating cells
to vehicle-treated tumours, levels of Ki67 were assessed. This revealed that sapatinib-
treated tumours had more Ki67-positive nuclei than vehicle-treated tumours (fig 4.4 A,
B and E; median [CI]: vehicle: 21.97% [13.95–39.88]; sapatinib: 69.93% [29.32–91.19];
p=0.0006).
Previous work in the Brunton lab determined that MMTV-NIC-PTEN+/- mice developed
tumours more quickly than MMTV-NIC-PTEN+/+ and that those tumours with loss
of PTEN had accelerated tumour progression. [84] To establish whether both treatment
groups had similar expression of PTEN within tumours, IHC was performed. This
confirmed that similar numbers of PTEN-positive cells can be seen across both vehicle-
treated and sapatinib-treated tumours and that these cells did not express high levels of
PTEN (fig 4.4 C, D and F).
4.3.2 Pathways downstream of HER2 are inhibited in tumours from
sapatinib-treated MMTV-NIC-PTEN+/- mice
The PI3K/AKT and MAPK pathways are downstream of HER2 signalling. The
activation of both pathways can result in increased proliferation due to their varied
downstream targets (fig 1.1). Inhibition of HER2 by sapatinib has been shown to reduce
signalling through these pathways in vivo after three days of treatment with sapatinib. [84]
Dysregulation of signalling through the PI3K/AKT and MAPK pathways has been
linked to resistance to HER2-targeted therapies. [109]
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Figure 4.4. Tumours from sapatinib-treated MMTV-NIC-PTEN+/- mice have greater
proliferative potential than vehicle-treated tumours. Representative immunohistochemical
(IHC) staining of (A–B) Ki67 (vehicle: n=23; sapatinib: n=9) and (C–D) phosphatase and tensin
homolog (PTEN; vehicle: n=24; sapatinib: n=12). Scale bar: 50 µm. Quantification of (E) Ki67
and (F) PTEN IHC staining by Definiens Architect. Results presented as mean ± standard
deviation. Two-tailed Mann-Whitney test, not significant = NS, p<0.001=***. Detailed results
can be found in table A.5.
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Figure 4.5. Sapatinib-treated MMTV-NIC-PTEN+/- tumours have reduced AKT signalling.
Representative immunohistochemical (IHC) staining of (A–D) phosphorylated protein kinase B
(phospho-AKT; vehicle: n=11; sapatinib: n=6) and (E–H) phosphorylated extracellular signal-
regulated kinase-1 (phospho-ERK; vehicle: n=25; sapatinib: n=10). (A–B, E–F) Scale bar: 250
µm. (C–D, G–H) Scale bar: 50 µm. Quantification of (I) phospho-AKT and (J) phospho-ERK
IHC staining by Definiens Architect. Results presented as mean ± standard deviation. Two-tailed
Mann-Whitney test, not significant = NS, p<0.05=*. Detailed results can be found in table A.5.
To test if activation of these pathways was increased in the tumours, IHC was carried out
for phospho-AKT and phospho-ERK. Levels of phospho-AKT were significantly reduced
in sapatinib-treated tumours (fig 4.5 A–D and I). Meanwhile, no significant difference
could be seen between treatment groups when comparing levels of phospho-ERK (fig 4.5
E–H and J). However, expression of phospho-ERK was highly variable across the tumours
(fig 4.5 E and F), whereas phospho-AKT expression was more consistent across the
whole tumour section (fig 4.5 A and B).
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4.4 Pathway analysis reveals alterations in iron
homeostasis
To assess differentially regulated pathways in sapatinib-treated tumours compared with
vehicle-treated tumours, index tumours from both treatment arms were subjected to
reverse phase protein array (RPPA) and proteomic analysis.
4.4.1 RPPA identifies increased phospho-SMAD1/5 in sapatinib-treated
tumours
To identify any potential changes in pathways known to often be dysregulated in
resistance, RPPA was used. [194] Key pathways investigated include AKT and MAPK
signalling and those associated with transcriptional regulation, cell cycle and apoptosis.
This revealed few changes in signalling pathways that were consistent across all sapatinib-
treated index tumours (fig 4.6 A). Proteins that were significantly downregulated in
sapatinib-treated tumours included downstream targets of EGFR and HER2 (fig 4.6
B) such as c-Myc, phospho-AKT and phospho-PLC-γ1. This result confirms previous
quantification of IHC for phospho-AKT and phospho-ERK (fig 4.5 I and J) which
showed significantly decreased phospho-AKT and no significant difference in levels of
phospho-ERK.
Only phospho-SMAD1/5 (pSMAD1/5) was significantly upregulated in all sapatinib-
treated tumours, compared with vehicle-treated tumours by RPPA. SMAD1 and SMAD5
are known to translocate to the nucleus when phosphorylated, in a complex with SMAD8,
and initiate transcription of target genes. [195–197] To validate this finding, IHC was carried
out. This revealed no significant difference in levels of nuclear pSMAD1/5/8 between
the two treatment groups (fig 4.6 C–E).
Western blotting revealed an increase in pSMAD1/5 in sapatinib-treated tumours.
However, these tumours also had higher levels of SMAD1 compared with vehicle-treated
tumours, despite having lower levels of SMAD5 (fig 4.6 F). Quantification of these
western blots by densitometry analysis revealed no significant difference between the
83
ratio of pSMAD1/5 to SMAD1 and SMAD5 between the two treatment groups (fig 4.6
G).
4.4.2 Sapatinib-treated tumours have dysregulated cellular iron
homeostasis
Proteomic analysis by mass spectrometry (Section 2.2.7) revealed a small number of
proteins that were significantly (p<0.05) and 2-fold differentially regulated between
vehicle-treated and sapatinib-treated tumours (n=123, increased: n=34, decreased:
n=89; fig 4.7 A; table B.1). However, gene ontology (GO) analysis of proteomic data
revealed several proteins upregulated in sapatinib-treated tumours related to control of
cellular iron homeostasis (n=4; fig 4.7 B; p=0.019). Fewer proteins involved in cellular
redox homeostasis (n=6; p=0.0017), response to endoplasmic reticulum stress (n=7;
p=0.00028) and protein folding (n=10; p<0.00001) were identified in sapatinib-treated
tumours compared with vehicle-treated tumours (fig 4.7 B).
As cellular iron homeostasis was the only GO term upregulated in sapatinib-treated
tumours compared with vehicle-treated tumours, it was decided that this represented
a good avenue to investigate. To understand if the proteins identified by proteomics
were located in the tumour tissue or the surrounding non-tumour tissue, including the
stromal compartment, analysis was divided into tumour and non-tumour staining.
Further validation of the proteins identified and involved in cellular iron homeostasis by
IHC confirmed increased ceruloplasmin (fig 4.8 A, B and I) in sapatinib-treated tumours.
No significant difference could be seen in levels of ferritin heavy chain (fig 4.8 C, D and
J) or ferritin light chain (fig 4.8 E, F and K). Heme oxygenase-1 was also significantly
upregulated in sapatinib-treated tumours (HO-1; fig 4.8 E, F and K).
Ferritins and HO-1 are known to have roles in the nucleus. [199–201] As a result, we looked
specifically at the nuclear expression of these proteins. The number of positive nuclei
in tumour sections stained with ferritin heavy chain, ferritin light chain and HO-1 was
quantified. This revealed no difference in levels of nuclear ferritin heavy chain (fig 4.9 A)
or nuclear ferritin light chain (fig 4.9 B). However, there was a significant increase in
nuclear HO-1 in sapatinib-treated tumours, but not in the non-tumour tissue (fig 4.9 C).
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QPCR was performed to evaluate the regulation of ceruloplasmin, ferritin heavy and light
chains, and HO-1 at the transcriptional level. This revealed no significant differences
in transcript levels of ceruloplasmin, ferritin heavy chain, ferritin light chain and HO-1
between vehicle-treated and sapatinib-treated tumours (fig 4.10 A).
As cellular iron homeostasis was identified as upregulated by GO terms (fig 4.7 B), iron
content and the location of ferric iron (Fe3+) within the tumours was assessed. Using
Perls’ ferric iron stain revealed significantly increased ferric iron in the non-tumour
tissue surrounding sapatinib-treated tumours (fig 4.11 A-C). Due to the presence of
significant deposits of ferric iron in the non-tumourous tissue, an iron assay was performed
to quantify levels of total iron, ferrous iron (Fe2+) and ferric iron. This revealed no
significant differences between vehicle-treated and sapatinib-treated tumours (fig 4.11
D).
As no difference could be seen in the quantity of different iron species between vehicle-
treated and sapatinib-treated tumours, cellular iron importers and exporters were
analysed. Transferrin receptor and divalent metal transporter 1 (DMT1) are the main
iron importers, whereas ferroportin is the only iron exporter identified thus far. [134,202]
Levels of these three proteins were assessed by IHC.
This analysis showed similar levels of the iron importers transferrin receptor and DMT1
(fig 4.12 A–D, G and H), but increased expression of the iron exporter ferroportin
(fig 4.12 E, F and I).
4.5 Changes in iron storage proteins are seen in
short-term treatments with sapatinib
To determine if the changes associated with cellular iron homeostasis seen in sapatinib-
treated tumours growing through the drug could be seen in tumours soon after treatment,
MMTV-NIC-PTEN+/- mice treated with vehicle (1% Tween 80 in PBS) or sapatinib
(100 mg/kg with 1% Tween 80 in PBS) for three days, once tumours had reached ≥0.3
cm3, were assessed by IHC.
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This revealed that no increase in ceruloplasmin was present (fig 4.13 A, B and I). However,
an increase could be seen in ferritin heavy chain (fig 4.13 C, D and J) and ferritin light
chain (fig 4.13 E, F and K). No increase could be seen in HO-1 (fig 4.13 G, H and L).
To determine if similar changes in iron deposition and iron transporters could be seen
from short-term treatments as is seen in long-term treatments, IHC was performed. This
analysis revealed no difference in levels of ferric iron in the tumour or non-tumour cells
(fig 4.14 A, B and I). Additionally, no difference could be seen in levels of transferrin
receptor and DMT1 (fig 4.14 C–F, J and K). However, tumours treated for 3 days with
sapatinib did show increased expression of ferroportin (fig 4.13 G, H and L).
4.6 Sapatinib-resistant fragment-derived tumours with an
epithelial morphology do not have altered iron
homeostasis
Sapatinib-resistant fragment-derived tumours had undergone EMT in 50% of cases
(chapter 3). It is currently unknown what the mechanism of resistance is in the remaining
50% of tumours which are morphologically similar to vehicle-treated fragment-derived
tumours. To ascertain if the mechanism of resistance is the same mechanism seen in
sapatinib-treated spontaneous tumours, IHC was performed for the proteins identified
by proteomics. This revealed no differences in the levels of ceruloplasmin, ferritin heavy
and light chains, and HO-1 (fig 4.15).
Sapatinib-treated spontaneous tumours also showed increased iron deposits in the non-
tumour compartment of the tissue. To confirm if the same could be seen in sapatinib-
resistant fragment-derived tumours, Perls’ ferric iron stain was performed. This showed
no changes in levels of ferric iron in either the tumour tissue, or the non-tumour tissue
(fig 4.16 A, B and I). Additionally, no changes could be seen in the levels of transferrin
receptor, DMT1 or ferroportin in the tumours (fig 4.16).
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Figure 4.6. Sapatinib-treated tumours have increased levels of phospho-SMAD1/5.
Heatmap of (A) all results and (B) significant results from reverse phase protein array (RPPA)
analysis of index tumours from MMTV-NIC-PTEN+/- mice treated with vehicle (n=5) or sapatinib
(n=5). Results presented as log2 fold change (sapatinib/vehicle). Multiple t-tests, Sidak-
Bonferroni post-hoc test, p<0.05. (C and D) Representative immunohistochemical (IHC)
staining of phosphorylated mothers against decapentaplegic homolog 1/5/8 (pSMAD1/5/8;
vehicle: n=27; sapatinib: n=11). Scale bar: 50 µm. Quantification of (E) pSMAD1/5/8 IHC
staining by Definiens Architect. Vehicle non-tumour was compared with sapatinib non-tumour,
vehicle tumour was compared with sapatinib tumour. Results presented as mean ± standard
deviation. Kruskal-Wallis test, Dunn’s post-hoc test, not significant = NS. (F) Western blot
analysis of SMAD1, SMAD5 and pSMAD1/5 in index tumours from MMTV-NIC-PTEN+/- mice
treated with vehicle or sapatinib. B-actin was used as a loading control (G) Quantification of
pSMAD1/5:SMAD1+SMAD5. Results presented as median ± interquartile range. Two-tailed
Mann-Whitney test, not significant = NS. Detailed results can be found in table A.5 and table A.6.
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Figure 4.7. Proteomics analysis reveals alterations in cellular iron homeostasis in
sapatinib-treated tumours. Index tumours from MMTV-NIC-PTEN+/- mice treated with vehicle
(n=4) or sapatinib (n=5) were subject to liquid chromatography-tandem mass spectrometry
(LC-MS/MS). Protein identification and quantitation were performed using MaxQuant. (A)
Volcano plot of proteins identified by MaxQuant. Highlighted are proteins associated with
cellular iron homeostasis, ferritin heavy chain (FTH), ferritin light chain (FTL), ceruloplasmin
(CP) and heme oxygenase-1 (HO-1). Dotted lines represent p of 0.05 and 2-fold ratio. (B)
Bar chart showing significantly upregulated gene ontology (GO) terms related to proteins that
were differentially regulated between vehicle-treated and sapatinib-treated tumours. Red bars
represent GO terms upregulated in sapatinib-treated tumours, whereas blue bars represent
those downregulated in sapatinib-treated tumours. Differentially regulated genes (table B.1)
were selected as those which showed >2-fold change and p<0.05, as determined by MaxQuant,
Wilcoxon-Mann-Whitney test. Benjamini-Hochberg corrected p-values and GO terms obtained
from DAVID. [198]
88
Figure 4.8. Sapatinib-treated tumours from MMTV-NIC-PTEN+/- mice have increased
ceruloplasmin and heme oxygenase-1. Immunohistochemistry (IHC) was performed on
tumours from MMTV-NIC-PTEN+/- mice treated with vehicle or sapatinib. Representative IHC
staining of (A–B) ceruloplasmin (vehicle: n=20; sapatinib: n=12), (C–D) ferritin heavy chain
(vehicle: n=18; sapatinib: n=10), (E–F) ferritin light chain (vehicle: n=23; sapatinib: n=10)
and (G–H) heme oxygenase-1 (HO-1; vehicle: n=23; sapatinib: n=9). Scale bar: 50 µm.
Quantification of cytoplasmic (I) ceruloplasmin, (J) ferritin heavy chain, (K) ferritin light chain
and (L) HO-1 IHC staining by Definiens Architect. Vehicle non-tumour was compared with
sapatinib non-tumour, vehicle tumour was compared with sapatinib tumour. Results presented
as mean ± standard deviation. Kruskal-Wallis test, Dunn’s post-hoc test, not significant = NS,
p<0.05=* , p<0.01=**. Detailed results can be found in table A.6.
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Figure 4.9. Sapatinib-treated tumours from MMTV-NIC-PTEN+/- mice have increased
nuclear heme oxygenase-1. Immunohistochemistry (IHC) was performed on tumours from
MMTV-NIC-PTEN+/- mice treated with vehicle or sapatinib. Quantification of nuclear (A) ferritin
heavy chain, (B) ferritin light chain and (C) heme oxygenase-1 (HO-1) IHC staining by Definiens
Architect. Vehicle non-tumour was compared with sapatinib non-tumour, vehicle tumour was
compared with sapatinib tumour. Results presented as mean ± standard deviation. Kruskal-
Wallis test, Dunn’s post-hoc, not significant = NS, p<0.05=*. Detailed results can be found in
table A.6.
Figure 4.10. No difference can be seen in levels of ceruloplasmin, heme oxygenase-
1 or ferritin heavy and light chains at the transcript level. (A) Quantitative PCR was
performed on tumours from MMTV-NIC-PTEN+/- mice treated with vehicle (n=9) or sapatinib
(n=10). Ceruloplasmin (Cp), ferritin heavy chain (Fth), ferritin light chain (Ftl) and heme
oxygenase-1 (Ho-1) messenger RNA (mRNA) levels were analysed and normalised to levels of
β-2 microglobulin (B2m) mRNA. Results presented as scatter plot with median ± interquartile
range. Two-tailed Mann-Whitney tests, not significant = NS. Detailed results can be found in
table A.5.
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Figure 4.11. Ferric iron deposits can be seen in the non-tumour tissue surrounding
sapatinib-treated tumours. Perls’ ferric iron stain was performed on tumours from MMTV-NIC-
PTEN+/- mice treated with vehicle (n=19) or sapatinib (n=10). (A-B) Representative Perls’ ferric
iron stain. Scale bar: 50 µm. Quantification of (C) Perls’ ferric iron stain by Definiens Architect.
Vehicle non-tumour was compared with sapatinib non-tumour, vehicle tumour was compared
with sapatinib tumour. Results presented as mean ± standard deviation. Kruskal-Wallis test,
Dunn’s post-hoc test, not significant = NS, p<0.001=***. (D) An iron assay was performed
on tumours from vehicle-treated (n=11) and sapatinib-treated (n=9) mice. Iron levels were
normalised to protein content. Results presented as scatter plot with median ± interquartile
range. Kruskal-Wallis test, Dunn’s post-hoc test, not significant = NS. Detailed results can be
found in table A.5 and table A.6.
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Figure 4.12. Sapatinib-treated MMTV-NIC-PTEN+/- tumours have increased levels of iron
exporter, ferroportin, in tumour cells. Representative immunohistochemical (IHC) staining
of (A–B) transferrin receptor (vehicle: n=26; sapatinib: n=11), (C–D) divalent metal transporter
1 (DMT1; vehicle: n=25; sapatinib: n=9) and (E–F) ferroportin (vehicle: n=25; sapatinib: n=11).
Scale bar: 50 µm. Quantification of (G) transferrin receptor, (H) DMT1 and (I) ferroportin by
Definiens architect. Results presented as mean ± standard deviation. Two-tailed Mann-Whitney
test, not significant = NS, p<0.01=**. Detailed results can be found in table A.5.
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Figure 4.13. Tumours treated with sapatinib for three days have increased ferritin.
Representative IHC staining of (A–B) ceruloplasmin (vehicle: n=8; sapatinib: n=19), (C–D)
ferritin heavy chain (vehicle: n=8; sapatinib: n=15), (E–F) ferritin light chain (vehicle: n=8;
sapatinib: n=19) and (G–H) heme oxygenase-1 (HO-1; vehicle: n=8; sapatinib: n=19). Scale
bar: 50 µm. Quantification of (I) ceruloplasmin, (J) ferritin heavy chain, (K) ferritin light chain and
(L) HO-1 by Definiens Architect. Results presented as mean ± standard deviation. Two-tailed
Mann-Whitney test, not significant = NS, p<0.05=*, p<0.01=**. Detailed results can be found in
table A.7.
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Figure 4.14. Tumours treated with sapatinib for three days do not show differences in
iron deposition but have increased iron exporter ferroportin. (A–B) Representative Perls’
ferric iron stain (vehicle: n=8; sapatinib: n=21). Representative immunohistochemical (IHC)
staining of (C–D) transferrin receptor (vehicle: n=8; sapatinib: n=19), (E–F) divalent metal
transporter 1 (DMT1; vehicle: n=8; sapatinib: n=19) and (G–H) ferroportin (vehicle: n=8;
sapatinib: n=19). Scale bar: 50 µm. Quantification of (I) Perls’ ferric iron stain by Definiens
Architect. Vehicle non-tumour was compared with sapatinib non-tumour, vehicle tumour was
compared with sapatinib tumour. Results presented as mean ± standard deviation (SD).
Kruskal-Wallis test, Dunn’s post-hoc test, not significant = NS. Quantification of (J) transferrin
receptor, (K) DMT1 and (L) ferroportin by Definiens Architect. Results presented as mean ± SD.
Two-tailed Mann-Whitney test, not significant = NS, p<0.05=*. Detailed results can be found in
table A.5 and table A.7.
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Figure 4.15. Sapatinib-treated fragment-derived tumours that have not undergone
EMT show no differences in proteins involved in iron homeostasis. Representative
immunohistochemical (IHC) staining of (A–B) ceruloplasmin (vehicle: n=9; sapatinib: n=3),
(C–D) ferritin heavy chain (vehicle: n=5; sapatinib: n=2), (E–F) ferritin light chain (vehicle: n=7;
sapatinib: n=3) and (G–H) heme oxygenase-1 (HO-1; vehicle: n=8; sapatinib: n=3). Scale bar:
50 µm. Quantification of (I) ceruloplasmin, (J) ferritin heavy chain, (K) ferritin light chain and
(L) HO-1 by Definiens Architect. Results presented as mean ± standard deviation. Two-tailed
Mann-Whitney test, not significant = NS. Detailed results can be found in table A.8.
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Figure 4.16. Sapatinib-treated fragment-derived tumours that have not undergone EMT
have no changes in ferric iron deposits or iron transporters. Perls’ ferric iron stain was
performed on fragment-derived tumours resistant to sapatinib, or treated with vehicle. (A–B)
Representative Perls’ ferric iron stain (vehicle: n=8; sapatinib: n=3). Scale bar: 50 µm.
Representative immunohistochemical (IHC) staining of (C–D) transferrin receptor (vehicle: n=6;
sapatinib: n=3), (E–F) divalent metal transporter 1 (DMT1; vehicle: n=7; sapatinib: n=2) and
(G–H) ferroportin (vehicle: n=6; sapatinib: n=2). Scale bar: 50 µm. Quantification of (I)
Perls’ ferric iron stain by Definiens Architect. Vehicle non-tumour was compared with sapatinib
non-tumour, vehicle tumour was compared with sapatinib tumour. Results presented as mean
± standard deviation (SD). Kruskal-Wallis test, Dunn’s post-hoc test, not significant = NS.
Quantification of (J) transferrin receptor, (K) DMT1 and (L) ferroportin by Definiens Architect.
Results presented as mean ± SD. Two-tailed Mann-Whitney test, not significant = NS. Detailed
results can be found in table A.5 and table A.8.
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4.7 Discussion
Using a GEMM of spontaneous HER2-driven breast cancer to study resistance mechanisms
allows cell-intrinsic and cell-extrinsic factors that can influence the development of
resistance to be studied. [203] This model accurately recapitulates the histopathology of
human cancer, making findings more translatable to the clinic. [204] In this chapter, we
have shown sapatinib-treated tumours from a mouse model of HER2-positive breast
cancer have perturbed iron storage and increased expression of proteins associated with
cellular iron homeostasis.
4.7.1 Mouse models of HER2-positive breast cancer
The most common model of HER2-positive breast cancer utilises oncogenic rat Neu, under
the control of the MMTV promoter to ensure expression is localised to the mammary
compartment. [147] MMTV-Neu mice develop rapidly growing mammary tumours, but the
initial period before mice develop these tumours is a median 197 days. To overcome this,
MMTV-NIC mice are utilised, simultaneously expressing Neu and Cre recombinase, with
an IRES element, allowing the expression of other oncogenes of interest or inactivation
of tumour suppressor genes, such as Pten. [149]
MMTV-NIC-PTENflox/flox mice develop mammary tumours in 43 days, compared with
197 days with no loss of Pten. [149] In our model, MMTV-NIC-PTEN+/- mice develop
tumours in a median of 102 days. [84] This longer latency period likely reflects the
time taken to acquire a ‘second hit’ before tumour progression. [205] As mentioned in
chapter 3, loss or reduction of PTEN results in worse progression-free survival and
increased resistance to targeted therapies. [109] This resistance profile is seen in the
MMTV-NIC-PTENflox/flox model: the absence of PTEN renders tumours de novo
resistant to trastuzumab and lapatinib, which can be targeted with AKT and MAPK
inhibitors. [176,206] Using a heterozygous Pten model allows the investigation of resistance
mechanisms in tumours that have retained some expression of PTEN (fig 4.4).
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4.7.2 Modelling resistance to HER2-targeted therapies
Heterogeneity within tumours presents a unique challenge for clinicians. [207] Despite
similar histopathology, tumours can be comprised of many different clones with different
mutational landscapes. [208–211] Once treatment has begun, resistant clones may emerge
and become the dominant clonal population within a tumour. [210] This may have occurred
in this model, as strong HO-1 could be seen in some cells within tumours treated with
sapatinib for three days, although the majority did not have increased expression and
were comparable to vehicle-treated tumours (fig 4.13).
The intratumoural heterogeneity in the MMTV-NIC-PTEN+/- model is advantageous,
as this more accurately reflects patients’ disease. [209,211] Unlike the sapatinib-resistant
fragment-derived tumour mouse model, sapatinib-treated spontaneous tumours did not
undergo EMT (fig 4.3). This may also reflect different clonal populations within the
tumour giving rise to different resistance mechanisms. [212] In particular, the different
treatment regimens between the two models may have encouraged the development of
different resistance mechanisms; in fragment-derived tumours, the cyclical treatment
regimen allowed tumours time to recover from treatment and adapt over time. Meanwhile,
the constant treatment of the spontaneous tumours did not allow for this. Thus, different
clonal populations present in the fragment-derived and spontaneous tumours prior to
treatment may have had selective advantages when exposed to the differing treatment
regimens.
Due to the nature of the MMTV-NIC-PTEN+/- spontaneous tumour model, it is not
possible to fully elucidate whether the resistance seen in these tumours is de novo or
acquired resistance. The fragment tumour model (chapter 3) represents a model of
acquired resistance; the treatment regimen used promotes the development of acquired
resistance by allowing the tumours to grow after a period of response, until tumours no
longer responded and grew through sapatinib treatment. [84]
It is possible that some tumour cells in the MMTV-NIC-PTEN+/- spontaneous model
were de novo resistant. [213] However, the long latency period seen before rapid growth
(fig 4.1 C) could be due to the time taken for the tumours to acquire resistance. With
the data currently available, it is difficult to say if these tumours had de novo or acquired
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resistance. Increases in some proteins associated with cellular iron homeostasis were
seen after short-term treatment with sapatinib. These initial changes may represent de
novo resistance in some clonal populations. However, changes associated with acquired
resistance may begin soon after treatment initiation.
Signalling downstream of HER2 may have been necessary tumour cells to survival and
failure to maintain signalling may have led to cell death and tumour regression in the
tumours which responded to drug and were no longer palpable. However, due to the
lack of tissue samples from responding or fully regressed tumours, it is not possible to
conclude what differences may have lay between tumours which progressed and regressed.
As each mouse is capable of developing up to ten tumours simultaneously, it can be
difficult to fully assess each tumour which presents.
4.7.3 Increased cell size does not indicate apoptosis in
sapatinib-treated tumours
Resistance to cancer therapies is classed as the failure of cancer cells to respond to a
drug intended to kill or weaken them. [213] With this in mind, most sapatinib-treated
tumours can be classed as resistant due to their progressive disease status (fig 4.1 B), as
stated in Eisenhauer et al. [193].
Increased cell size (oncosis) could be seen in sapatinib-treated tumours, whereas vehicle-
treated and untreated tumours did not have oncosis (fig 4.2 F). Oncosis can be caused
by many things, but its relevance in cancer is still undetermined. [214] Cell size can be
altered when cells are beginning to enter a cell death pathway. [215]
Apoptosis is associated with a smaller cell size, as cells begin to fragment and apoptotic
bodies are phagocytosed. [216–218] Thus, it is reasonable to assume that cells in sapatinib-
treated tumours are not undergoing apoptosis. However, without further investigation
by assessing levels of cleaved caspase 3, associated with the irreversible stage of apoptotic
cell death, [219] we are unable to definitively conclude whether sapatinib-treated tumours
have reduced apoptosis or not.
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Lapatinib acts by halting cell-cycle progression. [220] Treatment of BT474 and SKBR3
HER2 breast cancer cell lines with lapatinib have shown an increase in anti-apoptotic
protein B-cell lymphoma-extra large (Bcl-xL). [221] Thus, it is reasonable to assume
that sapatinib-treated tumours may have similar changes, evading regulated cell death.
However, no significant changes could be seen in proteins associated with apoptosis by
RPPA (fig 4.6).
Oncosis has been linked to non-apoptotic regulated cell death and is a morphological
feature of necroptosis. [215] During necroptosis, organelle swelling, plasma membrane
rupture and chromatin condensation can also be seen. [215,222] It is possible that sapatinib-
treated cells have a larger size due to entering the reversible stage of necrosis. This will be
investigated more fully in the following chapters. In another form of cell death, ferroptosis,
one defining morphological feature is oncosis, as well as shrinking mitochondria and
bioenergetic changes. [223]
In normal cells, increased nuclear size strongly correlates with polyploidy, but this
correlation is not as strong in cancer cells. [214] However, in normal physiology and cancer,
increased nuclear size does link more directly to overall cell size and cytoplasmic content.
As cell size is increased, it is expected that nuclear size would also be increased in
sapatinib-treated tumours due to the correlation between nuclear and cell size. [214]
4.7.4 Sapatinib is inhibiting pathways downstream of HER2
Previous work by Creedon et al. [84] has shown decreased phospho-AKT/AKT in both
MMTV-NIC-PTEN+/- and MMTV-NIC-PTEN+/+ mice treated with sapatinib for three
days. These results are in accordance with the results in this chapter which show
decreased phospho-AKT by IHC and RPPA (fig 4.5, 4.6). This is consistent with the
expected pathway inhibition resulting from the inhibition of HER2 phosphorylation as a
consequence of sapatinib treatment.
MAPK pathway signalling is often increased due to increased HER2 signalling. This is
mainly, but not exclusively, activated upon EGFR/HER2 heterodimer signalling. RAS
GTPase is activated by phosphorylated EGFR/HER2, resulting in a phosphorylation
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cascade through RAF, MEK and ERK1/2. This then leads to transcriptional regulation
of cell cycle progression by proteins such as c-MYC and CREB. [224]
Previous published data in the MMTV-NIC-PTEN+/- model showed decreased levels of
phospho-ERK. [84] The results presented here show similar levels of phospho-ERK across
all tumours (fig 4.5, 4.6). However, in Creedon et al. [84], changes were seen after short-
term treatments, whereas the data presented here are from long-term treatment with
sapatinib. It is likely that tumours initially responding to sapatinib would have decreased
phospho-ERK and phospho-AKT signalling, but upon development of resistance, these
signalling pathways may become active again.
In HER2-positive cell lines, high EGFR and low HER3 expression levels have been
shown to correlate with enhanced MAPK pathway dependence and lower PI3K/AKT
pathway signalling. [225] Using the same classifications used in Kirouac et al. [225], more
dependence on the PI3K/AKT pathway compared with the MAPK pathway would be
predicted in the MMTV-NIC-PTEN+/- model.
This supports the finding that levels of ERK phosphorylation did not change, as previous
characterisation of 3-day treatments has shown undetectable levels of EGFR and no
change in levels of HER3 after sapatinib treatment. [84,165] However, Kirouac et al. [225]
did not investigate the signalling changes that may occur in HER2-positive breast cancers
once treated with HER2-targeted therapies. Thus, it is difficult to fully predict which
signalling changes may be utilised by our model using this classifier.
4.7.5 Resistance to sapatinib is associated with an iron storage
phenotype in MMTV-NIC-PTEN+/- mice
As iron has been shown to be associated with increased tumour growth and cancer
risk, [226–228] treatment with iron chelating agents would disrupt the pro-proliferative
effects of iron. However, increased free iron within cells is key for ferroptosis to occur. In
these circumstances, iron chelation would result in less ferroptotic cell death. The results
presented in this chapter point towards altered iron storage as a mechanism to avoid
cell death, with no evidence of lower proliferation in sapatinib-treated tumours despite
extracellular iron deposition. Additionally, levels of iron were similar between treatment
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groups when levels of iron species were assessed; this is likely due to the differences in
technique: Perls’ stain is performed on a fixed tissue section and assesses levels of free
ferric iron, whereas the iron assay was performed on a piece frozen tissue and assesses
all iron present in the sample.
Dysregulation of the hepcidin-ferroportin axis results in tissue-specific iron overload;
decreased levels of hepcidin, HO-1 and ceruloplasmin have all shown similar iron
deposition phenotypes. [135,229–231] On the contrary, our data show iron deposition with
increased levels of HO-1, ceruloplasmin and ferroportin (fig 4.8, 4.11, 4.12). This
highlights the differences that can occur in different pathologies and model systems.
Of note is the location of the iron: in these studies, iron can be seen within the
cells, [135,229,230] whereas in our model, the iron is deposited extracellularly (fig 4.11 A
and B).Wu et al. 232 evidenced that increased resistance to cisplatin in ovarian cancer cell
lines was associated with expression of NRF2. However, they noted NRF2 and ferroportin
expression were inversely correlated. Additionally, overexpression of ferroportin reversed
NRF2-induced resistance. These results contradict our own, which show increased HO-1,
an NRF2 target gene, [233] and increased ferroportin.
4.7.6 Iron-associated proteins may protect cells from oxidative damage
Increased ferric iron deposits outside of the tumour cells may aid in avoiding ferroptosis,
an iron-dependent form of cell death characterised by oncosis, lipid peroxidation and
shrunken mitochondria. [223,234] HO-1 has been shown to protect against ferroptotic cell
death, [235] and is part of the NRF2-induced oxidative stress response, resulting in the
removal of reactive oxygen species (ROS). [233]
Despite having higher levels of ferric iron deposited in non-tumourous tissue, sapatinib-
treated tumours may contain fewer ferritin and hemosiderin complexes which would not
be identified by Perls’ ferric iron stain. [236] This is evident when assessing the total iron
species present in the tumours, as no difference could be seen between treatment groups
in levels of total, ferrous or ferric iron (fig 4.11). Nuclear HO-1 has been previously
linked to a reduction in the oxidative stress response via transcriptional activation of
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several factors involved in the oxidative stress response and modulation of NRF2, a key
transcriptional activator in response to increased oxidative stress. [200,237]
HO-1 could be acting to protect the cell from damage caused by ROS. GO terms
identified as down-regulated in sapatinib-treated tumours compared with vehicle-treated
tumours are indicative of reduced oxidative stress in sapatinib-treated tumours (fig 4.7).
With this in mind, it is possible that nuclear HO-1 is protecting cells against damage
from ROS. This will be further investigated in the following chapters.
Ceruloplasmin can be membrane bound or secreted and is involved in converting ferrous
iron to ferric iron. [134] This supports the hypothesis that sapatinib-treated tumours
have increased iron export through ferroportin (fig 4.12), which is also evidenced by the
increased extracellular iron deposition seen in these tumours (fig 4.11).
As there are differences in where ferritin heavy and light chain are located within the
cells, it is unlikely that the two subunits are forming ferritin complexes with ferric iron.
This would result in free iron being available in the cells, which would cause damage to
cellular components through the formation of hydroxyl radicals. [133,238]
4.7.7 Summary
To summarise, our data reveal a role for iron homeostasis in vivo in response to sapatinib.
We have shown that mice treated with the HER2-targeted tyrosine kinase inhibitor,
sapatinib, develop iron deposits in the surrounding non-tumour tissue and show increased
levels of iron homeostasis related proteins, ceruloplasmin and HO-1, as well as the iron
export protein ferroportin. Together, this may give rise to protection from oxidative
stress and increased intracelluar ferrous iron induced by sapatinib treatment (fig 4.17).
Future studies will focus on the mechanistic role that HO-1 is playing with respect to
resistance and examine the possibility of iron modulation to overcome resistance in vivo.
Development of in vitro models of HO-1 overexpression and further investigation of
HO-1’s role in vivo, will allow a better understanding of the potential links between the
proteins identified and perturbed iron homeostasis.
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Figure 4.17. Sapatinib-treated spontaneous tumours have increased HO-1, ferroportin
and ceruloplasmin. We hypothesise that after treatment with HER2-target tyrosine kinase
inhibitors, heme oxygenase-1 (HO-1) becomes upregulated, increasing free iron in the labile
iron pool (LIP). To avoid oxidative damage from free ferrous iron (Fe2+), ferroportin transports




Altering dietary iron intake affects
sapatinib resistance
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Many cancer patients initially present with functional iron deficiency (FID), which may
or may not be related to anaemia. These patients have worse Eastern Cooperative
Oncology Group (ECOG) scores and survival outcomes than patients without FID at
the time of diagnosis. [239] As sapatinib-treated tumours from MMTV-NIC-PTEN+/-
displayed altered iron storage, we investigated the role that altered dietary iron may
have on the development of resistance to sapatinib in vivo.
To study the effect of dietary iron intake, MMTV-NIC-PTEN+/- mice were randomised
to receive a control or iron-deficient diet once a palpable tumour developed. After
four days, mice were randomised to receive vehicle (1% Tween80 in PBS; p.o., q.d.) or
sapatinib (100 mg/kg, with 1% Tween80 in PBS; p.o., q.d.).
This chapter will explore these subsequent aims:
• Characterise tumour growth and response to sapatinib in mice fed an iron-deficient
diet.
• Assess changes associated with iron homeostasis seen in chapter 4.
5.1 Tumour growth is not impeded by an iron-deficient diet
Detailed results for this chapter can be found in tables A.9–A.10.
MMTV-NIC-PTEN+/- mice were randomised to receive a control or iron-deficient diet
once a tumour was ≥0.1 cm3. Four days after the diet commenced, mice were randomised
to receive vehicle (1% Tween80 in PBS; p.o., q.d.) or sapatinib (100 mg/kg, with 1%
Tween80 in PBS; p.o., q.d.). Once any tumour reached 15 mm in diameter, mice were
sacrificed.
Vehicle-treated mice on a iron-low control diet had a median survival time similar to
vehicle-treated mice on an iron-deficient diet (fig 5.1 A and B; median survival including
censored: vehicle iron-low control diet: 21 days; vehicle iron-deficient diet: 22.5 days;
NS; median tumour-related survival: vehicle iron-low control diet: 21 days; vehicle
iron-deficient diet: 22.5 days; NS). Sapatinib-treated mice on both diets had a longer
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median survival times than vehicle-treated mice (fig 5.1 A and B; median survival
including censored: sapatinib iron-low control diet: 133 days; sapatinib iron-deficient
diet: 56 days; NS; median tumour-related survival: sapatinib iron-low control diet: 82.5
days; sapatinib iron-deficient diet: 38 days; NS).
Although there was a trend towards decreased survival in sapatinib-treated mice on
an iron-deficient diet, this was not significant. Due to this, we looked at growth of
the individual tumours within the different cohorts. Growth kinetics of index tumours
from each mouse sacrificed due to tumour burden shows that tumours from vehicle-
treated mice in both diet arms grew rapidly after initial tumour onset (fig 5.2 A and
B). Sapatinib-treated mice on a iron-low control diet had two distinct groups; those
whose tumours grew through the drug treatment quickly and those with a longer period
of latency before growing through the drug treatment (fig 5.2 C). Index tumours from
sapatinib-treated mice on an iron-deficient diet had growth more similar to that seen in
vehicle-treated mice, with no extended period of latency as seen in sapatinib-treated
mice on a iron-low control diet (fig 5.2 D).
Based on guidelines set out in Eisenhauer et al. [193], 151 (86.78%) of all tumours were
classed as progressive disease (fig 5.3 A; vehicle iron-low control diet: n=39 [95.12%];
vehicle iron-deficient diet: n=36 [92.31%]; sapatinib iron-low control diet: n=37 [77.08%];
sapatinib iron-deficient diet: n=39 [84.78%]). Nine tumours (5.17%) were between 20%
increase in volume and a 30% decrease, classed as stable disease (vehicle iron-low control
diet: n=2 [4.87%]; vehicle iron-deficient diet: n=2 [5.13%]; sapatinib iron-low control
diet: n=2 [4.17%]; sapatinib iron-deficient diet: n=3 [6.52%]). Four tumours (2.30%)
had partial responses to treatment (vehicle iron-low control diet: n=0 [0%]; vehicle
iron-deficient diet: n=0 [0%]; sapatinib iron-low control diet: n=3 [6.25%]; sapatinib
iron-deficient diet: n=1 [2.08%]). Ten tumours had pCR to treatment (vehicle iron-low
control diet: n=0 [0%]; vehicle iron-deficient diet: n=1 [2.56%]; sapatinib iron-low
control diet: n=6 [12.50%]; sapatinib iron-deficient diet: n=3 [6.52%]).
Analysis of the percentage volume change from baseline, when each tumour was first
palpable, shows that there was a significant difference in tumour volume between vehicle-
treated tumours from mice on a iron-low control diet and sapatinib-treated tumours from
mice on both a iron-low control diet and an iron-deficient diet (fig 5.3 B). Vehicle-treated
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Figure 5.1. An iron-deficient diet reduces survival time in sapatinib-treated mice. MMTV-
NIC-PTEN+/- mice on a control or iron-deficient diet were treated with vehicle or sapatinib. The
diet began at the onset of the first palpable tumour. Drug treatment began four days after the
diet commenced. (A, i) Kaplan-Meier curve showing survival time from the commencement of
a control or iron-deficient diet in all randomised MMTV-NIC-PTEN+/- mice treated with vehicle
or sapatinib. (A, ii) Log-rank test comparing each group within (A, i). Not significant = NS,
p<0.05=*. (B, i) Kaplan-Meier curve showing survival time to tumour-related death from the
commencement of a control or iron-deficient diet in MMTV-NIC-PTEN+/- mice treated with
vehicle or sapatinib. (B, ii) Log-rank test comparing each group within (B, i). Not significant =
NS, p<0.05=*, p<0.01=**, p<0.001=***.
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Figure 5.2. Index tumours from sapatinib-treated mice on an iron-deficient diet have a
shorter period of latency compared with sapatinib-treated mice on a iron-low control
diet. Graphs showing the growth curves of index tumours in MMTV-NIC-PTEN+/- mice on a
control or iron-deficient diet, treated with vehicle or sapatinib. The diet began at the onset of the
first palpable tumour. Drug treatment began four days after the diet commenced. (A) iron-low
control diet, vehicle treatment (n=6). (B) Iron-deficient diet, vehicle treatment (n=6). (C) iron-low
control diet, sapatinib treatment (n=6). (D) Iron-deficient diet, sapatinib treatment (n=7).
tumours from mice on an iron-deficient diet also showed significant differences when
compared with sapatinib-treated tumours from mice on a iron-low control diet. However,
there was no significant difference between vehicle-treated and sapatinib-treated tumours
from mice on an iron-deficient diet.
Despite changes in tumour volume, there was no significant difference in the number
of tumours that developed per mouse in each treatment group over the course of the
experiment (fig 5.4 A; median number of tumours [CI]: vehicle iron-low control diet: 7
[4.40–9.26]; vehicle iron-deficient diet: 8 [3.78–9.22]; sapatinib iron-low control diet: 5
[1.00–8.00]; sapatinib iron-deficient diet: 4 [2.61–5.10]; NS). However, sapatinib-treated
mice on a iron-low control diet had significantly more tumours with pCR or which
had a decreasing volume for a minimum of seven days prior to sacrifice compared with
vehicle-treated mice on a iron-low control diet, classed as responding (fig 5.4 B; median
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Figure 5.3. An iron-deficient diet does not reduce change in tumour volume from
baseline compared with a iron-low control diet. MMTV-NIC-PTEN+/- mice on a control
or iron-deficient diet were treated with vehicle or sapatinib. The diet began at the onset of the
first palpable tumour. Drug treatment began four days after the diet commenced. (A) Waterfall
plot showing volume change from baseline (%) of all tumours from MMTV-NIC-PTEN+/- mice on
a control or iron-deficient diet, treated with vehicle or sapatinib, sacrificed due to tumour burden.
Dotted blue lines represent 20% increase, 30% decrease and 100% decrease in tumour volume
from baseline, respectively. (B) Kruskal-Wallis test, Dunns post-hoc test comparing tumour
volume in each group from (A). Not significant = NS, p<0.05=*, p<0.01=**, p<0.001=***.
tumours [CI]: vehicle iron-low control diet: 0 [0–0]; vehicle iron-deficient diet: 0 [0–2];
sapatinib iron-low control diet: 3 [0–4]; sapatinib iron-deficient diet: 1 [0–2]; p<0.05).
No significant difference could be seen between other groups.
To look for changes in iron due to the iron-deficient diet, an iron assay was performed to
assess changes in the quantities of iron species present in serum. Despite not reaching
significance, this showed a trend towards lower quantities of total and ferrous iron in
both sapatinib- and vehicle-treated mice on an iron-deficient diet compared with mice
on a iron-low control diet (fig 5.5).
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Figure 5.4. Sapatinib-treated mice on an iron-deficient diet have fewer responding
tumours than sapatinib-treated mice on a iron-low control diet. MMTV-NIC-PTEN+/- mice
on a control or iron-deficient diet were treated with vehicle or sapatinib (iron-low control diet,
vehicle; n=6; iron-deficient diet, vehicle: n=6; iron-low control diet, sapatinib: n=6; iron-deficient
diet, sapatinib: n=7). Drug treatment began four days after the diet commenced. (A) Graph
showing the number of tumours developed in each treatment group, from the first palpable
tumour to time of sacrifice. All groups compared with iron-low control diet, vehicle-treated
mice. Results presented as scatter plot with mean ± standard deviation (SD). Kruskal-Wallis
test, Dunn’s post-hoc test, not significant = NS. (B) Graph showing the number of tumours per
mouse during the whole treatment period that had fully regressed or had decreasing volume
for a minimum of 7 days prior to sacrifice. All groups compared with iron-low control diet,
vehicle-treated mice. Results presented as scatter plot with mean ± SD. Kruskal-Wallis test,
Dunn’s post-hoc test, p<0.05=*.
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Figure 5.5. MMTV-NIC-PTEN+/- mice on an iron-deficient diet have similar serum iron
levels as mice on a iron-low control diet. MMTV-NIC-PTEN+/- mice on a control or iron-
deficient diet were treated with vehicle or sapatinib. Drug treatment began four days after the
diet commenced. (A) An iron assay was performed on serum from mice in each treatment
group (iron-low control diet, vehicle; n=3; iron-deficient diet, vehicle: n=3; iron-low control diet,
sapatinib: n=3; iron-deficient diet, sapatinib: n=3). All groups compared with iron-low control
diet, vehicle-treated mice. Results presented as scatter plot with median ± interquartile range.
Kruskal-Wallis test, Dunn’s post-hoc test, not significant = NS. Detailed results can be found in
table A.9.
To summarise, an iron-deficient diet reduced survival time in sapatinib-treated mice
but had no effect on tumour growth of vehicle-treated tumours. Additionally, sapatinib-
treated mice on an iron-deficient diet had fewer responding tumours than sapatinib-
treated mice on a iron-low control diet. Despite the iron-deficient diet, mice showed no
significant changes in serum iron levels, but there was a trend towards lower total and
ferrous iron.
5.2 Tumours responding to sapatinib treatment have
changes in iron-related proteins and iron storage
Index tumours from MMTV-NIC-PTEN+/- mice on a control or iron-deficient diet
treated with vehicle or sapatinib were analysed by IHC for proteins identified as being
involved in cellular iron homeostasis (fig 4.7). This revealed no significant difference
in levels of ceruloplasmin in sapatinib-treated tumours as seen in the previous in vivo
experiment (fig 4.8). Furthermore, the iron-deficient diet had no significant effect on
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ceruloplasmin levels. Sapatinib-treated tumours from mice on a iron-low control diet
had increased staining, although this did not reach significance (fig 5.6 A–E and K).
Increased HO-1 was found in tumours from sapatinib-treated mice on a iron-low control
diet, reflecting the previous in vivo experiment (fig 4.8). However, only the responding
tumours had significantly increased HO-1, which most likely reflects the large variation
within the progressing sapatinib-resistant tumours from these mice (fig 5.6 F–J and
L). Index tumours from sapatinib-treated mice on an iron-deficient diet did not have
increased HO-1. It was not possible to analyse responding tumours from sapatinib-
treated mice on an iron-deficient diet, as material was only available from one tumour.
No difference can be seen in levels of ferritin heavy chain (fig 5.7 A–E and K). Tumours
from sapatinib-treated mice had a tendency towards increased ferritin light chain staining,
but this was not significant (fig 5.7 F–J and L).
Perls’ ferric iron stain was used to identify any changes in iron storage as seen in sapatinib-
treated tumours (fig 4.11 A–C). This revealed that all sapatinib-treated tumours, on
both diets, had increased iron deposition in non-tumour cells, as seen in the previous
experiment (fig 5.8 A–J). However, only tumours responding to sapatinib had significantly
increased iron within the tumour cells (fig 5.8 E and G). Interestingly, sapatinib-treated
tumours from both diets had similar extracellular iron deposits. Despite the changes
in iron deposition, no differences could be seen in levels of iron transporters. Levels
of transferrin receptor, DMT1 and ferroportin were not significantly different between
groups (fig 5.9 A–O, 5.10 A–C).
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Figure 5.6. Sapatinib-treated mice on an iron-deficient diet do not have increased HO-1.
MMTV-NIC-PTEN+/- mice on a control (C) or iron-deficient (ID) diet were treated with vehicle
or sapatinib. Drug treatment began four days after the diet commenced. Representative
immunohistochemical staining of (A–E) ceruloplasmin (iron-low control diet, vehicle; group A,
n=6; iron-deficient diet, vehicle: group B, n=6; iron-low control diet, sapatinib: group C, n=5;
iron-deficient diet, sapatinib: group D, n=5; responding tumours, iron-low control diet, sapatinib;
group Cr, n=6) and (F–J) heme oxygenase-1 (Group A: n=6; Group B: n=5; Group C: n=6;
Group D: n=7; Group Cr: n=6) in index tumours. Scale bar: 50 µm. Quantification of (K)
ceruloplasmin and (L) HO-1 by Definiens Architect. All groups compared with iron-low control
diet, vehicle-treated tumours. Results presented as mean ± standard deviation. Kruskal-Wallis
test, Dunn’s post-hoc test, not significant = NS, p<0.05=*. Detailed results can be found in
table A.10.
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Figure 5.7. Tumours from sapatinib-treated mice have increased ferritin light chain.
MMTV-NIC-PTEN+/- mice on a control (C) or iron-deficient (ID) diet were treated with vehicle
or sapatinib. Drug treatment began four days after the diet commenced. Representative
immunohistochemical staining of (A–E) ferritin heavy chain (iron-low control diet, vehicle; group
A, n=6; iron-deficient diet, vehicle: group B, n=5; iron-low control diet, sapatinib: group C, n=6;
iron-deficient diet, sapatinib: group D, n=6; responding tumours, iron-low control diet, sapatinib;
group Cr, n=7) and (F–J) ferritin light chain (Group A: n=6; Group B: n=5; Group C: n=6; Group
D: n=7; Group Cr: n=6) in index tumours. Scale bar: 50 µm. Quantification of (K) ferritin heavy
chain and (L) ferritin light chain by Definiens Architect. All groups compared with iron-low control
diet, vehicle-treated tumours. Results presented as mean ± standard deviation. Kruskal-Wallis
test, Dunn’s post-hoc test, not significant = NS. Detailed results can be found in table A.10.
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Figure 5.8. Tumours from sapatinib-treated mice have altered iron storage. MMTV-NIC-
PTEN+/- mice on a control (C) or iron-deficient (ID) diet were treated with vehicle or sapatinib.
Drug treatment began four days after the diet commenced. (A–E) Representative Perls’ ferric
iron stain (iron-low control diet, vehicle; group A, n=6; iron-deficient diet, vehicle: group B,
n=5; iron-low control diet, sapatinib: group C, n=5; iron-deficient diet, sapatinib: group D, n=7;
responding tumours, iron-low control diet, sapatinib; group Cr, n=8) in index tumours. Scale
bar: 50 µm. (F–H) Representative example of extracellular iron deposition. Scale bar: 25 µm.
Quantification of Perls’ ferric iron stain by Definiens Architect in (I) non-tumour and (J) tumour.
All groups compared with iron-low control diet, vehicle-treated tumours. Results presented as
mean ± standard deviation. Kruskal-Wallis test, Dunn’s post-hoc test, p<0.05=*, p<0.01=**.
Detailed results can be found in table A.10.
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Figure 5.9. Tumours from sapatinib-treated mice do not have differences in levels of
iron transporters. MMTV-NIC-PTEN+/- mice on a control (C) or iron-deficient (ID) diet were
treated with vehicle or sapatinib. Drug treatment began four days after the diet commenced.
Representative immunohistochemical staining of (A–E) transferrin receptor (iron-low control diet,
vehicle; group A, n=6; iron-deficient diet, vehicle: group B, n=5; iron-low control diet, sapatinib:
group C, n=6; iron-deficient diet, sapatinib: group D, n=5; responding tumours, iron-low control
diet, sapatinib; group Cr, n=6), (F–J) divalent metal transporter-1 (DMT1; Group A: n=6; group
B: n=4; group C: n=6; group D: n=5; group Cr: n=6) and (K–O) ferroportin (Group A: n=5; group
B: n=5; group C: n=6; group D: n=4; group Cr: n=5). Scale bar: 50 µm. Detailed results can be
found in table A.10.
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Figure 5.10. Tumours from sapatinib-treated mice have varied levels of iron transporters.
MMTV-NIC-PTEN+/- mice on a control (C) or iron-deficient (ID) diet were treated with vehicle
or sapatinib. Drug treatment began four days after the diet commenced. Quantification of
(A) transferrin receptor, (B) DMT1 and (C) ferroportin staining by Definiens Architect (iron-low
control diet, vehicle; group A; iron-deficient diet, vehicle: group B; iron-low control diet, sapatinib:
group C; iron-deficient diet, sapatinib: group D; responding tumours, iron-low control diet,
sapatinib; group Cr). All groups compared with iron-low control diet, vehicle-treated tumours.
Results presented as mean ± standard deviation. Kruskal-Wallis test, Dunn’s post-hoc test, not
significant = NS.
5.3 Discussion
Iron is involved in many cellular processes including respiration, DNA synthesis and
fatty acid metabolism, amongst other roles. [227,240] Here, we have shown that reducing
dietary iron intake alters the development of resistance to sapatinib, negating the need
for overexpression of HO-1, which is otherwise key in maintaining resistance.
5.3.1 Maintenance of serum iron levels can mask functional iron
deficiency
Short-term treatment with an iron-deficient diet over a 3-day period has been shown to
induce a non-anaemic iron-deficient state and alter hepatic gene expression, while long-
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term treatment showed some changes similar to initial short-term treatments in vivo. [241]
Other long-term treatments investigating the effect of iron-deficient diets on pathological
conditions were associated with changes in ferritin levels and lipid peroxidation, [242,243]
and increases in pro-angiogenic factors. [243]
Interestingly, long-term iron-deficient diets were not associated with differences in serum
iron levels, suggesting tissue specific effects of iron deficiency, which is consistent with our
data (fig 5.5). However, Kamei et al. [241] showed decreased serum iron after short-term
treatments, indicating initial changes in iron availability that may induce compensatory
mechanisms to maintain sufficient serum iron levels long-term. This is reflective of
FID, [226] which is often seen in patients and is associated with worse progression-free
survival. [239]
Despite no changes in iron-related proteins or serum iron levels evidenced (fig 5.6, 5.7),
the development of resistance to sapatinib was able to be modulated by a change in diet.
Although not significant, due to variation within the iron-low control diet sapatinib-
treated arm, sapatinib-treated mice had survival times more similar to vehicle-treated
mice (fig 5.1).
5.3.2 Restricting dietary iron did not impede tumour growth
Many studies have shown that increased iron availability can increase the rate of cell
growth and cancer risk. [227,243–246] Similarly, iron deficiency has been shown to reduce
tumourigenesis and continued tumour growth. [245,247,248] An iron-deficient diet did not
impede tumourigenesis or tumour growth in MMTV-NIC-PTEN+/- mice (fig 5.4 A, 5.3).
From this, it can be seen that reducing dietary iron intake has not had a deleterious
impact on tumour initiation or progression in our study.
However, the diet used in chapter 4 contained 150 ppm of iron, whereas the matched
iron-low control diet used in this chapter contained 49 ppm of iron. Although this is
still greater than the 2 ppm iron in the iron-deficient diet, and within the normal range
(35–350 ppm), [243] this difference between ‘normal’ and ‘control’ diets may explain the
bimodal growth distribution in sapatinib-treated iron-low control diet mice (fig 5.2 C).
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In this experiment, none of the iron-related proteins identified in chapter 4 were altered
in response to an iron-deficient diet. This was likely due to different iron-low control
diets used and the altered iron within the iron-low control diet compared with the normal
diet. As such, all mice experienced some reduction in dietary iron intake, although those
on the iron-deficient arms more so than the control arms.
5.3.3 Expression of HO-1 in response to sapatinib is affected by
altering dietary iron
Although no changes in expression of ceruloplasmin or ferritins could be seen, we did see
an effect on the response to sapatinib. Sapatinib-treated mice on an iron-deficient diet
did not have increased HO-1 which was seen in tumours from sapatinib-treated mice on
a iron-low control diet (fig 5.6). However, these tumours still showed similar levels of
extracellular iron deposition as seen in tumours from sapatinib-treated iron-low control
diet mice (fig 5.8).
Expression of HO-1 has been associated with the development of resistance to radio-,
chemo- and targeted therapies. [249–256] This supports our data which show increased
expression of HO-1 in sapatinib-treated tumours (fig 4.8). However, increased HO-1 was
also seen in tumours responding to sapatinib-treatment (fig 5.6). As such, it is unclear
how HO-1 is involved in the development and maintenance of resistance.
In tumours from sapatinib-treated mice on an iron-deficient diet, HO-1 was not increased
(fig 5.6 H and L). Despite no increase in HO-1, all sapatinib-treated tumours had
increased extracellular iron deposition, as seen in sapatinib-treated iron-low control diet
mice (fig 5.8). Through its canonical role of heme breakdown, [257] and by increasing
autophagic degradation of damaged iron-containing proteins, [249–251] HO-1 can increase
the LIP.
Despite being able to increase the LIP, HO-1 is not responsible for extracellular iron
deposition. It is likely that through increasing the LIP, other proteins acted to counteract
this to prevent generation of excess ROS due to high levels of intracellular free iron. [133,238]
Mice with reduced dietary iron intake showed small but insignificant changes in serum
iron levels, consistent with the literature. [242,243] As such, and in keeping with the
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Figure 5.11. An iron-deficient diet negates the need for increased expression of HO-1 to
develop resistance to sapatinib. We hypothesise that upon treatment with HER2-targeted
tyrosine kinase inhibitors, heme oxygenase-1 (HO-1) becomes upregulated, increasing free iron
in the labile iron pool (LIP). To avoid oxidative damage from free ferrous iron (Fe2+), ferroportin
transports the iron from the cell where it is converted to ferric iron (Fe3+) by ceruloplasmin and
deposited extracellularly. An iron-deficient diet reduces the amount of iron in the LIP, reducing
oxidative damage making HO-1 unnecessary as there is less oxidative damage to respond to.
literature, reduced dietary iron intake would result in a reduced LIP. [242,258,259] This
would result in less oxidative damage and increased autophagy to release iron from
ferritin complexes. [260]
HO-1 may be required by the tumours to increase autophagy, which is also increased in
iron-deficiency. If tumours on an iron-deficient diet have insufficient iron, this would
result in increased autophagy without the need to increase expression of HO-1. Therefore,
we hypothesise that increased HO-1 expression and reduced dietary iron have overlapping
mechanisms in the development of resistance to sapatinib (fig 5.11).
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5.3.4 Summary
Development of resistance can be affected by altering dietary iron intake in vivo. If these
results translate to the clinic, increasing patients’ dietary iron could represent a novel
way to combat the development of resistance to HER2-targeted therapies without the
addition of new drugs which may have additional side effects.
As HO-1 has been consistently increased in sapatinib-treated tumours, its role in
maintaining resistance and the overlapping function of an iron-deficient diet should be
the focus of further studies. As tumours responding to sapatinib also had increased
HO-1, it will be important to identify what mechanism controls the switch between
resistance and response. This will be investigated further in the following chapter.
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Chapter 6
The role of HO-1 in resistance to
sapatinib
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The canonical role of HO-1 is the breakdown of haem groups into biliverdin, releasing
carbon monoxide and iron in the process. [257] HO-1 is known to be involved in both
autophagy and the oxidative stress response and has been shown in multiple cancer
types to induce autophagy as a resistance mechanism. [249–251] An additional role for
HO-1 is protection against ferroptotic cell death, thought to be associated with reaction
to the oxidative stress response. [235] The accumulation of lipid peroxides, generated by
hydroxyl radicals formed through the reaction of ferrous iron and hydrogen peroxide,
leads cells to undergo ferroptosis. [133,238]
Sapatinib-treated tumours from MMTV-NIC-PTEN+/- mice exhibited changes in iron
storage and increased expression of HO-1, as shown in chapter 4. When mice were given
an iron-deficient diet and treated with sapatinib, HO-1 was no longer upregulated, but
iron deposition was still seen (chapter 5).
With this in mind, the following chapter will explore these aims:
• Assess if increased HO-1 expression is associated with autophagy induction or
increased oxidative stress.
• Determine if HER2-targeted therapies can induce ferroptosis.
• Elucidate the role of HO-1 on resistance to sapatinib and lapatinib in vitro.
6.1 Sapatinib-treated tumours have increased autophagic
flux
Detailed results for this chapter can be found in tables A.11–A.14.
As HO-1 is known to induce autophagy, [249–251] we investigated if the increased HO-1 seen
in sapatinib-treated tumours (fig 4.8 G, H and L) was associated with increased autophagy.
Levels of autophagy-related proteins, sequestosome 1 (p62) and microtubule-associated
proteins 1A/1B light chain 3B (LC3B), were assessed. p62 targets ubiquitinated proteins
for autophagic degradation and is degraded during this process, thus when levels of
autophagy are increased, levels of p62 are decreased. [261] Meanwhile, LC3B is present in
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Figure 6.1. Increased autophagic flux can be seen in MMTV-NIC-PTEN+/- tumours treated
with sapatinib. (A) Western blot analysis of sequestosome 1 (p62) and microtubule-associated
proteins 1A/1B light chain 3B (LC3B) in index tumours from MMTV-NIC-PTEN+/- mice treated
with vehicle (n=4), or sapatinib (n=5). B-actin was used as a loading control. (B) Quantification
of LC3BII:LC3BI. Results presented as bar graph, mean ± standard deviation (SD). Two-tailed
Mann-Whitney test, p=0.016. Representative immunohistochemical (IHC) staining of (C–D) p62
(vehicle: n=22; sapatinib: n=10) and (E–F) LC3B (vehicle: n=19; sapatinib: n=8). Scale bar: 50
µm. (G–H) Higher magnification of LC3B puncta. Scale bar: 10 µm. (I) Quantification of p62 by
Definiens Architect. Results presented as mean ± SD, two-tailed Mann-Whitney test, p<0.05=*.
Detailed results can be found in table A.12.
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two forms: the cytosolic form, LC3B-I becomes conjugated to phosphatidylethanolamine
(PE), forming LC3B-II which is recruited to autophagosomal membranes, appearing as
puncta in cells. [262]
Western blot analysis revealed decreased p62 in sapatinib-treated tumours (fig 6.1 A)
and increased autophagic flux, evidenced by an increased ratio of LC3BII to LC3BI
(fig 6.1 A and B). To verify this result, levels of both proteins were assessed by IHC.
This confirmed decreased p62 (fig 6.1 C, D and I) and increased LC3B-positive puncta
in sapatinib-treated tumours (fig 6.1 E–H and J). A more diffuse staining can be seen in
vehicle-treated tumours, as well as some puncta.
This was not reflected in tumours from mice on the iron-deficient diet experiment.
Levels of p62 were comparable across treatments, except vehicle-treated mice on an
iron-deficient diet which had increased levels of p62 compared with vehicle-treated
iron-low control diet mice (fig 6.2 A–E and K, 6.3). However, there was a lot of variation
within the sapatinib-treated iron-low control diet mice, which may reflect the two groups
seen in the growth kinetics within this group (fig 5.2 C).
Interestingly, the p62 levels did not reflect the number of LC3B-positive puncta within
the tumours (fig 6.2 F–J). Although, p62 is an indirect read out of autophagy, as it
is under tight transcriptional and post-transcriptional control, [263] therefore it can be
expected that p62 levels may not always correlate with the number of LC3B-positive
puncta. Few puncta were seen in vehicle-treated mice on a iron-low control diet, but in
tumours from vehicle-treated mice on an iron-deficient diet, many puncta could be seen.
Some puncta could be seen in progressing tumours from sapatinib-treated mice on a
iron-low control diet, but no puncta were detected in tumours responding to sapatinib.
Tumours from sapatinib-treated mice on an iron-deficient diet had many puncta, increased
compared with vehicle-treated mice on the iron-deficient diet. Therefore, induction
of autophagy may have occurred in mice on an iron-deficient diet to release iron
from storage. [260] This may circumvent the need for HO-1 to increase autophagy as
a mechanism of resistance. Furthermore, the cargo receptor for ferritin targeted for
autophagic degradation is not p62, which may explain the lack of concordance between
p62 and LC3B-positive puncta.
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Figure 6.2. Tumours responding to sapatinib do not have increased autophagic flux.
MMTV-NIC-PTEN+/- mice on a control (C) or iron-deficient (ID) diet were treated with vehicle
or sapatinib. Drug treatment began four days after the diet commenced. Representative
immunohistochemical staining of (A–E) sequestosome 1 (p62; iron-low control diet, vehicle;
group A, n=5; iron-deficient diet, vehicle: group B, n=5; iron-low control diet, sapatinib: group
C, n=6; iron-deficient diet, sapatinib: group D, n=4; responding tumours, iron-low control diet,
sapatinib; group Cr, n=6) and (F–J) microtubule-associated proteins 1A/1B light chain 3B (LC3B;
Group A: n=6; group B: n=4; group C: n=5; group D: n=6; group Cr: n=6). Scale bar: 50 µm.
(K–O) Higher magnification of LC3B puncta. Scale bar: 10 µm. Detailed results can be found
in table A.11.
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Figure 6.3. Levels of p62 are not significantly different between treatment arms. (A)
Quantification of sequestosome 1 (p62; iron-low control diet, vehicle; group A, n=5; iron-deficient
diet, vehicle: group B, n=5; iron-low control diet, sapatinib: group C, n=6; iron-deficient diet,
sapatinib: group D, n=4; responding tumours, iron-low control diet, sapatinib; group Cr, n=6) in
tumours from the iron-deficient diet experiment by Definiens Architect. All groups compared with
iron-low control diet, vehicle-treated tumours. Results presented as mean ± standard deviation,
Kruskal-Wallis test, Dunns post-hoc test, p<0.05=*.
Figure 6.4. Sapatinib-treated tumours do not have increased ferritinophagy.
Representative immunohistochemical staining of (A–B) nuclear receptor coactivator 4 (NCOA4)
in tumours from vehicle- (n=23) and sapatinib-treated (n=9) MMTV-NIC-PTEN+/- mice. Scale
bar 50 µm. (C) Quantification of NCOA4 staining by Definiens Architect. Results presented
as mean ± standard deviation. Two-tailed Mann-Whitney test, not significant = NS. Detailed
results can be found in table A.12.
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To ascertain if increased autophagy has resulted in higher turnover of ferritin to release
iron in mice on a normal diet, levels of nuclear receptor coactivator 4 (NCOA4), the cargo
receptor for ferritin-specific autophagy, [264] were assessed in tumours from chapter 4.
This showed no difference in NCOA4 levels between treatment groups (fig 6.4 A–C).
This suggests that the increased autophagic flux and iron deposition in these tumours is
not due to increased ferritin degradation.
Autophagy can be induced when there is reduced nutrient availability or increased
oxidative stress. [265] To determine if the increased autophagy seen was correlated with
insufficient blood flow causing a lack of nutrient availability or oxygen deprivation, the
number of blood vessels within a tumour section was assessed using CD31 staining. This
revealed no significant difference in the number of CD31-positive blood vessels, when
normalised to the tumour section area, between the two treatment groups (fig 6.5 A–C).
In addition, there was no difference in expression of key regulators of vascularisation
including vascular endothelial growth factor A (VEGFA; Vegfa; Hoeben et al. [266])
and its receptors, vascular endothelial growth factor receptor 1 and 2 (VEGFR1: Flt1 ;
VEGFR2: Kdr ; fig 6.5 D). Furthermore, levels of hypoxia-inducible factor-1α (Hif1α)
which can promote angiogenesis and thrombospondin 1 (Thbs1 ), [266] a potent inhibitor
of angiogenesis, were not significantly different between treatment groups (fig 6.5 D).
6.2 Levels of oxidative stress are similar between
sapatinib- and vehicle-treated tumours
Resistance to chemotherapy has been linked to induction of an oxidative stress response
in breast cancer, neuroblastoma and squamous cell carcinoma. [252–254] Furthermore,
several groups have shown increased oxidative stress after treatment with HER2-targeted
therapies trastuzumab, pertuzumab and lapatinib. [267,268] HO-1 is intricately linked to
the oxidative stress response and is a key effector of nuclear factor erythroid-2 related
factor 2 (NRF2)-mediated maintenance of redox homeostasis. [269]
Cellular oxidative stress can be measured by the level of nicotinamide adenine dinucleotide
phosphate (NADPH) available to provide reducing power. To measure this, we looked
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Figure 6.5. No difference can be seen in the number of blood vessels in sapatinib-treated
tumours compared with vehicle-treated tumours. Representative immunohistochemical
(IHC) staining of (A–B) cluster of differentiation 31 (CD31) in tumours from vehicle- (n=26) and
sapatinib-treated (n=10) MMTV-NIC-PTEN+/- mice. Scale bar: 50 µm. (C) Quantification of
CD31-positive vessels across whole sections by Definiens Architect, normalised to area. Results
presented as median ± interquartile range (IQR). Unpaired two-tailed t-test, not significant =
NS. (D) Quantitative PCR was performed on tumours from MMTV-NIC-PTEN+/- mice treated
with vehicle (n=9) or sapatinib (n=9). Vascular endothelial growth factor A (Vegfa), vascular
endothelial growth factor receptor 1 (Flt1), vascular endothelial growth factor receptor 2 (Kdr ),
hypoxia inducible factor 1α (Hif1α) and thrombospondin 1 (Thbs1) mRNA levels were analysed
and normalised to levels of β-2 microglobulin (B2m) mRNA. Results presented as scatter plot
with median ± IQR. Two-tailed Mann-Whitney tests, not significant = NS. Detailed results can
be found in table A.12.
at the activity of glucose-6-phosphate dehydrogenase (G6PDH) which catalyses the rate
limiting step of the pentose phosphate pathway, responsible for maintaining cellular levels
of NADPH. [270] This revealed that both sapatinib-treated and vehicle-treated tumours
show similar levels of G6PDH activity (fig 6.6 A). Reduced glutathione (GSH) is another
key cellular antioxidant; increased oxidised glutathione (GSSG) is indicative of oxidative
stress. [271] To investigate this, we measured the ratio of GSH to GSSG. This revealed
no significant difference between vehicle-treated and sapatinib-treated tumours (fig 6.6
B). Despite seeing no difference in the oxidative status of sapatinib-treated tumours
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Figure 6.6. Sapatinib-treated tumours have similar reducing capacity to vehicle-treated
tumours. Vehicle-treated (n=4) and sapatinib-treated (n=5) tumours were analysed using (A) a
glucose-6-phosphate dehydrogenase (G6PDH) kinetic assay at 5 and 30 minutes to calculate
G6PDH activity. Linear regression, not significant = NS. Vehicle-treated (n=4) and sapatinib-
treated tumours (n=5) were analysed using (B) a thiol green indicator assay to determine the
reduced glutathione to oxidised glutathione (GSH/GSSG) ratio. Results presented as scatter
plot with median ± interquartile range. Two-tailed Mann-Whitney test, not significant = NS.
Detailed results can be found in table A.12.
compared with vehicle-treated tumours, levels of glutathione peroxidase 4 (GPX4), which
detoxifies lipid peroxides, [272] were increased (fig 6.7 A–C).
Lipid peroxidation is associated with increased cell death due to ferroptosis. Oxidation
of PE species containing arachidonic- and adrenic acid (AA and AdA, respectively)
drive cells towards ferroptotic cell death. [273–275] Despite increased GPX4, assessment
of the oxidation state of PE species containing AA or AdA revealed no significant
difference between the oxidation state of these lipids between vehicle- and sapatinib-
treated tumours (fig 6.7 D). However, without comparing these results with those from
tumours responding to sapatinib, it is difficult to conclude whether higher levels of GPX4
reduced lipid peroxidation to the same level as vehicle-treated tumours in response to
sapatinib treatment.
As HO-1 and GPX4 are both NRF2-target genes, and increased in sapatinib-treated
tumours (fig 4.8 G and H, 6.7 A and B), we assessed levels of nuclear NRF2. Despite
NRF2 target genes being upregulated, analysis of NRF2 by IHC showed significantly
reduced levels in sapatinib-treated tumours compared with vehicle-treated tumours
(fig 6.8 A, B and E).
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Figure 6.7. Sapatinib-treated tumours have increased GPX4. Representative IHC staining
of (A–B) glutathione peroxidase 4 (GPX4) in vehicle-treated (n=25) and sapatinib-treated (n=8)
tumours. Scale bar: 50 µm. Quantification of (C) GPX4 by Definiens Architect. Results
presented as mean ± standard deviation. Two-tailed Mann-Whitney test, p<0.0001=****.
(D) Assessment of phosphatidylethanolamine (PE) lipid species in vehicle-treated (n=4) and
sapatinib-treated (n=5) tumours by liquid chromatography-tandem mass spectroscopy (LC-
MS/MS). Peak detection and lipid identification were performed as described in Wills et al. 156
Results presented as median ± interquartile range. Multiple t-tests, not significant = NS.
Detailed results can be found in table A.12.
6.3 Sapatinib and lapatinib induce ferroptotic cell death
Ferroptosis is a form of caspase-independent, regulated cell death. [223] As there are no
protein markers identified which indicate if cells are dying via ferroptosis, [250] rescue by
iron chelation (deferoxamine; DFO) or prevention of lipid ROS accumulation by trapping
peroxyl radicals (ferrostatin) are used to verify ferroptotic cell death in vitro. [276,277]
Despite not indicating the development of ferroptosis as the process can be reversed at
this point, cyclooxygenase 2 (COX2) is used to indicate cells entering the start of the
ferroptotic pathway. [272,278]
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Figure 6.8. Sapatinib-treated tumours have less NRF2. (A–B) Representative
immunohistochemical (IHC) staining of nuclear factor erythroid 2–related factor 2 (NRF2)
(vehicle: n=20; sapatinib: n=9). Scale bar: 50 µm. (C) Quantification of NRF2 by Definiens
Architect. Results presented as mean ± standard deviation. Two-tailed Mann-Whitney test,
p<0.01=**. Detailed results can be found in table A.12.
Therefore, to identify if responding tumours from the iron-deficient diet experiment
are undergoing apoptosis or ferroptosis, IHC was performed for cleaved caspase 3, the
irreversible step of apoptosis, [219] and COX2. Analysis of progressing and responding
tumours by IHC revealed no difference in levels of cleaved caspase 3 in each treatment
group and responding tumours (fig 6.9 A–E and K).
However, increased COX2 was seen in sapatinib-treated iron-low control diet tumours
that were progressive or responding (fig 6.9 F–J and L). Despite increased COX2 in
sapatinib-treated mice on a iron-low control diet, this could not be seen in sapatinib-
treated mice on an iron-deficient diet. This may be due to less iron in the labile iron
pool, thus a reduced incidence of iron-dependent ferroptosis occurring compared with
tumours from mice on a iron-low control diet.
Due to the increased COX2 in sapatinib-treated tumours on a iron-low control diet,
we established if SKBR3 cells were susceptible to ferroptosis, to allow modulation
of ferroptosis in vitro and study the effects of sapatinib and lapatinib. Cells were
treated with erastin, which inactivates system xc-, leading to ferroptotic cell death. [279]
Treatment with erastin revealed that SKBR3 cells are susceptible to ferroptosis, which
can be rescued by co-treatment with DFO, which chelates iron, or ferrostatin, which
traps peroxyl radicals (fig 6.10 A). [276,277]
To investigate if HER2-targeting agents could be inducing ferroptotic cell death, SKBR3
cells were treated with sapatinib or lapatinib in combination with DFO or ferrostatin.
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Figure 6.9. Responding tumours from sapatinib-treated mice on a iron-low control diet
have increased COX2. MMTV-NIC-PTEN+/- mice on a control (C) or iron-deficient (ID) diet
were treated with vehicle or sapatinib. Drug treatment began four days after the diet commenced.
Representative immunohistochemical staining of (A–E) cleaved caspase 3 (iron-low control diet,
vehicle; group A, n=6; iron-deficient diet, vehicle: group B, n=6; iron-low control diet, sapatinib:
group C, n=5; iron-deficient diet, sapatinib: group D, n=5; responding tumours, iron-low control
diet, sapatinib; group Cr, n=6) and (F–J) cyclooxygenase 2 (COX2; Group A: n=6; group B: n=5;
group C: n=6; group D: n=7; group Cr: n=6) in index tumours. Scale bar: 50 µm. Quantification
of (K) cleaved caspase 3 and (L) COX2 by Definiens Architect. All groups compared with
iron-low control diet, vehicle-treated tumours. Results presented as mean ± standard deviation.
Kruskal-Wallis test, Dunn’s post-hoc test, not significant = NS, p<0.01=**. Detailed results can
be found in table A.11.
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Table 6.1. GI50 values to sapatinib and lapatinib of SKBR3 cells in the presence or absence of
DFO and ferrostatin.
Drug
Cell Line Sapatinib (M) Lapatinib (M)
SKBR3 5.83x10-12 1.12x10-12
SKBR3 plus DFO 5.49x10-7 7.36x10-10
SKBR3 plus ferrostatin 4.74x10-7 7.87x10-10
GI50: Growth inhibition 50%; DFO: deferoxamine
Increased resistance to sapatinib and lapatinib was seen with both DFO and ferrostatin
by assessing cell viability (table 6.1). Additionally, cell death analyses showed that both
sapatinib- and lapatinib-induced cell death was partially rescued by anti-ferroptotic
agents (fig 6.10 A).
As mentioned previously, a key indicator of ferroptosis is lipid peroxidation. To ascertain
if sapatinib and lapatinib increased levels of oxidised lipids, SKBR3 cells treated with
erastin, sapatinib or lapatinib were stained with C11 BODIPY dye. This has an altered
emission spectrum upon binding to oxidised lipids. [280] FACS analysis showed a lower
mean RFI ratio 695:530 in SKBR3 cells treated with erastin for 24 or 48 hours compared
with DMSO control, as expected. The ratio in erastin-treated cells was similar to that in
cells treated with sapatinib and lapatinib (fig 6.10 B; mean ratio 695:530 [SD]; DMSO:
35.83 [±4.02]; erastin 24 hours: 8.36 [±1.72]; erastin 48 hours: 11.26 [±8.30]; sapatinib
48 hours: 15.05 [±0.37]; lapatinib: 14.15 [±6.76]; p<0.01).
To confirm that sapatinib- and lapatinib-induced cell death was caspase-independent,
SKBR3 cells were treated with sapatinib or lapatinib in the presence or absence of
pan-caspase inhibitor benzyloxycarbonyl-phenylalanyl-alanyl-fluoromethyl ketone (Z-
VAD-FMK). [281] There was a small but non-significant rescue of sapatinib-induced cell
death in Z-VAD-FMK treated cells. However, there was no rescue of lapatinib-induced
cell death with Z-VAD-FMK (fig 6.11 A).
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Figure 6.10. Sapatinib and lapatinib induce ferroptotic cell death in SKBR3 cells. SKBR3
cells were treated for 48 hours with dimethyl sulfoxide (DMSO; 0.01%), erastin (10 µM), sapatinib
(0.67 µM) or lapatinib (5 µM) in the presence or absence of deferoxamine (DFO; 100 µM) or
ferrostatin (5 µM). (A) Cells were stained with propidium iodide and percentage of cell death was
analysed using a Tali Image Cytometer. Results presented as box and whisker plot, minimum
of four biological repeats. All conditions were compared with DMSO control and single agent
treatments. One-way ANOVA, Bonferroni’s post-hoc test, p<0.05=*, p<0.01=**, p<0.001=***,
p<0.0001=****. (B) Cells were incubated with 2.5 µM C11 BODIPY 581/591 for 30 minutes
then analysed by flow cytometry. Dead cells were excluded by gating based on forward and
side scatter. The ratio of geometric mean relative fluorescence intensity (RFI) 695/530 was
calculated. Results presented as bar chart ± standard deviation, minimum of two biological
repeats. One-way ANOVA, Bonferroni’s post-hoc test, p<0.01=**. Detailed results can be found
in table A.13.
136
Figure 6.11. Caspase inhibition does not rescue sapatinib- or lapatinib-induced cell
death in SKBR3 cells. SKBR3 human epidermal growth factor receptor 2 (HER2)-positive
breast cancer cells were treated for 48 hours with dimethyl sulfoxide (DMSO; 0.01%),
sapatinib (0.67 µM) or lapatinib (5 µM) in the presence or absence of pan-caspase inhibitor
benzyloxycarbonyl-phenylalanyl-alanyl-fluoromethyl ketone (Z-VAD-FMK; 20 µM). (A) Cells were
stained with propidium iodide and percentage of cell death was analysed using a Tali Image
Cytometer. Results presented as box and whisker plot, minimum of three biological repeats.
All conditions were compared with DMSO control and single agent treatments. One-way
ANOVA, Bonferroni’s post-hoc test, p<0.01=**, p<0.0001=****. Detailed results can be found in
table A.13.
6.4 HO-1-overexpressing cells have increased resistance
to HER2-targeted therapies
HO-1 was consistently upregulated in sapatinib-treated tumours (fig 4.8), but its
expression was altered in response to an iron-deficient diet (fig 5.6). To further clarify
the role of HO-1 in response to HER2-targeted therapies, SKBR3 cells overexpressing
HO-1 were made. Overexpression of HO-1 was confirmed by western blot (fig 6.12 A).
To establish if HO-1 overexpression increased cell viability, GI50 values to sapatinib
and lapatinib were determined. This revealed that overexpression of HO-1 resulted in
increased GI50 values against both sapatinib and lapatinib. However, co-treatment of
HO-1-overexpressing cells with DFO or ferrostatin did not further increase GI50 values
to sapatinib and lapatinib (table 6.2), suggesting that ferroptosis was not involved in
the HO-1-dependent cytoprotection following treatment with sapatinib and lapatinib.
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Figure 6.12. HO-1 expression in SKBR3 cells. SKBR3 human epidermal growth factor
receptor 2 (HER2)-positive breast cancer cell line was stably transfected with a plasmid
containing the heme oxygenase-1 (HO-1) gene or an empty plasmid. (A) Representative
western blot analysis (n=2) of HO-1. B-actin was used as a loading control.
Table 6.2. GI50 values to sapatinib and lapatinib of SKBR3 cells overexpressing HO-1.
Drug
Cell Line Sapatinib (M) Lapatinib (M)
SKBR3 5.83x10-12 1.12x10-12
SKBR3 HO-1 9.53x10-7 4.31x10-8
SKBR3 HO-1 plus DFO 9.91x10-7 5.08x10-8
SKBR3 HO-1 plus ferrostatin 1.04x10-6 2.04x10-8
GI50: Growth inhibition 50%; HO-1: heme oxygenase-1; DFO: deferoxamine
Furthermore, HO-1 cells were resistant to erastin-induced ferroptosis, while empty vector
cells were still susceptible (fig 6.13).
HO-1 cells were still undergoing similar levels of cell death as empty vector cells in
response to sapatinib and lapatinib (fig 6.14 A and B). This difference between cell
viability and cell death read out was expected, as the main mechanism of action
of sapatinib and lapatinib is growth arrest. [282] As cytoprotective agents, DFO and
ferrostatin would prevent cell death but not growth arrest, leading to increased cell
viability as there would be less cell death thus more cells able to proliferate. Additionally,
DFO and ferrostatin were unable to rescue cell death in HO-1 cells and did not rescue
empty vector cells to the same extent seen in SKBR3 cells (fig 6.10 A). Since cell death
could not be rescued by anti-ferroptotic agents, cells were co-treated with Z-VAD-FMK
to ascertain if the death was caspase-dependent. This did not rescue death in HO-1 cells,
but did result in some decrease in empty vector cells, similar to that seen in SKBR3
cells (fig 6.15 A).
138
Figure 6.13. HO-1-overexpressing cells are resistant to erastin-induced cell
death.SKBR3 human epidermal growth factor receptor 2 (HER2)-positive breast cancer cell
line was stably transfected with a plasmid containing the heme oxygenase-1 (HO-1) gene or an
empty plasmid and were treated for 48 hours with dimethyl sulfoxide (DMSO; 0.01%), (A) erastin
(10 µM), in the presence of absence of deferoxamine (DFO; 100 µM) or ferrostatin (5 µM). Cells
were stained with propidium iodide and percentage of cell death was analysed using a Tali Image
Cytometer. Results presented as box and whisker plot, minimum of four biological repeats. All
conditions were compared with DMSO control and single agent treatments. One-way ANOVA,
Bonferroni’s post-hoc test, p<0.01=**. Detailed results can be found in table A.13.
To further understand the type of cell death occurring, caspase 3 and 7 activity, associated
with apoptotic cell death, was analysed in HO-1 and empty vector cells treated with
DMSO, erastin, sapatinib and lapatinib. This showed decreased activity relative to
DMSO controls in all treatments in both cell lines (fig 6.15 B), indicating that apoptosis
was not occurring in response to treatment.
6.4.1 Inhibition of autophagy increases sapatinib- and
lapatinib-induced cell death
HO-1 has been shown to increase levels of autophagy as a resistance mechanism in
chronic myeloid leukaemia, breast cancer and ovarian cancer. [249–251] This was also seen
in SKBR3 cells overexpressing HO-1 (fig 6.16 A), consistent with the mouse model where
increased HO-1 correlated with increased autophagic flux (fig 6.1). The contribution of
autophagy to resistance to sapatinib and lapatinib was investigated further.
Firstly, chemical inhibition of autophagy was confirmed by western blot. 3-methyladenine
(3-MA) blocks phagophores maturing into autophagosomes, whereas bafilomycin A1
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Figure 6.14. HO-1-overexpressing cells still experience similar levels of cell death due
to sapatinib and lapatinib. SKBR3 human epidermal growth factor receptor 2 (HER2)-positive
breast cancer cell line was stably transfected with a plasmid containing the heme oxygenase-
1 (HO-1) gene or an empty plasmid and were treated for 48 hours with dimethyl sulfoxide
(DMSO; 0.01%), (A) sapatinib (0.67 µM) or (B) lapatinib (5 µM) in the presence of absence of
deferoxamine (DFO; 100 µM) or ferrostatin (5 µM). Cells were stained with propidium iodide and
percentage of cell death was analysed using a Tali Image Cytometer. Results presented as box
and whisker plot, minimum of four biological repeats. All conditions were compared with DMSO
control and single agent treatments. One-way ANOVA, Bonferroni’s post-hoc test, p<0.05=*,
p<0.01=**, p<0.001=***. Detailed results can be found in table A.13.
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Figure 6.15. Caspase inhibition does not rescue sapatinib- or lapatinib induced death
in HO-1-overexpressing SKBR3 cells. SKBR3 human epidermal growth factor receptor 2
(HER2)-positive breast cancer cell line was stably transfected with a plasmid containing the
heme oxygenase-1 (HO-1) gene or an empty plasmid. (A) Cells were treated for 48 hours with
dimethyl sulfoxide (DMSO; 0.01%), sapatinib (0.67 µM) or lapatinib (5 µM) in the presence of
pan-caspase inhibitor benzyloxycarbonyl-phenylalanyl-fluoromethyl ketone (Z-VAD-FMK; 20
µM). Cells were stained with propidium iodide and percentage of cell death was analysed
using a Tali Image Cytometer. Results presented as box and whisker plot, minimum of four
biological repeats. All conditions were compared with DMSO control and single agent treatments.
One-way ANOVA, Bonferroni’s post-hoc test, p<0.05=*, p<0.01=**, p<0.001=***. (B) Caspase
3 and 7 activity was assessed in empty vector and HO-1-overexpressing cells treated with
DMSO (0.01%), erastin (10 µM), sapatinib (0.67 µM) and lapatinib (5 µM) for 48 hours. Results
presented as bar chart ± standard deviation, from 3 biological repeats. Kruskal-Wallis test,
Dunn’s post-hoc test, not significant = NS, p<0.05=*. Detailed results can be found in table A.13.
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Figure 6.16. Chemical inhibition of autophagy is successful in HO-1-overexpressing
SKBR3 cells. SKBR3 human epidermal growth factor receptor 2 (HER2)-positive breast cancer
cell line was stably transfected with a plasmid containing the heme oxygenase-1 (HO-1) gene or
an empty plasmid. (A) Representative western blot analysis (n=2) of sequestosome 1 (p62) and
microtubule-associated proteins 1A/1B light chain 3B (LC3B). B-actin was used as a loading
control. Cells were treated for 48 hours with dimethyl sulfoxide (DMSO; 0.01%), 3-methyladenine
(3-MA; 5 mM) or bafilomycin A1 (bafilomycin; 5 nM). (B) Representative western blots, from three
biological repeats, of p62 and LC3B. B-actin was used as a loading control. (C) Quantification
of LC3BII:LC3BI. Results presented as bar graph, mean ± standard deviation. Kruskal-Wallis
test, Dunn’s post-hoc test, p<0.05=*.
inhibits autophagosomes fusing with lysosomes, thus preventing their acidification. [283,284]
Both 3-MA and bafilomycin A1 were able to successfully inhibit autophagy (fig 6.16).
Increased LC3BI can be seen after 3-MA treatment, compared with DMSO control,
which is in accordance with 3-MA inhibiting autophagosome formation. [283] Bafilomycin
A1 increased levels of LC3BI and LC3BII (fig 6.16 A), resulting in a higher ratio
of LC3BII:LC3BI (fig 6.16 B) consistent with inhibition of autophagosomes fusing to
lysosomes. [284] Bafilomycin A1 treatment also increased p62 levels compared with DMSO,
indicating blockage of autophagy, whereas this cannot be seen after 3-MA treatment.
HO-1 and empty vector cells were co-treated with 3-MA or bafilomycin A1 and erastin.
This showed that HO-1 cells, previously resistant to erastin-induced ferroptotic cell
death (fig 6.14 A), had increased susceptibility when co-treated with either 3-MA or
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Figure 6.17. Inhibition of autophagy increases ferroptotic cell death in HO-1-
overexpressing SKBR3 cells. SKBR3 human epidermal growth factor receptor 2 (HER2)-
positive breast cancer cell line was stably transfected with a plasmid containing the heme
oxygenase-1 (HO-1) gene or an empty plasmid. Cells were treated for 48 hours with (A) dimethyl
sulfoxide (DMSO; 0.01%) or (B) erastin (10 µM) in the presence of absence of autophagy
inhibitors 3-methyladenine (3-MA, 5 mM) or bafilomycin A1 (bafilomycin; 5 nM). Cells were
stained with propidium iodide and percentage of cell death was analysed using a Tali Image
Cytometer. Results presented as box and whisker plot, minimum of three biological repeats. All
conditions were compared with DMSO control and single agent treatments. One-way ANOVA,
Bonferroni’s post-hoc test, not significant = NS, p<0.05=*, p<0.01=**, p<0.001=***. Detailed
results can be found in table A.14.
bafilomycin A1 (fig 6.17 B). When exposed to 3-MA and bafilomycin A1 alone, no
difference in cell death could be seen in HO-1-overexpressing cells (fig 6.17 A).
No significant difference in cell death was seen in empty vector cells co-treated with
erastin and 3-MA or bafilomycin, compared with erastin alone. Treatment of HO-1-
overexpressing cells with 3-MA or bafilomycin alone had no effect, but when combined
with erastin significantly enhanced cell death. Therefore, resistance to ferroptosis by
HO-1 is dependent on autophagy induction.
Co-treatment of empty vector cells with sapatinib or lapatinib and 3-MA or bafilomycin
A1 resulted in little change in cell death (fig 6.18 A and B). In HO-1 cells, autophagy
inhibition resulted in significantly increased cell death in response to both sapatinib and
lapatinib (fig 6.18 A and B). Thus, in the context of HO-1-overexpression, autophagy is
essential to maintain resistance.
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Figure 6.18. Inhibition of autophagy increases sapatinib- and lapatinib-induced cell
death in HO-1-overexpressing SKBR3 cells. SKBR3 human epidermal growth factor receptor
2 (HER2)-positive breast cancer cell line was stably transfected with a plasmid containing the
heme oxygenase-1 (HO-1) gene or an empty plasmid. Cells were treated for 48 hours with (A)
sapatinib (0.67 µM) or (B) lapatinib (5 µM) in the presence of absence of autophagy inhibitors
3-methyladenine (3-MA, 5 mM) or bafilomycin A1 (bafilomycin; 5 nM). Cells were stained with
propidium iodide and percentage of cell death was analysed using a Tali Image Cytometer.
Results presented as box and whisker plot, minimum of three biological repeats. All conditions
were compared with DMSO control and single agent treatments. One-way ANOVA, Bonferroni’s
post-hoc test, not significant = NS, p<0.05=*, p<0.01=**, p<0.001=***, p<0.0001=****. Detailed
results can be found in table A.14.
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6.5 Discussion
Altered iron metabolism and increased levels of HO-1 have been evidenced in many
cancer types as a mechanism of resistance. [136–140,199,232,249–251,285] Increased ferrous iron
within cells can lead to ferroptotic cell death through increased lipid peroxidation. [223]
However, HO-1 can counteract increased oxidative damage, [286] and has been shown to
protect against ferroptosis. [235] The results presented here show that HO-1 upregulation
resulted in resistance to HER2-targeted therapies, sapatinib and lapatinib and that
resistance is reliant on autophagy induction. Additionally, both agents can induce
ferroptotic cell death in HER2-positive breast cancer cells.
6.5.1 Apoptotic cell death does not occur in response to sapatinib or
lapatinib
Many pathways can be induced by HER2 signalling, including suppression of apoptosis
through activation of AKT. [179] Inhibition of HER2 results in activation of the apoptotic
pathway, through a lack of AKT and ERK signalling. [179,221] However, upon addition of
lapatinib, both BT474 and SKBR3 human HER2 breast cancer cell lines have increased
levels of Bcl-xL. [221] Results from a clinical trial support this, as no increase in apoptosis
markers were evidenced in patients whose tumours were responding to treatment. [287]
This is in accordance with results presented in this chapter, which show no detectable
cleaved caspase 3 upon treatment with sapatinib or lapatinib in vitro (fig 6.11 B),
despite cell death. Additionally, treatment with pan-caspase inhibitor Z-VAD-FMK
failed to rescue sapatinib- and lapatinib-induced cell death. Tumours responding to
sapatinib treatment (fig 6.9 A–E and K) also showed no increase in cleaved caspase 3,
despite a consistent reduction in volume over a minimum of 7 days. This indicates that
our in vitro and in vivo models evidence that sapatinib and lapatinib do not induce
caspase-dependent cell death, in accordance with the literature. [221,287]
However, it is unknown how HO-1-overexpressing cells are dying in vitro in response to
sapatinib and lapatinib. Other methods of regulated cell death include caspase-dependent
necrosis (caspase 8) and pyroptosis (caspase 1), although this would have been inhibited
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by Z-VAD-FMK, as a broad spectrum pan-caspase inhibitor. [219,281] It is possible that
these cells are undergoing accidental cell death — an instantaneous, catastrophic form
of cell death which can result from cells being exposed to severe physical, chemical or
mechanical insults. [219] Further investigation should focus on how this subset of cells
are dying, which may allow a better understanding of how HO-1-induced resistance to
HER2-targeted therapies can be overcome.
6.5.2 Sapatinib and lapatinib induce ferroptosis
SRC tyrosine kinase inhibitor, sorafenib, has been shown to induce ferroptosis in vitro
in cell lines from a variety of cancer types. [288,289] The mechanism by which sorafenib is
thought to induce ferroptosis is similar to erastin: inhibiting system xc- and therefore
glutathione synthesis. Both studies investigated other tyrosine kinase inhibitors, including
lapatinib and concluded that they were unable to induce ferroptosis in the cell lines
tested in the same way as sorafenib.
These results contradict the findings presented here which show that reduced viability
and cell death caused by sapatinib and lapatinib can be rescued by iron chelator DFO
and lipophilic antioxidant ferrostatin, indicating that cells are dying by ferroptosis
(table 6.1; fig 6.10 A). Further supporting this conclusion is the lipid peroxidation seen
after treatment with sapatinib and lapatinib, which is similar to that in cells treated
with erastin (fig 6.10 B). Increased levels of COX2 in sapatinib-treated progressing
and responding tumours (fig 6.9 F–J and L) provides further evidence for induction of
ferroptosis, as COX2 has been identified as a marker of ferroptosis. [272,278]
In both published studies assessing the ferroptotic potential of lapatinib, no HER2-
positive cell lines were used. [288,289] This indicates that HER2-targeting tyrosine kinase
inhibitors may induce ferroptosis downstream of HER2, rather than by a tyrosine kinase-
independent mechanism seen with sorafenib. A study by Ma et al. [290] showed that
lapatinib was able to induce ferroptotic cell death in HER2-positive breast cancer cell
line SKBR3 and triple-negative breast cancer cell line MDA-MB-231 in combination
with a lysosome disrupting agent, siramesine.
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The group showed that lapatinib treatment increased expression of transferrin receptor,
whilst siramesine reduced expression of ferroportin. This suggests that lapatinib is
capable of inducing ferroptosis in a HER2-independent manner, but only in combination
with another agent. [290] However, in our studies we have seen no increase in transferrin
receptor in response to sapatinib treatment (fig 4.12, 5.9). As such, in our system
sapatinib and lapatinib may be inducing ferroptosis in both a HER2-dependent and
HER2-indepedent manner. However, this has not been investigated as part of this work.
6.5.3 Dietary iron modulation represents a novel way to study
ferroptosis in vivo
Thus far, no in vivo or ex vivo cancer model has evidenced ferroptosis, despite many in
vitro studies. [223,288,290–292] Treatment of MMTV-NIC-PTEN+/- mice with an iron-
deficient diet was able to alter tumours’ response to sapatinib, resulting in fewer
responding tumours in mice on an iron-deficient diet, compared with iron-low control
diet mice (fig 5.4).
In vivo models of ferroptosis have so far been limited. Recently, models of ischemia-
reperfusion injury, such as stroke, myocardial infarction and acute kidney injury, have
evidenced ferroptosis in vivo and ex vivo. [293–296] Using ferroptosis inhibitors, these
groups were able to show that ischemia-reperfusion injuries undergo ferroptotic cell
death and inhibition of ferroptosis could reduce the injury sustained. [293–295]
Altering dietary iron intake in vivo is a novel method to modulate ferroptosis. Many
features of dementia are consistent with ferroptosis: decreased cortical GSH, increased
cortical iron and lipoxygenase activity and elevated lipid peroxidation products. [297]
Using a GEMM in which Gpx4 was conditionally knocked out, Hambright et al. [298]
evidenced that forebrain neurons are susceptible to ferroptosis and that the features
observed were consistent with this.
Despite not studying ferroptosis, Pino et al. [242] showed changes in lipid peroxidation
after long-term iron deficiency in the brain. This provides good supporting evidence to
suggest that an iron-deficient diet in MMTV-NIC-PTEN+/- mice is capable of modulating
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cellular iron metabolism within tumours, as dietary iron modulation was able to show
alterations in key changes associated with ferroptosis, such as lipid peroxidation.
6.5.4 Regulation of HO-1 is NRF2-independent
Treatment with trastuzumab or pertuzumab have been shown to result in generation
of ROS in HER2-expressing ovarian cancer cell lines. [267] GSH depletion and reduced
NRF2 signalling were also noted as a result of HER2 inhibition. A reduction in nuclear
NRF2 was seen in MMTV-NIC-PTEN+/- tumours treated with sapatinib in accordance
with the literature (fig 6.8 A, B and E), [252,267,299] although no GSH depletion was seen
in our system (fig 6.6). Both HO-1 and GPX4, which are regulated by NRF2, were
increased in sapatinib-treated mice (fig 4.8, 6.7). [252,267,299] However, HO-1 and GPX4
are also regulated in an NRF2-independent manner, [300,301] which is likely the case in
our model.
In the literature, HO-1 can be induced via several different pathways. [249–251] Such
pathways include NRF2-dependent, SRC/STAT3-dependent and MAPK-dependent
regulation of HO-1-induced autophagy. [249,250,302] Sapatinib-treated tumours also displayed
similar levels of ERK phosphorylation despite HER2 inhibition (fig 4.5, 4.6). This
suggests that HO-1 may be regulated via the MAPK pathway in our model.
6.5.5 HO-1 mediates resistance to HER2-targeted therapies and is
dependent on autophagy
Consistent with observations in many cancer types and therapies, [249–256] our data
display a clear and novel role for HO-1 in resistance to sapatinib and lapatinib. HO-
1-overexpressing cells were 5-fold more resistant to sapatinib-induced and 4-fold more
resistant to lapatinib-induced growth inhibition than SKBR3 cells (table 6.2).
The mechanisms underlying resistance mediated by HO-1 involve induction of autophagy,
response to oxidative stress or a combination of both. [249–256] This is consistent with
our findings: HO-1 resulted in increased autophagy (fig 6.16). Inhibiting autophagy
and exposing HO-1 expressing cells to HER2-targeted therapies resulted in increased
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cell death, while having no deleterious effect on control cells (fig 6.18 B and C). In
addition, while tumours responding to sapatinib had increased HO-1, there was no
evidence of LC3B-positive puncta (fig 6.2), indicative of a lack of autophagy, suggesting
that HO-1-mediated resistance is dependent on increased autophagic flux.
However, an iron-deficient diet was sufficient to induce autophagy without increased
expression of HO-1. This may have been linked to increased degradation of ferritin to
increase cellular iron levels. [260] Thus, when tumours from mice on an iron-deficient
diet are initially exposed to sapatinib, autophagy induction may have already occurred,
mitigating the need for HO-1. Therefore, irrespective of the mechanism of induction,
increased autophagy protected cells from the effects of sapatinib. This is in contention
with the literature, which evidences a mixed role for autophagy in ferroptosis. Although
ferroptosis is still ill-defined, thus the exact role of autophagy cannot be determined to
be supportive of ferroptosis or suppressive. [219,297]
6.5.6 Summary
Overall, our findings indicate that HER2-targeted agents sapatinib and lapatinib induce
ferroptosis in vitro and in vivo. We have shown that expression of HO-1, an iron-
deficient diet and anti-ferroptotic agents are able to maintain a resistant phenotype
in response to sapatinib. Additionally, resistance due to increased HO-1 is reliant on
autophagy induction, inhibition of which increases sapatinib- and lapatinib-induced cell
death. However, an iron-deficient diet increases autophagic flux independently of HO-1,





Targeted therapies against HER2 have revolutionised treatment options for patients
with HER2-positive breast cancer. Despite this, development of resistance remains a
key problem; approximately half of patients experience de novo resistance, while 70%
of those that initially responded will develop acquired resistance within two years of
treatment. [69–71]
Many in vitro studies have uncovered resistance mechanisms including: epitope masking,
lineage changes, mutations in HER2, downstream pathway activation and bypass RTK
activation. However, translating these findings into the clinic and therapeutically
targeting them has proven difficult or unreliable. [22,93,96,131] With this in mind, the aims
of this thesis were:
• Understand the link between EMT and resistance to HER2-targeted therapy
previously identified in the Brunton lab. [84]
• Use a mouse model of HER2-driven mammary cancer to identify novel mechanisms
of resistance to HER2-targeted therapy.
The first aim was addressed by analysing the expression of several EMT-associated
transcription factors to understand how EMT was being maintained at a transcriptional
level. Consistent with the literature, we showed that ZEB1 and ZEB2 were highly
expressed in sapatinib-resistant tumours that had undergone EMT, compared with those
that maintained an epithelial phenotype. [85,171,172] Analysis of patient data confirmed
that this finding translated to the clinic and that patients with high expression of ZEB1
had worse RFS than those with low expression.
Generation of drug resistant lines in vitro did not recapitulate the phenotype seen in
vivo, which may be due to discordance between the PTEN status of the in vivo and in
vitro models. Transient overexpression of ZEB1 did not induce overt EMT and despite
a trend towards lower levels of HER2 protein and transcript, did not give rise to loss of
HER2. The lack of pro-inflammatory cytokines, which would be present in vivo may
have prevented a full program of EMT being induced.
However, loss of HER2 did induce some features of EMT; increased ZEB1 and migratory
capacity were seen. These results contradict the literature, which shows that EMT can
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drive loss of HER2. [90,157] Although without external factors such as pro-inflammatory
cytokines, the full program of EMT may not be realised by loss of HER2 alone.
The second aim was addressed using a proteomics approach to identify differentially
regulated proteins in sapatinib-treated tumours compared with vehicle-treated tumours.
This revealed increased levels of proteins associated with cellular iron homeostasis: HO-1
and ceruloplasmin. Further investigation revealed extracellular iron deposition and
increased levels of iron exporter ferroportin in sapatinib-treated tumours.
As iron is known to impact tumour growth, we then looked at the effect of altering
dietary iron intake on the development of resistance to sapatinib. This showed that
an iron-deficient diet can reduce the time taken for tumours to progress on sapatinib.
Additionally, these tumours did not upregulate HO-1, despite tumours from mice on a
iron-low control diet treated with sapatinib showing increases similar to the previous in
vivo experiment.
Assessment of ferroptosis induction by HER2-targeting agents revealed increased COX2, a
marker of ferroptosis induction, [272,278] in sapatinib-treated mice fed an iron-deficient diet.
In vitro studies supported this, showing higher levels of lipid peroxidation, associated
with ferroptotic cell death, after treatment with sapatinib and lapatinib. This finding
has not been evidenced in the literature, [288,289] but increased ROS and GSH depletion
have been shown after treatment with trastuzumab and pertuzumab, supporting our
findings. [267] Additionally, studies have shown no increase in apoptosis markers in
regressing tumours, [221,287] which is also supported by our data.
Overexpression of HO-1 showed that this rendered cells resistant to sapatinib, lapatinib
and erastin, which is known to induce ferroptosis. Further investigation of HO-1 revealed
a correlation with increased autophagic flux in sapatinib-treated tumours, which was
also seen in tumours from mice fed iron-deficient diets regardless of treatment arm.
Increased autophagic flux was confirmed in the HO-1-overexpressing cells in vitro.
Furthermore, inhibition of autophagy was able to resensitise cells to HER2-targeted
therapies and erastin. Expression of HO-1 driving resistance via autophagy is noted in
the literature, [249–251] but these data are the first evidence of this mechanism in response
to HER2-targeted therapies.
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Although HO-1 expression was able to increase cell viability, the same level of cell
death as SKBR3 or empty vector cells could be seen after treatment with sapatinib and
lapatinib. Furthermore, this couldn’t be rescued by anti-ferroptotic agents, as seen in
SKBR3 and empty vector cells, or a pan-caspase inhibitor. This raises the question
of how these cells are dying and if this could be exploited to overcome resistance in
patients.
7.1 Future work
The results presented in this thesis have partially fulfilled the aims set out above.
However, my findings have raised additional questions which will be the focus of future
work.
7.1.1 Why did in vitro models fail to replicate EMT and loss of HER2?
In chapter 3, generation of resistant cell lines, overexpression of ZEB1 and knockdown of
ERBB2 failed to accurately represent the resistant fragment-derived tumours which had
undergone EMT. This limitation resulted in the question of how EMT and loss of HER2
were linked remaining unanswered. However, some EMT-like features were evidenced
in ERBB2 knockdown cells, despite not undergoing overt EMT. Future studies should
utilise these cells, treating them with pro-inflammatory cytokines, such as IL-6 and
TGF-β which have been noted in the literature to induce EMT in response to targeted
therapies, maintaining a positive feedback loop.
The experiments mentioned above will address how EMT can be induced by loss of HER2,
but performing these experiments will not answer how cells initially lost expression
of HER2. As material from the fragment-derived tumours is limited, other in vitro
techniques will need to be utilised to address this question. Initial work on SKBR3 cells
with CRISPR knockout of PTEN has begun; FACS analysis has shown that they have
lower levels of HER2 on the cell surface compared with parental SKBR3 cells. This may
be transient, but further characterisation will confirm this.
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Treating SKBR3 PTEN-/- cells with sapatinib and lapatinib to generate resistant lines
may give rise to cell lines with loss of HER2, better representing the in vivo loss.
Furthermore, if these cell lines are generated using 3D culture methods, co-culture or
treatment with pro-inflammatory cytokines, to mimic the TME, it may encourage a
switch to a mesenchymal phenotype with concurrent loss of HER2.
7.1.2 What effect would iron overload have on the development of
resistance?
In chapter 5, mice fed an iron-deficient diet had tumours that progressed more quickly
and were less likely to respond to sapatinib than tumours from mice fed a iron-low control
diet. Studies have shown that patients presenting with FID, sometimes associated with
iron-deficiency anaemia, have worse ECOG scores and lower OS than those without
FID. [239] A question that was not answered as part of this thesis is how a diet rich in
iron would affect tumour development and progression in sapatinib-treated mice.
However, iron is often associated with increasing tumour growth and proliferation, thus
providing an iron rich diet may not have the opposite effect as an iron-deficient diet on
the development of resistance. [227,243–246] Therefore, before progressing with further in
vivo studies, this should be explored by supplementing cells with iron in conjunction
with sapatinib and lapatinib treatments to ascertain if this is likely to enhance cell death
or, conversely, proliferation in vitro.
7.1.3 How does an iron-deficient diet drive autophagy?
As seen in chapter 6, expression of HO-1 and increased autophagic flux were correlated
in tumours progressing on sapatinib treatment. However, similar levels of LC3B-positive
puncta were seen in mice fed an iron-deficient diet, irrespective of treatment regimen and
did not correlate with HO-1 expression. In the literature, recycling of iron-containing
proteins and ferritin complexes is performed differently in iron deficiency compared
with iron sufficiency. Ferritin degradation is dependent on the acidic environment of
lysosomes; when iron is sufficiently available within cells, this process is independent
154
of autophagy. However, in iron-deficient conditions, ferritin is targeted for lysosomal
degradation via autophagy. [260,303]
We have shown that iron chelation with DFO can increase cell viability and decrease
cell death in response to sapatinib and lapatinib. To investigate this further, autophagy
induction should be studied in SKBR3 cells in the presence or absence of iron chelation.
This will provide confirmation that altering iron availability can induce autophagy,
which provides protection from HER2-targeted therapies. Uncovering the mechanisms
governing autophagy in our systems, we will be able to gain a better understanding
of how this may be targeted clinically. Due to the lack of clinically-approved specific
inhibitors of autophagy, this is of particular importance. [304]
7.1.4 How are HO-1-overexpressing cells dying in vitro?
Despite increased viability, HO-1-overexpressing cells experienced levels of cell death
similar to SKBR3 and empty vector cells (fig 6.14 6.15). Iron chelation and pan-caspase
inhibitor Z-VAD-FMK failed to rescue sapatinib- and lapatinib-induced death, indicating
that these cells are not dying by ferroptosis or apoptosis.
As a pan-caspase inhibitor, Z-VAD-FMK would be expected to inhibit pyroptosis and
necroptosis in addition to apoptosis, although there are conflicting studies showing
enhanced activation of caspase 8 after Z-VAD-FMK treatment. [219] However, treatment
did not increase cell death, thus it can be assumed this did not occur in our system.
More in depth analysis of caspase activation would rule out caspase-dependent cell
death mechanisms. [219] Autophagic cell death could be occurring, due to inappropriately
increased autophagy resulting in enhanced degradation rather than a protective mechanism.
However, inhibition of autophagy increased cell death, therefore this method of cell
death is unlikely to be occuring in our system.
The most likely form of cell death occurring is accidental cell death. [219] Providing
evidence for this will rely on ruling out other cell death mechanisms. By understanding
the mechanisms involved, it may be possible to enhance cell death, thus overcoming
resistance and restoring sensitivity to HER2-targeted therapies. Although concentrations
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of sapatinib and lapatinib exceeded the concentration required for target inhibition,
they were similar to concentrations seen in plasma and patients tumours, therefore
maintaining clinical relevance. [61,162–164]
7.1.5 Are these changes seen in patients?
The findings presented in chapters 4–6 indicate a novel role for dietary iron and HO-1
in inducing autophagy to overcome ferroptosis caused by HER2-targeted therapies and
resistance to these agents. However, if these mechanisms are not observed in the clinic,
the findings presented here would have limited significance.
Trastuzumab is first-line treatment for patients presenting with HER2-positive breast
cancer. Studies with trastuzumab and pertuzumab have shown increased ROS generation
and GSH depletion after treatment in vitro, [267] which are indicative of ferroptosis. This
indicates that our findings that sapatinib and lapatinib induce ferroptosis are likely to
be applicable across all HER2-targeted therapies.
With this in mind, analysis of patient material will allow further validation of our
findings. Work is currently ongoing analysing gene expression data in matched pre- and
post-trastuzumab treatment patient samples. This will allow interrogation of a wide
range of genes associated with cellular iron homeostasis to support the results presented
here. However, several studies have shown that HO-1 is regulated post-transcriptionally
by miR-377, miR-217 and embryonic lethal abnormal vision (ELAV) RNA-binding
proteins. [305,306] As such, this analysis will likely not highlight HO-1, although other
proteins involved in iron homeostasis may be indicated.
Therefore, analysis of patient material for iron deposition, HO-1 expression and the
presence of LC3B-positive puncta may give a better indication of how these findings
may be translated to the clinic. If these results were able to be linked to pathology




The results presented in this thesis have so far focused on their relevance to resistance
to HER2-targeted therapies. However, they may have wider implications in other fields.
7.2.1 Dietary iron modulation
In our study, we showed modulation of the development of resistance by utilising an iron
deficient diet. This reduced the number of tumours responding to sapatinib treatment,
which were shown to have increased COX2, a marker of ferroptosis. Together with the
in vitro data presented in chapter 6, this supported the hypothesis that HER2-targeted
therapies induced ferroptosis. These data are the first indication that susceptibility to
ferroptosis can be affected by dietary modulation of iron. Ferroptosis has been implicated
in a wide range of pathologies including degenerative brain diseases, ischemia-reperfusion-
induced injuries and kidney disease.
Degenerative brain diseases such as Alzheimer’s and Parkinson’s disease are caused by
the loss of synaptic neurons. [236] There is mounting evidence linking disease progression
to increased iron deposition and ferroptosis. [242,297] Supporting this, inducible deletion
of Gpx4 in adult mice resulted in increased neuronal loss in the hippocampus together
with astrogliosis, which is seen in patients with Alzheimer’s. [298]
A clinical trial administering iron chelator deferiprone showed lower levels of iron deposits
in the substantia nigra and improved motor scores in patients with beginning treatment
earlier compared with those who started later. [307] With this in mind, administering an
iron-deficient diet to patients with degenerative brain diseases such as Alzheimer’s or
Parkinson’s could reduce the rate of disease progression and improve patient outcomes.
In chapter 6, we evidenced increased autophagy as a result of an iron deficient diet.
Impairment of autophagy has been shown in both patients and models of Alzheimer’s
and Parkinson’s disease. [308–311] Several studies have investigated autophagy induction
to increase the removal of extracellular plaques consisting of β-amyloid, tau and α-
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synuclein aggregates. [308,310,311] Thus, dietary iron modulation may serve a dual purpose
in alleviating the symptoms and progression of degenerative brain diseases.
Ischemia-reperfusion-induced injuries include myocardial infarction, stroke and peripheral
vascular disease. Nutrient starvation is a key feature of these injuries, resulting in amino
acid deprivation. [296] A recent study showed that organ injury as a result of ischemia-
reperfusion was mediated by glutaminolysis and transferrin and that reversal of these
processes, or treatment with DFO or ferrostatin, could reduce cell death caused by
ischemia-reperfusion. [296] Thus, in patients that are deemed to have an increased risk of
myocardial infarction or stroke, adherence to an iron-deficient diet could reduce injuries
sustained in an acute event.
Acute kidney injury, if unresolved, can progress to chronic kidney disease. Acute injury
can be caused by a range of factors, including ischemia-reperfusion, toxic substances or
obstruction of the urinary tract. [235] In these instances, the proximal tubule becomes
increasingly sensitive to injury and cell death. A recent study showed that this cell
death occurred by ferroptosis and that ex vivo treatment of proximal tubules with
iron chelating agents attenuated cell death. [235,312] Therefore, in patients presenting
with acute kidney injury, an iron-deficient diet may represent a novel way to minimise
proximal tubule cell death.
7.2.2 Autophagic flux induced by HO-1
Direct inhibition of autophagy has proved difficult so far, thus targeting upstream
proteins resulting in increased autophagy could represent a good avenue to prevent
autophagy induction. Chloroquine, an anti-malarial, is the main clinically-approved
autophagy inhibitor. However prolonged exposure to chloroquine at clinically relevant
concentrations for autophagy inhibition results in severe side effects. [304] Although it
is currently indicated for treatment of systemic lupus erythematosus and rheumatoid
arthritis, this does not rely on autophagy inhibition and uses much lower doses than
those required to inhibit autophagy. [313]
A derivative of chloroquine, hydroxychloroquine, has shown promising in phase I and
II clinical trials. However, treatment frequently results in dose-limiting fatigue and
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gastrointestinal side effects. Similar to chloroquine treatment, hydroxychloroquine at
higher doses for longer periods of time results in severe toxicities. [314–316]
Pantoprazole, a proton pump inhibitor approved for gastro-oesophageal reflux, has
recently been investigated at higher doses as an autophagy inhibitor. [317,318] Despite
effectively inhibiting autophagy, higher doses give rise to similar adverse events as
hydroxychloroquine. [317] Therefore, despite being clinically-approved, pantoprazole faces
the same challenges as other autophagy inhibitors.
In our model, autophagy was induced due to HO-1 expression both in vivo and in vitro.
Other studies have also shown this mechanism of induction in several cancer types. [249–251]
With this in mind, inhibition of HO-1 may provide a novel way in which to inhibit
autophagy without the adverse events commonly seen due to off-target effects. [304,314]
Metalloporphyrins show good inhibition of HO-1 in vitro, but this has failed to translate
to the clinic. Inhibition of HO-1 with zinc protoporphyrin IX showed good anti-tumour
effects in vivo. However, when combined with chemotherapy agents, it was unable to
enhance their anti-tumour effects, despite potentiating toxicities. [319]
Conversely, autophagy induction has been shown to have a protective effect from
chemotherapy-induced damage to the proximal tubules of the kidneys. [304] Recent
studies have linked this damage and cell death to ferroptosis, which can be mitigated by
expression of HO-1. [235,312] Further understanding the link between HO-1 and autophagy
could aid in selectively increasing autophagy in the kidneys, minimising damage, while
maintaining autophagy inhibition in tumours.
Studies have looked at induction of HO-1 through dietary supplements or administration
of hemin. However, these trials have so far failed to show any clinical benefit due to HO-1
expression as a result of the interventions applied. [320,321] Despite this, HO-1 induction
remains a promising avenue for treating acute kidney and ischemia-reperfusion injuries.
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7.3 Summary and conclusions
In this study, we explored the mechanisms governing a previously uncovered link between
EMT and HER2 loss and the role of HO-1 and iron in response to HER2-targeted
therapies. To achieve this, we utilised two mouse models of HER2-positive breast cancer;
one GEMM which develops HER2-driven mammary tumours and one allogeneic model
using tumour fragments derived from the GEMM. To confirm results from the in vivo
models, a range of in vitro models were utilised.
In a fragment-derived tumour mouse model, we showed that expression of ZEB1 and
ZEB2 maintained EMT in vivo. Furthermore, loss of HER2 induced some properties
associated with EMT: increased expression of ZEB1 and migration. Although, the
mechanism behind loss of HER2 in vivo is still unknown.
In another mouse model of HER2-positive breast cancer, we demonstrated a link between
resistance to HER2-targeted therapies and ferroptosis, which was modulated by altering
dietary iron intake. This resistance was also associated with HO-1 expression, which
correlated with increased autophagic flux. However, dietary iron modulation did not
increase HO-1, with tumours showing increased autophagy induction in response to an
iron-deficient diet regardless of treatment arm.
In conclusion, the results presented within this thesis support the hypothesis of ferroptotic
cell death in response to HER2-targeted therapies, which may be mitigated by expression
of HO-1 or administration of an iron-deficient diet to induce autophagy. With a better





Table A.1. Chapter 3 fragment-derived tumour results
Vehicle Sapatinib Sapatinib-EMT
Figure 3.2
ZEB1, % (95% CI) 87.5 (62.23–94.17) 95.26 (88.28–96.30) 45.87 (37.03–51.38)
ZEB2, % (95% CI) 80.21 (68.05–92.57) 78.21 (66.63–86.95) 50.29 (40.51–60.06)
SNAIL, % (95% CI) 19.44 (14.79–51.13) 22.38 (17.19–50.96) 16.11 (11.97–16.56)
SLUG, % (95% CI) 11.08 (3.04–30.01) 9.34 (5.67–33.85) 8.78 (4.81–56.76)
TWIST, % (95% CI) 0.85 (0.30–5.78) 1.12 (0.84–1.41) 1.20 (048–1.92)
Table A.2. Chapter 3 resistant cell line results

























































Table A.3. Chapter 3 ZEB1-overexpressing cell line results
Empty vector ZEB1 -overexpressing Significance
Figure 3.15
ERBB2, ∆CT (95% CI) 2.91 (2.83–4.40) 3.71 (3.35–4.90) NS
Table A.4. Chapter 3 ERBB2 shRNA cell line results
Empty vector ERBB2 shRNA Significance
Figure 3.16
ERBB2, ∆CT (95% CI) 3.12 (1.12–3.37) 9.49 (9.11–10.13) 0.0001
ERBB3, ∆CT (95% CI) 5.34 (4.13–5.74) 5.64 (4.82–7.36) NS
Figure 3.17
ZEB1, ∆CT (95% CI) ND 17.26 (16.96–17.55) 0.0001
ZEB2, ∆CT (95% CI) 19.76 (14.26–23.17) 18.32 (14.21–19.21) NS
SNAIL, ∆CT (95% CI) 11.44 (8.57–11.52) 12.13 (11.51–12.31) NS
SLUG, ∆CT (95% CI) 9.15 (8.40–10.09) 6.27 (5.73–6.35) 0.01
Figure 3.18
Confluency, % (95% CI) 29.33 (13.79–37.49) 14.25 (3.81–20.79) 0.0001
Figure 3.19
Wound closure, % (95% CI) 39.14 (37.04–44.01) 91.26 (89.93–100.00 0.01
Table A.5. Chapter 4 results
Vehicle Sapatinib Significance
Figure 4.2
Tumour, % of section
(95% CI)
81.02 (76.49–87.02) 76.46 (65.43–89.33) NS
Cell area, µm2 (95% CI) 89.30 (86.59–91.93) 94.61 (91.09–97.18) 0.05
Nuclear area, µm2 (95%
CI)
57.05 (56.33–58.10) 62.76 (59.86–64.68) 0.01
Figure 4.3
HER2, % (95% CI) 79.54 (70.72–85.80) 78.3 (55.57–91.31) NS
Vimentin, % (95% CI) 2.91 (1.59–5.93) 2.56 (1.63–8.38) NS
β-catenin, % (95% CI) 58.72 (51.66–65.37) 84.09 (66.11–88.11) NS
Figure 4.4
Ki-67, % (95% CI) 21.97 (13.95–39.88) 69.93 (29.32–91.19) 0.0006




80.18 (64.37–87.20) 36.45 (31.29–80.83) 0.05
phospo-ERK, % (95% CI) 63.75 (54.93–73.13) 63.22 (35.01–89.43) NS
Figure 4.6
Continued on the next page
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c-Myc, log10 RFI (SD) 2.492 (±0.01) 2.487 (±0.03) 0.05
phospho-AKT, log10 RFI
(SD)
1.643 (±0.43) 2.747 (±0.47) 0.01
phospho-PLC-γ1, log10
RFI (SD)
1.746 (±0.19) 2.002 (±0.11) 0.05
phospho-ERK, log10 RFI
(SD)
3.251 (±0.2116) 3.464 (±0.1304) NS
phospho-SMAD1/5, log10
RFI (SD)










Cp, ∆CT (95% CI) 0.63 ((3.07)–4.51) 1.82 ((5.55)–5.58) NS
Fth, ∆CT (95% CI) 2.00 ((2.83)–1.19) 1.97 ((4.14)–(0.33)) NS
Ftl, ∆CT (95% CI) 1.824 ((3.92)–0.74) 2.37 ((4.10)–(0.20)) NS
Ho-1, ∆CT (95% CI) 3.47 ((0.93)–4.64) 0.40 ((1.46)–4.77) NS
Figure 4.11
Total iron, ng/µg protein
(95% CI)
2.59 (1.40–4.60) 2.30 (1.75–4.68) NS
Ferrous (Fe2+) iron,
ng/µg protein (95% CI)
2.26 (1.22–3.07) 2.22 (1.60–2.98) NS
Ferric iron (Fe3+) iron,
ng/µg protein (95% CI)




49.63 (40.06–60.01) 59.40 (13.61–87.62) NS
DMT-1, % (95% CI) 98.02 (93.55–99.33) 98.35 (96.53–99,86) NS
Ferroportin, % (95% CI) 98.30 (94.49–99.18) 99.73 (97.17–99.93) 0.01
Table A.6. Chapter 4 results
Non-tumour Tumour
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Non-tumour Tumour










































































































































51.48 (33.74–80.09) 74.12 (45.91–92.97) NS
Ferritin heavy chain, %
(95% CI)
85.40 (41.57–97.56) 96.41 (85.85–98.54) 0.05
Ferritin light chain, %
(95% CI)
29.09 (14.57–51.53) 64.82 (38.63–81.96) 0.01
HO-1, % (95% CI) 67.36 (36.95–78.41) 81.64 (51.20–96.45) NS





59.64 (22.10–99.72) 89.60 (53.70–96.25) NS
DMT-1, % (95% CI) 46.99 (4.26–63.66) 41.99 (23.57–70.45) NS
Ferroportin, % (95% CI) 40.21 (17.13–69.80) 67.00 (43.28–76.10) 0.05





61.84 (15.68–75.97) 64.82 (20.59–76.26) NS
Ferritin heavy chain, %
(95% CI)
82.63 (78.54–97.86) 93.48 (88.57–98.40) NS
Ferritin light chain, %
(95% CI)
49.23 (8.81–71.91) 28.81 (14.28–54.83) NS




88.78 (7.53–99.02) 43.78 (23.38–64.57) NS
DMT-1, % (95% CI) 99.40 (99.19–100.00) 99.65 (99.40–99.91) NS
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A.12. Chapter 6 spontaneous tumour results
Vehicle Sapatinib Significance
Figure 6.1
p62, % (95% CI) 69.88 (52.65–85.71) 31.59 (18.97–69.80) 0.05
Figure 6.4




2.94 (±1.22) 2.88 (±2.31) NS
Figure 6.7







0.6186 (0.2980–5.689) 0.4666 (0.0009–1.2710) NS
GPX4, % (95% CI) 88.60 (79.52–95.40) 99.40 (95.05–99.82) 0.0001
Figure 6.8
NRF2, % (95% CI) 98.05 (86.40–99.50) 71.36 (46.39–92.96) 0.01
Table A.13. Chapter 6 cell death results
Mean cell death, % (±SD) SKBR3 Empty vector HO-1-overexpressing
Figure 6.10, 6.13
DMSO 8.67 (±2.95) 8.99 (±3.00) 10.41 (±3.53)
Erastin 21.93 (±2.19) 20.33 (±2.99) 13.05 (±3.30)
Erastin+DFO 13.37 (±2.44) 16.07 (±2.59) 12.66 (±3.34)
Erastin+ferrostatin 11.84 (±3.80) 16.8 (±2.53) 13.22 (±2.70)
Figure 6.10, 6.14
Sapatinib 19.50 (±3.84) 19.44 (±8.06) 20.01 (±5.97)
Sapatinib+DFO 15.42 (±1.90) 17.00 (±2.17) 16.91 (±3.48)
Sapatinib+ferrostatin 11.90 (±3.04) 19.07 (±4.01) 20.20 (±7.37)
Lapatinib 19.16 (±4.31) 20.52 (±5.92) 22.19 (±4.70)
Lapatinib+DFO 15.77 (±4.29) 13.91 (±4.85) 22.42 (±6.91)
Lapatinib+ferrostatin 11.13 (±2.03) 18.56 (±3.94) 23.23 (±7.81)
Figure 6.11, 6.15
Sapatinib+Z-VAD-FMK 13.81 (±4.92) 14.43 (±1.31) 17.77 (±4.17)
Lapatiib+Z-VAD-FMK 17.11 (±0.87) 16.46 (±3.59) 19.29 (±5.67)
Table A.14. Chapter 6 autophagy cell death results
Mean cell death, % (±SD) Empty vector HO-1-overexpressing
Figure 6.17
Continued on the next page
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DMSO+3-MA - 12.30 (±1.39)
DMSO+Bafilomycin - 11.17 (±1.26)
Erastin+3-MA 22.86 (±6.37) 20.55 (±6.45)
Erastin+Bafilomycin 15.33 (±3.90) 17.38 (±4.61)
Figure 6.18
Sapatinib+3-MA 18.92 (±2.29) 29.54 (±9.80)
Sapatinib+Bafilomycin 19.68 (±0.52) 30.69 (±4.70)
Lapatinib+3-MA 18.34 (±4.86) 28.57 (±6.03)
Lapatinib+Bafilomycin 16.28 (3±.26) 35.31 (±5.04)
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Appendix B
Hits identified by proteomics
Table B.1. Proteins identified by proteomics that were significantly and 2-fold differentially
regulated between vehicle- and sapatinib-treated tumours
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Use of a genetically engineered mouse model as a preclinical tool
for HER2 breast cancer
Helen Creedon1, Lucy A. Balderstone1,*, Morwenna Muir1, Jozef Balla1, Laura Gomez-Cuadrado1,
Natasha Tracey1, Joseph Loane2, Teresa Klinowska3, William J. Muller4 and Valerie G. Brunton1,‡
ABSTRACT
Resistance to human epidermal growth factor receptor 2 (HER2)-
targeted therapies presents a major clinical problem. Although
preclinical studies have identified a number of possible mechanisms,
clinical validation has been difficult. This is most likely to reflect the
reliance on cell-line models that do not recapitulate the complexity and
heterogeneity seen in human tumours. Here, we show the utility of a
genetically engineered mouse model of HER2-driven breast cancer
(MMTV-NIC) to define mechanisms of resistance to the pan-HER
family inhibitor AZD8931. Genetic manipulation of MMTV-NIC mice
demonstrated that loss of phosphatase and tensin homologue (PTEN)
conferred de novo resistance to AZD8931, and a tumour fragment
transplantation model was established to assess mechanisms of
acquired resistance. Using this approach, 50% of tumours developed
resistance to AZD8931. Analysis of the resistant tumours showed two
distinct patterns of resistance: tumours in which reducedmembranous
HER2 expression was associated with an epithelial-to-mesenchymal
transition (EMT) and resistant tumours that retained HER2 expression
and an epithelialmorphology. The plasticity of the EMTphenotypewas
demonstrated upon re-implantation of resistant tumours that then
showed a mixed epithelial and mesenchymal phenotype. Further
AZD8931 treatment resulted in the generation of secondary resistant
tumours that again had either undergone EMTor retained their original
epithelial morphology. The data provide a strong rationale for basing
therapeutic decisions on the biology of the individual resistant tumour,
which can be very different from that of the primary tumour and will be
specific to individual patients.
KEY WORDS: HER2, Breast cancer, Resistance, Epithelial-to-
mesenchymal transition
INTRODUCTION
Human epidermal growth factor receptor 2 (HER2) gene
amplification and/or protein overexpression occurs in around 20%
of breast cancers and is associated with poor prognosis. Several
drugs capable of specifically targeting the HER2 pathway have been
developed for use in both early and late HER2-positive disease and
have had a significant impact on the treatment of HER2-positive
breast cancer (Arteaga et al., 2012); these include antibodies
directed against HER2, such as trastuzumab and pertuzumab, and
small molecule tyrosine kinase inhibitors that target the kinase
activity of HER2 and HER1, such as lapatinib. Although initial
response rates to the current HER2-targeted therapies are good,
resistance is inevitable. Further tyrosine kinase inhibitors, including
AZD8931 (sapatinib) and neratinib, have been developed in an
attempt to improve efficacy rates and the duration of response.
Preclinical studies have identified numerous mechanisms of both
de novo and acquired resistance (Creedon et al., 2014; Rexer and
Arteaga, 2012), although their clinical validation has been more
difficult, which reflects the inability of the conventional cell-based
approaches to model the complexity of the human disease
adequately.
The limitation of conventional cell culture and mouse xenograft
studies is well recognized as an obstacle to the effective translation
of preclinical findings into clinical benefit (Sharpless and Depinho,
2006). Use of genetically engineered models in which tumours
develop in situ in the context of an intact microenvironment is a
viable alternative for preclinical assessment of both drug response
and mechanisms of resistance (van Miltenburg and Jonkers, 2012).
Generation of autochthonous tumours driven by cell-specific
expression of oncogenic drivers or loss of tumour suppressors
relevant to human tumours gives rise to tumours in which the
histopathology and disease progression also recapitulate many
aspects of the human disease, providing more relevant models with
which to study drug response.
Here, we describe the use of a HER2-driven model of mammary
tumorigenesis as a preclinical tool to study response and resistance
mechanisms in HER2-positive breast cancer. We have used the
MMTV-NIC (Neu-IRES-Cre) model (Ursini-Siegel et al., 2008),
which employs a bicistronic transcript to co-express activated
ErbB2/Neu (HER2) with MMTV-Cre recombinase, resulting in the
formation of activated ErbB2/Neu-driven mammary tumours. The
advantage of this model is that the coupling of activated ErbB2/Neu
with Cre recombinase in the same cell means that Cre-negative
tumour cells are not generated, allowing the efficient Cre-mediated
deletion of additional conditional alleles (Schade et al., 2009). This
allows validation of potential mechanisms of de novo resistance,
such as loss of phosphatase and tensin homologue (PTEN). Loss of
PTEN and subsequent activation of the phosphoinositide 3-kinase
(PI3K) pathway has been identified as a key determinant of
trastuzumab sensitivity and has been associated with poorer overall
survival in trastuzumab-treated patients (Berns et al., 2007; Esteva
et al., 2010; Nagata et al., 2004), although the impact on lapatinib
resistance remains unclear (Xia et al., 2007). Here, we have coupled
loss of PTEN with HER2 activation in the MMTV-NIC model and
demonstrate that loss of PTEN is associated with de novo resistance
to the small molecule tyrosine kinase inhibitor sapatinibReceived 2 September 2015; Accepted 23 December 2015
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(AZD8931). We also show the utility of the model for identifying
mechanisms of acquired resistance to HER2-targeted therapy and
identify the induction of an epithelial-to-mesenchymal transition
(EMT) in a subpopulation of AZD8931-resistant tumours.
RESULTS
Loss of PTEN confers resistance to AZD8931
Initial experiments were carried out to determine whether the
MMTV-NICmodel was sensitive to the HER family tyrosine kinase
inhibitor AZD8931. As loss of PTEN and activation of the PI3K
signalling pathway have previously been reported to confer
resistance to trastuzumab, cohorts of both MMTV-NIC PTEN+/+
and MMTV-NIC PTEN+/− mice were used. Both MMTV-NIC
PTEN+/+ and MMTV-NIC PTEN+/− mice developed on average
four tumours per mouse with 100% penetrance. As described
previously, loss of PTEN accelerated tumour onset in the MMTV-
NIC mice (Schade et al., 2009). The median age of tumour onset
was 102 days in the MMTV-NIC PTEN+/− cohort compared with
150 days in the MMTV-NIC PTEN+/+ cohort (P=0.0001, Gehan–
Breslow–Wilcoxon test; Fig. S1A). Western blot analysis of
tumours showed reduced expression of PTEN and increased
phosphorylation of Akt in tumours taken from the MMTV-NIC
PTEN+/− mice, consistent with increased signalling through the
PI3K pathway (Fig. S1B).
To assess the response to AZD8931, we randomized cohorts of
MMTV-NIC PTEN+/+ andMMTV-NIC PTEN+/−mice to treatment
with either AZD8931 or vehicle. Median survival in the vehicle arm
of the MMTV-NIC PTEN+/+ cohort after the start of treatment was
35 days (range 10-39 days), compared with 18 days (range 11-
24 days) in vehicle-treated MMTV-NIC PTEN+/− mice. Drug
treatment was stopped at 40 days, when all vehicle-treated animals
were sacrificed because of tumour burden. At this time, none of the
drug-treated animals had to be sacrificed because of tumour burden
(Fig. 1A,B). When we looked at the growth of the individual index
tumours (defined as the largest tumour at the time of sacrifice) in the
different cohorts after 40 days, we saw that all AZD8931-treated
MMTV-NIC PTEN+/+ tumours initially responded to treatment and
two out of five tumours fully resolved. The growth of a further two
tumours was inhibited, whereas the final tumour initially responded
but after 17 days of drug treatment became insensitive, and after
40 days of treatment its volume had increased by 134.2%. By
comparison, the tumours in the vehicle-treated arm continued to
grow throughout the experiment, and the median percentage change
in tumour volumewas an increase of 294.6% (Fig. 1C). By contrast,
all but one of five AZD8931-treatedMMTV-NIC PTEN+/− tumours
became rapidly insensitive to AZD8931, and by day 40 all
AZD8931-treated tumours had grown beyond their initial starting
volume, with a median percentage change in tumour volume of
131.1%. As expected, all vehicle-treated tumours continued to grow
steadily throughout the experiment, with a median percentage
change in tumour volume of 415.1% (Fig. 1D). In summary,
AZD8931 resulted in tumour shrinkage in the majority of MMTV-
NIC PTEN+/+ animals, but although it slowed tumour growth in
MMTV-NIC PTEN+/− animals it did not cause tumour resolution.
We also noted that by day 40 there were fewer additional tumours in
both the MMTV-NIC PTEN+/+ and MMTV-NIC PTEN+/− animals
treated with AZD8931, and although this did not reach statistical
significance the reduction in tumour burden was greater in the
MMTV-NIC PTEN+/+mice, consistent with the increased sensitivity
of the MMTV-NIC PTEN+/+ tumours to AZD8931 (median values
for tumours per mouse: MMTV-NIC PTEN+/+, vehicle=5; MMTV-
NIC PTEN+/+, AZD8931=1; MMTV-NIC PTEN+/−, vehicle=6;
MMTV-NIC PTEN+/−, AZD8931=3; P=0.1025, Kruskal–Wallis).
This illustrates the significant heterogeneity in response to AZD8931
between the two different cohorts and demonstrates that loss of
PTEN, leading to activation of the PI3K pathway, confers de novo
resistance to AZD8931.
As there was little residual tissue from the AZD8931-treated
MMTV-NIC PTEN+/+ animals at the completion of the experiment,
additional cohorts of both MMTV-NIC PTEN+/+ and MMTV-NIC
PTEN+/−micewere treated with vehicle or AZD8931 for 3 days and
effects on HER family signalling pathways assessed. There was a
reduction in phosphorylation of HER2 and HER3 in MMTV-NIC
PTEN+/+ and MMTV-NIC PTEN+/− tumours following treatment
with AZD8931 compared with vehicle-treated animals, although
this did not reach statistical significance after histoscoring (Fig. 1E).
This reflects the heterogeneous expression and activation of both
HER2 and HER3 in the tumours (Fig. S1C). No significant
epidermal growth factor receptor (EGFR/HER1) expression was
detected in the MMTV-NIC tumours, so it was not possible to
assess effects on EGFR activation (results not shown). We used
reverse-phase protein arrays to look at downstream signalling to
Akt, mitogen-activated protein kinase (MAPK) and S6 in the
AZD8931-treated tumours and found that their activation was
significantly inhibited in MMTV-NIC PTEN+/+ and MMTV-NIC
PTEN+/− tumours (Fig. 1F). Immunohistochemical analysis showed
that pAkt was confined to the tumour cells and not expressed in the
surrounding stroma, whereas pMAPK was also expressed in the
stroma, and the reduced expression of pMAPK might therefore also
reflect reduced activation of MAPK in the surrounding stroma (Fig.
S1D). Thus short-term treatment with AZD8931 inhibits HER
family signalling in both tumour types, and therefore, the
differential response of the MMTV-NIC PTEN+/+ and MMTV-
NIC PTEN+/− tumours does not reflect an inability of the drug to
inhibit the target in the different tumours.
Establishment of orthotopic transplanted tumours
The multifocal nature of the MMTV-NIC model means that it is not
possible to study mechanisms of acquired drug resistance. We
therefore established whether theMMTV-NIC PTEN tumours could
be orthotopically transplanted into syngeneic wild-type FVB/Nmice
to provide a more tractable model for drug-resistance studies. We
were able to establish tumours after transplantation of tumour
fragments from MMTV-NIC PTEN+/− tumours but not from
MMTV-NIC PTEN+/+ tumour fragments. Examination of sections
stained with haematoxylin and eosin (H&E) from the fragment-
derived MMTV-NIC PTEN+/− tumours confirmed the presence of
highly mitotic, grade 3 carcinomas, which were indistinguishable
from tumours that developed in the parental MMTV-NIC PTEN+/−
model (Fig. 2A). Both parental and fragment-derived tumours
demonstrated inter-and intratumoral heterogeneity in HER2
expression (Fig. 2B) and, consistent with the frequent observation
of mitotic figures on H&E sections, a high percentage of nuclei
stained positively for Ki67 in both parental and fragment-derived
tumours (Fig. 2C). The orthotopic transplantation model therefore
provides a useful tool by circumventing problems associatedwith the
multifocal nature of the genetically engineered model.
Initial studies to determine the suitability of the MMTV-NIC
transplantation model for drug-efficacy studies were carried out
using the taxane paclitaxel, whose role in the management of both
early and metastatic breast cancer is well established (Gajria et al.,
2010; Ghersi et al., 2005). Paclitaxel treatment resulted in a
statistically significant increase in overall survival of mice bearing
fragment-derived tumours. Median overall survival was increased
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from 14 days in vehicle-treated animals (range 7-14 days) to
24 days (range 24-24 days) in drug-treated animals (P=0.03,
Gehan–Breslow–Wilcoxon test). Looking at the response of
individual tumours to treatment, we found that although
paclitaxel slowed tumour growth, it did not result in tumour
shrinkage (Fig. 2D).
Fig. 1. PTEN status determines the sensitivity to AZD8931. Cohorts of MMTV-NIC-PTEN+/+ and NIC-PTEN+/− mice were randomized to treatment with daily
AZD8931 or vehicle, and the tumour response was monitored. (A) Overall survival in vehicle- (n=5) and AZD8931-treated (n=5) NIC-PTEN+/+ mice (P=0.0043,
Gehan–Breslow–Wilcoxon test). (B) Overall survival in vehicle- (n=5) and AZD8931-treated (n=5) NIC-PTEN+/− mice (P=0.0039, Gehan–Breslow–Wilcoxon
test). (C) Waterfall plot of percentage tumour volume change over duration of experiment in NIC-PTEN+/+ vehicle- and AZD8931-treated animals (P=0.0079,
Mann–Whitney U-test). (D) Waterfall plot of percentage tumour volume change over duration of experiment in NIC-PTEN+/− vehicle- and AZD8931-treated
animals (P=0.0079, Mann–WhitneyU-test). Vehicle-treated mice were sacrificed when the tumour burden reached the maximal permitted size, at 10-39 days for
MMTV-NIC PTEN+/+ mice and 11-24 days for MMTV-NIC PTEN+/− mice. AZD8931 treatment was stopped at 40 days, when all vehicle-treated animals were
sacrificed because of tumour burden. (E) Immunohistochemical analysis was performed on paraffin-embedded sections of AZD8931- and vehicle-treated
tumours with pTyr 1221/1222 HER2 and pTyr 1289 HER3 antibodies. Membranous histoscore calculated as the sum of the product of the percentage of cells
stained by the intensity graded from 0 to 3, where 1=weak, 2=moderate and 3=strong staining [histoscore=(% *1)+(% *2)+(% *3)]. pTyr 1221/1222 HER2 staining:
NIC-PTEN+/+, P=0.48; NIC-PTEN+/−, P=1.0; and pTyr1289 HER3 staining: NIC-PTEN+/+, P=0.20; NIC-PTEN+/−, P=0.07; Mann–Whitney U-test comparing
vehicle- and AZD8931-treated tumours. Black data points represent vehicle-treated tumours. Red data points represent AZD8931-treated tumours. Bars
represent mean value for each genotype. (F) Reverse-phase protein array analysis was performed on lysate from AZD8931- (red data points) and vehicle-treated
(black data points) NIC-PTEN+/+ and NIC-PTEN+/− tumours. The ratio of phospho:total protein relative fluorescence intensity (RFI) value is presented and
normalized to the maximal value in each data set. *P≤0.05 and **P≤0.01 comparing vehicle and AZD8931 for each antibody, Mann–Whitney U-test.
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Development of resistance to AZD8931
We next determined whether the MMTV-NIC tumours could be
used to model acquired resistance to AZD8931. We generated
tumour fragments from three MMTV-NIC PTEN+/− donor mice.
From each mouse, donor tumour fragments were then transplanted
into cohorts of six wild-type FVB/Nmice. After the development of
established tumours, mice were randomized to treatment with either
vehicle (n=3) or AZD8931 (n=3). AZD8931 treatment resulted in
an initial inhibition of tumour growth in all mice. When tumours
had regressed to ≤0.1 cm3, AZD8931 treatment was stopped. After
the subsequent regrowth of the tumour, treatment was then resumed
when tumours reached ≥0.3 cm3. This cycle was repeated until
tumours either resolved or became resistant and were able to
continue growing in the presence of ongoing treatment. The
resistant tumours originated from different donors, and the duration
of treatment required for the individual tumours to become resistant
varied between individual tumours (Fig. 3A).
Histopathological examination of the matched AZD8931-naïve
and -resistant tumours revealed that although all the AZD8931-
naïve tumours were histologically indistinguishable from each other
(Fig. 3B,C) there were significant differences in the AZD8931-
resistant tumours (Fig. 3D,E). Although some of the resistant
tumours had the same histopathological phenotype as their matched
naïve tumour (Fig. 3D), a subset of resistant tumours had a more
pleomorphic appearance and were composed of spindle cells,
suggestive of tumours undergoing EMT (Fig. 3E).
Loss of cell surface E-cadherin is an established marker of EMT,
and although strong membranous expression of E-cadherin was
seen in all drug-naïve tumours, loss of E-cadherin in the resistant
tumours was associated with the conversion to a spindle cell
morphology (Fig. 4A-D), with the resistant tumours that had not
undergone the morphological change retaining expression of E-
cadherin (Fig. 4I-L). This loss of E-cadherin was accompanied by
expression of the mesenchymal marker vimentin in the resistant
spindle cell tumours (Fig. 4E,F), indicating that these resistant
tumours had undergone EMT. HER2 expression was preserved in
the resistant tumours that had retained the histopathological features
of the drug-naïve tumours (Fig. 4O,P), but total loss of membranous
HER2 expression was seen in the resistant spindle cell tumours
(Fig. 4G,H).
To establish whether the resistant phenotype was stable,
fragments from one individual resistant tumour were re-implanted
into cohorts of wild-type FVB/N mice. After the development of
established tumours, mice were randomized to treatment with either
vehicle or AZD8931. AZD8931 treatment prevented the growth of
one tumour, although tumour regression did not occur (Fig. 5A,
red growth curve, ‘AZD8931 responsive’). The remaining three
tumours responded initially to AZD8931, although resistance did
develop over time (Fig. 5A, black growth curves, ‘AZD8931
resistant’). The onset of secondary resistance was faster than in the
original drug-naïve tumour fragments (compare Figs 3A and 5A).
The vehicle-treated tumours were all highly mitotic, containing
rounded cells with pleomorphic nuclei (Fig. 5B). The tumour whose
growth was inhibited by AZD8931 had mild to moderately
pleomorphic nuclei and no mitoses (Fig. 5C). The resistant
tumours had distinct morphologies; two of the tumours were
composed of highly mitotic spindle cells with similar histology to
those seen in the primary resistant tumours that had undergone EMT
(compare Fig. 5E,F with Fig. 3C), whereas the remaining resistant
tumour had a papillary architecture with moderate/marked nuclear
pleomorphism (Fig. 5D). As we had previously demonstrated a
reduction in pAkt and pMAPK after acute treatment with AZD8931
(Fig. 1F), we looked at activation of Akt and MAPK following
development of resistance to AZD8931 (Fig. 5G-P). Chronic
exposure to AZD8931 did not reduce pAkt and pMAPK levels,
although one AZD89231 resistant tumour showed an overall
reduction in pMAPK staining, with only small pockets of
pMAPK-positive cells scattered throughout the tumour (Fig. 5N).
Further analysis of the tumours revealed that all vehicle-treated
tumours expressed both E-cadherin and vimentin (Fig. 6A). The
AZD8931-responsive tumour was also both E-cadherin and
vimentin positive, although the number of vimentin-positive
tumour cells was much lower than in the vehicle-treated tumours
(Fig. 6B). As with the primary resistant tumours, the two spindle
cell AZD8931-resistant tumours had lost E-cadherin and were
strongly vimentin positive. Strikingly, this was associated with loss
of membranous HER2 expression (Fig. 6D,E). The remaining
AZD8931-resistant tumour resembled the vehicle-treated tumours,
being both E-cadherin and vimentin positive (Fig. 6C). Thus, the
Fig. 2. Transplantation of NIC-PTEN+/− fragments generated tumours that
were indistinguishable from the parental tumours. (A) Representative H&E
images of fragment-derived and spontaneous tumours from NIC-PTEN+/−
mice. (B,C) Representative images of HER2 (B) and Ki67 (C) expression in
fragment-derived and spontaneous tumours. Scale bar: 100 µm. (D) Growth
rate of vehicle- (n=3) and paclitaxel-treated (n=3) fragment-derived tumours.
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development of resistance to AZD8931 in a subpopulation of
tumours is linked to increased expression of markers associated with
the induction of EMT and loss of membranous HER2.
In order to explore further the mechanisms of EMT induction in
the resistant tumours, we looked at expression of Zeb1, which is a
known transcriptional regulator of EMT. Upregulation of nuclear
Zeb1 was seen only in the resistant spindle cell tumours, consistent
with a Zeb1-regulated induction of EMT (Fig. 7).
DISCUSSION
It is widely acknowledged that the use of conventional xenograft
models for preclinical drug testing has limited predictive clinical
value. Use of genetically engineered mouse models provides a
useful alternative, in which drug response and resistance can be
evaluated in situations that more faithfully recapitulate the human
disease (Olive et al., 2009; Singh et al., 2010; Wang et al., 2012).
Here, we show that the MMTV-NIC model has utility in assessing
efficacy and resistance mechanisms of HER2-targeted therapies.
Comparison of tumours with the same genotype demonstrated
heterogeneity in the rate and extent of response to AZD8931,
despite the use of predefined genetic mutations to drive tumour
development. This variation in therapeutic response has been
described previously in other genetically engineered models
(Rottenberg et al., 2007) and contrasts with the more uniform
response seen in xenograft studies (Becher and Holland, 2006). This
is an important advance because it enables us more accurately to
recapitulate the behaviour of human tumours and is most probably a
result of the random acquisition of secondary mutations during
tumour development and progression in these models. In addition,
we show, for the first time, that acquired resistance to a HER2-
targeted therapy can be modelled in MMTV-NIC tumours. The
majority of studies exploring resistance to HER2-directed therapies
have used cell-line-based approaches and, although numerous
resistance mechanisms have been identified in vitro, clinical
validation has proved challenging. The use of genetically
engineered models to explore resistance mechanisms offers a
more physiologically relevant system, with tumours developing
resistance whilst exposed to ongoing in vivo selection pressures.
Therefore, any resistance strategies identified might be more
predictive of clinically relevant resistance mechanisms.
We identified PTEN loss as an important determinant of de novo
AZD8931 resistance. Loss of PTEN and subsequent activation of
the PI3K pathway has been identified as a key determinant of
trastuzumab sensitivity and has been associated with poorer overall
survival in trastuzumab-treated patients (Berns et al., 2007; Esteva
et al., 2010; Nagata et al., 2004), although the impact on lapatinib
resistance remains unclear (Xia et al., 2007). Like lapatinib,
AZD8931 is a dual inhibitor of both HER2 and HER1; however,
it has a unique profile of activity, being a more effective inhibitor of
HER family signalling than lapatinib, resulting in a distinct profile
of anti-tumour activity (Hickinson et al., 2010). Current trials are
underway to determine whether the more effective simultaneous
inhibition of HER family signalling provided by AZD8931 could
have clinical benefit (Tjulandin et al., 2014); therefore,
Fig. 3. Generation of fragment-derived tumours with acquired resistance to AZD8931. (A) Representative growth curves of three independent NIC-PTEN+/−
tumour fragments treated with AZD8931. Repeated cycles of AZD8931 were administered to facilitate the selection of tumours with acquired resistance to
AZD8931. Green arrows indicate the start of treatment and red arrows indicate when treatment was stopped. (B,C) Representative H&E images of AZD8931-
naïve (vehicle) and AZD8931-resistant tumours. (D) AZD8931-resistant tumour phenotypically indistinguishable from AZD8931-naïve tumour. (E) AZD8931-
resistant tumour consisting of spindle-shaped cells. Scale bar: 100 µm.
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understanding potential mechanisms of resistance to AZD8931 is
required. Both MMTV-NIC PTEN+/+ and MMTV-NIC PTEN+/−
tumours displayed reduced Akt activity after treatment with
AZD8931, although in both models there was still evidence of
residual activity following AZD8931 treatment. Incomplete
inhibition of Akt signalling is a well-established mechanism of
resistance to HER2-targeted therapies (Rexer and Arteaga, 2012)
and is likely to contribute to the continued tumour progression in the
MMTV-NIC PTEN+/− model. In support of this, we saw no
reduction in pAkt in AZD8931-resistant MMTV-NIC PTEN+/−
tumours following chronic drug treatment. Other studies have
shown that combination therapy using a HER2 monoclonal
antibody and an Akt inhibitor inhibited growth of MMTV-NIC
PTEN−/− tumours that were resistant to treatment with either drug
alone (Wang et al., 2012). Taken together, this supports the use of
Akt inhibitors in combination with HER2-targeted therapies, and a
number of clinical trials are currently underway to evaluate the use
of trastuzumab and/or lapatinib with Akt inhibitors.
One of the major advantages of using the MMTV-NIC tumours
formodelling drug resistancewas the generation of resistant tumours
with distinct molecular phenotypes, which recapitulates in part the
heterogeneity seen in the clinic. This provides a strong rationale for
basing therapeutic decisions on the biology of the individual
resistant tumour, which might be very different from that of the
primary tumour. For example, the observation that a subset of our
resistant tumours no longer expressed high levels of membranous
HER2 could have a significant impact on future treatments. To date,
major advances in overcoming clinical resistance to trastuzumab
have focused on alternative strategies for targeting HER2 signalling,
either by combining drugs that target different HER family receptors
or through use of drug-antibody conjugates, such as trastuzumab-
emtansine. As it is rarely mandatory to re-biopsy tumours at the time
of entry into clinical trials, patients whose tumours no longer express
HER2 risk being exposed to the toxicity of treatments that might not
be anticipated to be effective.
Several in vitro studies have shown that resistance to lapatinib and
trastuzumab is associated with induction of EMT (Creedon et al.,
2014; Kim et al., 2013; Korkaya et al., 2012; Oliveras-Ferraros
et al., 2012), and our finding that a subset of the resistant tumours
have undergone EMT indicates that targeting pathways that regulate
EMT might be effective in a subpopulation of resistant tumours
(Singh and Settleman, 2010). Interestingly, the generation of mixed
vimentin- and E-cadherin-positive tumours following re-
implantation of an AZD8931-resistant tumour shows that the
induction of EMT is not binary and that the tumours are highly
plastic and can respond to microenvironmental factors that can
affect their EMT status. The initial response of the re-implanted
resistant tumour fragments to AZD8931 most probably reflects this
plasticity, with the reversion to a more epithelial phenotype and the
concomitant re-expression of HER2 conferring initial drug
sensitivity. Although we have shown that the induction of EMT is
associated with acquired resistance to AZD8931, induction of EMT
Fig. 4. AZD8931 resistance is
associated with EMT in a
subpopulation of tumours. Analysis of
AZD8931-naïve (vehicle) and AZD8931-
resistant tumours showing representative
images of H&E staining and
immunohistochemical analysis of E-
cadherin, vimentin and HER2. Scale bar:
50 µm. (A-H) AZD8931-resistant spindle
cell tumour and corresponding vehicle-
treated tumour. (I-P) AZD8931-resistant
tumour phenotypically indistinguishable
fromAZD8931-naïve (vehicle) tumour and
corresponding vehicle-treated tumour.
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in HER2-driven mouse mammary tumours via expression of an
activating PI3K mutation was associated with de novo resistance to
HER2-targeted therapies (Hanker et al., 2013), whereas in vitro
studies showed that expression of transcription factors that drive
EMT was causally related to de novo trastuzumab resistance
(Oliveras-Ferraros et al., 2012).
One of the main challenges for the future is the identification of
effective drug combinations to combat resistance to HER2-targeted
therapies. Use of the transplantable tumour model described here
provides a powerful preclinical tool with which to test potential
novel drug combinations in resistant tumours, studies which to date
rely on use of resistant cell lines established in vitro. For example,
exploitation of the molecular differences in resistant tumours that
have undergone EMT might provide alternative combination
strategies for overcoming resistance in these tumours.
MATERIALS AND METHODS
Animals
MMTV-NIC mice expressing an oncogenic ErbB2/Neu allele and Cre
recombinase under the control of the MMTV promoter were generated as
previously described (Ursini-Siegel et al., 2008) and inter-crossed with
floxed Pten (strain C;129S4-Ptentm1Hwu/J; Jackson Laboratory) mice to
generate either MMTV-NIC PTEN+/+ or MMTV-NIC PTEN+/− progeny on
a FVB/N background. Genotyping was carried out by Transnetyx (Cordova,
TN, USA). All experiments were conducted in compliance with UK Home
Office guidelines. Nulliparous females were monitored twice weekly, using
manual palpation, for tumour formation. The greatest tumour dimension and
its perpendicular measurement were recorded, and when tumours had
reached their maximal size (1.5 cm in one direction) as determined by Home
Office regulations, mice were sacrificed. Tumours were then collected and
fixed in 10% neutral buffered formalin. Tumours used for the generation of
fragments were washed in ice-cold PBS and cut into 1 mm3 fragments and
any macroscopic necrotic areas removed and then centrifuged at 450 g for
1 min. The supernatant, containing fibrous and necrotic material, was
removed and the remaining fragments were suspended in cryopreservation
buffer (50% Dulbecco’s modified Eagle’s medium, 45% fetal bovine serum
and 5% dimethyl sulfoxide) and stored at −80°C. At the time of
transplantation, fragments were defrosted at room temperature, washed in
PBS and inserted into the fourth mammary fat pad.
For drug studies using AZD8931 (AstraZeneca Oncology iMed, Alderley
Park, Macclesfield, UK), treatment was commenced when mice had at least
one tumour ≥0.1 cm3 (index tumour) and continued until complete
resolution of the index tumour or until the animal was sacrificed because
of tumour size ≥1.5 cm (in any direction). Mice were dosed daily with
Fig. 5. Generation of secondary resistance in NIC-PTEN+/− tumour fragments. (A) Growth curves of NIC-PTEN+/− AZD8931-resistant tumour fragments
following treatment with repeated cycles of AZD8931. Black lines represent tumours that developed resistance to AZD8931. Red line represents tumour with
growth inhibited by AZD8931. Treatment was stopped after 90 days because of lack of tumour growth. (B) Representative H&E staining of vehicle-treated
tumours. (C-F) H&E staining of AZD8931-treated tumours. (C) AZD8931-responsive tumour (red line in A) with growth inhibited by AZD893. (D) AZD8931-
resistant tumour that has retained the morphology of the AZD8931-naïve (vehicle) tumours. (E,F) AZD8931-resistant tumours with a spindle cell morphology.
(G-P) Immunohistochemical analysis of pAkt (G-K) and pMAPK (L-P) in vehicle- and AZD8931-treated tumours. Scale bar: 50 µm.
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vehicle (1% Tween 80 in PBS) or AZD8931 (100 mg/kg) suspended in 1%
Tween 80 (in PBS) by oral gavage. To generate tumours that were resistant
to AZD8931, an intermittent drug treatment schedule was performed. After
transplantation of tumour fragments, tumours were allowed to grow to
≥0.1 cm3 before treatment with AZD8931 as above was started. When
tumours regressed to <0.1 cm3, AZD8931 treatment was stopped and
tumours were monitored twice weekly. If the tumour regrew, treatment was
then restarted when tumours reached ≥0.3 cm3. This cycle was repeated
until tumours developed resistance, and mice were sacrificed when the
maximal tumour size (1.5 cm in any direction) was reached as permitted
Fig. 6. Development of EMT in AZD8931-resistant
tumours. Immunohistochemical analysis of E-cadherin,
vimentin and HER2 in (A) vehicle- and (B-E) AZD8931-treated
tumours. (B) AZD8931-responsive tumour with growth
inhibited by AZD8931. (C) AZD8931-resistant tumour that has
retained the morphology of the AZD8931-naïve (vehicle)
tumours. (D,E) AZD8931-resistant tumours with a spindle cell
morphology. Scale bar: 50 µm.
Fig. 7. Nuclear Zeb1 expression in spindle cell AZD8931-resistant tumours. Immunohistochemical analysis of Zeb1 in (A) vehicle- and (B-E) AZD8931-
treated tumours. (B) AZD8931-responsive tumour with growth inhibited by AZD8931. (C) AZD8931-resistant tumour that has retained the morphology of the
AZD8931-naïve (vehicle) tumours. (D,E) AZD8931-resistant tumours with a spindle cell morphology. Scale bar: 50 µm.
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under UK Home Office regulations. For drug studies using paclitaxel,
treatment was commenced when mice had at least one tumour ≥0.15 cm3
(index tumour) and continued until the animal was sacrificed because of
tumour size or when the experiment was terminated 72 h after the fourth
dose of paclitaxel. Mice were dosed weekly with vehicle (cremaphor EL:
ethanol, 1:1, v:v) or paclitaxel (10 mg/kg) suspended in cremaphor EL:
ethanol by intraperitoneal injection.
Immunohistochemistry
Immunohistochemistry of formalin-fixed, paraffin-embedded tissues was
performed as described previously (Karim et al., 2013). Primary antibodies
used were as follows: HER2 (Invitrogen; catalogue no. AHO1011; 1:1000),
pY1221/1222 HER2 (catalogue no. 2243; 1:400; Cell Signaling, UK),
pY1289 HER3 (catalogue no. 4791; 1:100; Cell Signaling, UK), Ki67
(Vector; catalogue no. VP-RM04; 1:500), E-cadherin (catalogue no. 3195,
1:5000; Cell Signaling, UK), vimentin (catalogue no. 5741; 1:100; Cell
Signaling, UK), pS473 Akt (catalogue no. 4060; 1:50; Cell Signaling, UK)
and pT202/Y204 MAPK (catalogue no. 4370; 1:400; Cell Signaling, UK).
Western blotting
Western blot analysis was performed as described previously (Karim et al.,
2013). Primary antibodies used were HER2 (catalogue no. 2248; 1:1000;
Cell Signaling, UK), pS473 Akt (catalogue no. 4060; 1:1000; Cell
Signaling, UK), Akt (catalogue no. 9272; 1:1000; Cell Signaling, UK),
PTEN (catalogue no. 9552; 1:1000; Cell Signaling, UK) and β-actin
(catalogue no. A4700; Sigma, UK; 1:5000).
Reverse-phase protein array analysis
Tumours were washed with PBS and lysed in 1% Triton X-100, 50 mM
HEPES (pH 7.4), 150 mM sodium chloride, 1.5 mM magnesium chloride,
1 mM EGTA, 100 mM sodium fluoride, 10 mM sodium pyrophosphate,
1 mM sodium vanadate and 10% glycerol, supplemented with cOmplete
ULTRA protease inhibitor and PhosSTOP phosphatase inhibitor cocktails
(Sigma, UK). Cleared lysates were serially diluted to produce a dilution
series comprising four serial twofold dilutions of each sample, which were
spotted onto nitrocellulose-coated slides (Grace Bio-Labs, supplied by
Sigma, UK) in triplicate in conditions of constant 70% humidity using the
Aushon 2470 array platform (Aushon Biosystems, Billerica, MA, USA).
Slides were hydrated in blocking buffer (Thermo Fisher Scientific, UK)
and then incubated with primary antibodies (all 1:250; all from Cell
Signaling, UK). Bound antibodies were detected by incubation with anti-
rabbit DyLight 800-conjugated secondary antibody (New England
BioLabs, UK). An InnoScan 710-IR scanner (Innopsys, Carbonne,
France) was used to read the slides, and images were acquired at the
highest gain without saturation of the fluorescence signal. The relative
fluorescence intensity of each sample replicate was quantified using Mapix
software (Innopsys).
The linear fit of the dilution series of each samplewas determined for each
primary antibody, from which median relative fluorescence intensities were
calculated, and samples with R2<0.8 in all three replicates were excluded.
Signal intensities were normalized by global sample median normalization
(Guo et al., 2012).
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Mouse models of metastasis: progress and prospects
Laura Gómez-Cuadrado1,*, Natasha Tracey1,*, Ruoyu Ma2, Binzhi Qian2,3 and Valerie G. Brunton1,‡
ABSTRACT
Metastasis is the spread of cancer cells from a primary tumor to
distant sites within the body to establish secondary tumors. Although
this is an inefficient process, the consequences are devastating as
metastatic disease accounts for >90% of cancer-related deaths. The
formation of metastases is the result of a series of events that allow
cancer cells to escape from the primary site, survive in the lymphatic
system or blood vessels, extravasate and grow at distant sites. The
metastatic capacity of a tumor is determined by genetic and epigenetic
changeswithin the cancer cells aswell as contributions fromcells in the
tumor microenvironment. Mouse models have proven to be an
important tool for unraveling the complex interactions involved in the
metastatic cascade and delineating its many stages. Here, we critically
appraise the strengths and weaknesses of the current mouse models
and highlight the recent advances that have been made using these
models in our understanding of metastasis. We also discuss the use of
these models for testing potential therapies and the challenges
associated with the translation of these findings into the provision of
new and effective treatments for cancer patients.
KEY WORDS: Cancer, Metastasis, Mouse models, Stroma
Introduction
Metastasis, the process of tumor cell migration from the primary site
to distant organs, remains the major cause of cancer-related deaths,
despite therapeutic advances in recent years (Steeg, 2016). This
highlights the urgent need to better understand the mechanisms that
underlie metastasis and to identify new therapeutic strategies and
drug targets to treat metastatic disease. A number of excellent
review articles have covered the exciting new advances in our
understanding of the genetic and molecular events that govern
metastatic spread (Lambert et al., 2017; Massagué and Obenauf,
2016; Sethi and Kang, 2011; Turajlic and Swanton, 2016; Valastyan
and Weinberg, 2011), which will not be covered in detail here. In
this Review, we discuss the different mouse models of metastasis
that are currently used, and focus on how they have contributed to
the field thus far. We consider their strengths and weaknesses and
the technological advances that are driving the development of more
refined models, which have the potential to impact on the translation
and development of better therapeutic interventions. We first
provide an overview of the metastatic process.
The metastatic cascade
Metastasis is a multistep process, as illustrated in Fig. 1. The first
step of the metastatic cascade is local invasion at the primary tumor
site. This process is initiated by the activation of signaling pathways
that regulate cytoskeletal dynamics, loss of adhesion amongst tumor
cells and turnover of the surrounding extracellular matrix (ECM)
(Friedl and Alexander, 2011). This allows the tumor cells to migrate
away from the primary tumor and infiltrate into surrounding tissues.
To initiate the spread to secondary sites, the tumor cells must then
intravasate (see Glossary, Box 1) into the blood circulation or
lymphatic system. Dispersal of tumor cells in the lymphatic system
leads to lymph node metastasis in the first instance, while distal
metastasis usually requires tumor cells to disseminate via the blood
circulation (hematogenous) with the choice of a tumor cell to use
either lymphatic or hematogenous dissemination, governed by a
number of factors (Chiang et al., 2016; Wong and Hynes, 2006). In
this article, we will focus on hematogenous metastasis.
After entry into the circulation, tumor cells can disseminate
widely throughout the body and are known as circulating tumor cells
(CTCs) (see Glossary, Box 1). CTCs have the potential to serve as
prognostic markers of metastasis and survival, as has been discussed
extensively in recent reviews (Alix-Panabieres̀ and Pantel, 2013;
Plaks et al., 2013). On reaching distal organs, surviving tumor cells
can be intercepted in small capillaries or actively adhere to larger
blood vessels and extravasate through paracellular or transcellular
transendothelial migration (see Glossary, Box 1) (Reymond et al.,
2013), prior to colonization (see Glossary, Box 1). This process can
be promoted by alterations induced by secreted factors and
extracellular vesicles derived from the primary tumor, before the
establishment of metastases (McAllister and Weinberg, 2014).
These alterations involve fibroblasts, endothelial cells and immune
cells, especially bone marrow-derived immature myeloid cells,
which can collectively establish a pre-metastatic niche (Box 2) that
provides an environment favoring the recruitment of CTCs and their
subsequent growth (Liu and Cao, 2016; Peinado et al., 2017).
Once settled in the metastatic organ, tumor cells are referred to as
disseminated tumor cells (DTCs) (see Glossary, Box 1). DTCs can
be present for years or decades and stay in a latent state as single
cells or micrometastases (Massagué and Obenauf, 2016). This
tumor dormancy may result from single DTCs entering a quiescent
state or may be due to inadequate vascularization or immune
clearance of micrometastases (Gay and Malanchi, 2017).
Eventually, clinically relevant macrometastases (see Glossary,
Box 1) arise from the outgrowth of DTCs, a process termed
colonization (see Glossary, Box 1).
Models of metastasis
In this section, we provide an overview of the main mouse models of
metastatic cancer that are currently in use, from mice generated
using transplantable cancer cells and tumors to genetically
engineered mouse models (GEMMS) (see Glossary, Box 1)
(Francia et al., 2011; Kabeer et al., 2016; Kersten et al., 2016;
Saxena and Christofori, 2013). These mouse models are classified
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and summarized in Table 1, and examples of models that have been
used are listed in Table 2.
Transplantation models
Spontaneous models of metastasis
Spontaneous metastasis models allow the spread of cells from a
primary tumor to secondary sites to be followed in animals that have
received ectopic or orthotopic (see Glossary, Box 1) transplants of
cancer cells or tissue. The advantage of these models is that they
allow the entire metastatic cascade to be modeled. However,
although ectopic subcutaneous transplantation of multiple cell or
tumor types is widely used to monitor tumor growth as it induces
rapid tumor growth in the highly vascularized skin, and tumor
development can be monitored easily through the use of caliper
measurements, metastasis is not often seen in these models and
tends to be restricted to allograft models (see below) such as the B16
melanoma and Lewis lung carcinoma model (Table 2). Orthotopic
studies are able to better recapitulate human cancers by enabling
interactions with the tissue of origin, which can impact on the initial
invasion and intravasation and may reflect the increased metastatic
spread seen in orthotopic models (Francia et al., 2011; Kellar et al.,
2015) (Table 2). This is dependent on the ability to implant tumor
cells in the orthotopic site from which the original tumor was
derived, which has been successful for a number of tumor types
including mammary, pancreatic, lung and colon (Table 2). In some
models, there is a long latency, and resection of the primary tumor is
needed to allow development of metastases; this is only possible for
certain cancers, such as mammary tumors and melanoma (Coffelt
et al., 2015; Cruz-Munoz et al., 2008). However, models in which
resection of the primary tumor is possible have the benefit of
allowing potential adjuvant therapies to be tested.
Experimental models of metastasis
Experimental models of metastasis are used to evaluate the capacity
of cancer cells to arrest, extravasate and grow in particular organs in
ectopic sites following intravascular injection. Different sites of
vascular injection in the mouse, including the lateral tail vein, intra-
portal, intra-carotid and intra-cardiac, define the site of colonization
(reviewed in Khanna and Hunter, 2005). For example, injection into
the tail vein leads to the formation of lung metastases, which reflects
the rapid trapping of cells within the microvasculature of the lung
minutes after injection. Intra-cardiac injection allows wider
dissemination of cancer cells and is commonly used to model
bone and brain metastasis. Other models include intra-peritoneal
injection to model the local dissemination of ovarian cancer or intra-
splenic injection of colon cancer cells leading to metastasis
formation within the liver. A drawback of experimental metastasis
models is that they do not recapitulate the first steps of the metastatic
cascade, and only reflect homing of tumor cells circulating in the
bloodstream to a limited set of secondary organs. Despite this, they
have been instrumental in elucidation of tumor-host interactions
required for the initial arrest and colonization at metastatic sites, as
discussed below.
Both allograft and xenograft (see Glossary, Box 1) transplantation
models are used in spontaneous and experimental metastasis assays
and the characteristics of these models are explained in further detail
below.
Allografts
Allograft transplantation models are generated by the transplantation
of mouse-derived cancer cells and tumors into mice. The use of
genetically identical syngeneic (see Glossary, Box 1) models, to
prevent graft versus host reactions, allows investigation of the
immune system in cancer progression and identification of new
therapeutic opportunities (Serrels et al., 2015).
Fidler (1973) described the first syngeneic mouse model of
metastasis and provided the first demonstration that the metastatic
potential of tumor cells could be enhanced through in vivo selection.
B16 melanoma tumor cells are derived from a spontaneous
melanoma that developed in the common C57BL/6 strain of
laboratory mice. B16 cells with enhanced metastatic properties were
generated after several rounds of in vivo selection by subcutaneous
injection of melanoma cancer cells into the syngeneic C57BL/6J
mouse. The occurrence of metastasis to the lungs increases
significantly with the clonally selected tumor lines derived from
successive pulmonary metastases (Fidler, 1973).
Xenografts
In contrast to allograft models, xenografts involve human cancer












Tumor cell Cytokines 
Blood vessels Epithelial cell 
Endothelial cell 
Key
Fig. 1. Metastatic cascade. Metastasis is a multistep
process. Initially, tumor cells migrate into adjacent tissues,
referred to as local invasion. This involves breakdown of the
basement membrane and invasion into the surrounding
ECM. Intravasation then allows cells to enter the circulation.
In blood vessels, CTCs exist as single cells or clusters,
coated with platelets. They need to survive shear stress
and evade clearance by the immune system to successfully
reach distant organs. Tumor cells then attach to endothelial
cells, which facilitates their extravasation. After settling in
the metastatic target organ, tumor cells must survive in this
foreign environment and establish micrometastases.
These DTCs can remain dormant for many years before
proliferating into large macrometastases in a process
termed colonization. The primary site also regulates the
development of metastasis via secretion of factors (such as
cytokines and exosomes) that can prime a pre-metastatic
niche (Box 2) and support survival of DTCs. See Glossary
in Box 1 for an explanation of key terms.
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immunocompromised (see Glossary, Box 1) or immune-deficient
mice in order to prevent rejection by the host. An advantage of these
tumormodels is that the donor cells are human in origin; however, the
key drawback is lack of the host adaptive immune system, which is
now recognized to contribute to many aspects of primary tumor
growth andmetastatic spread (Hanahan andWeinberg, 2011). The use
of xenograft mouse models in metastatic studies has been restricted to
studies in which highly metastatic variants have been derived through
in vivo selection (e.g.MDA-MB-231 breast cancer cells, KM12 colon
carcinoma cells and WM239Amelanoma cells), which overcome the
problemof limitedmetastatic potential (Table 2). Thismethod has also
been used extensively to identify gene expression signatures that
regulate organ-specific patterns of breast cancer metastasis (Bos et al.,
2009; Kang et al., 2003; Minn et al., 2005).
Cancer cell lines often fail to retain the characteristics of the
original tumor when cultured in vitro. Therefore, they do not reflect
the phenotypic and genetic heterogeneity of human cancers and,
consequently, xenograft models are poor predictors of clinical
responses (Kersten et al., 2016). Patient-derived xenografts (PDXs)
(see Glossary, Box 1) have emerged as a potential solution to this
problem (reviewed inWhittle et al., 2015). PDXs are generated from
resected tumors, propagated directly in immunocompromised mice
following orthotopic or subcutaneous injection, avoiding in vitro
selection pressures. PDXs have been shown to reflect the diversity
of human cancer, recapitulating the histology and the metastatic
characteristics of the original tumor (DeRose et al., 2011; Eyre et al.,
2016; Hiroshima et al., 2016; Julien et al., 2012; Puig et al., 2013).
Other studies show that the site and frequency of PDX metastasis
may vary from that seen in the patient and the engraftment rate is
relatively low. Furthermore, the lack of an intact immune system and
the presence of mouse stroma mean that PDXs are not an ideal
model for studying the role of the tumor microenvironment in
disease progression (Jackson and Thomas, 2017; Pompili et al.,
2016; Whittle et al., 2015). To overcome these limitations,
humanized xenograft mouse models are being developed, in
which the human components of the tumor microenvironment,
such as immune cells, peripheral blood and stromal tissue have been
engrafted (Bankert et al., 2011; Cassidy et al., 2015; Kuperwasser
et al., 2005; Morton et al., 2016). There are also challenges
associated with these mice, however, including the technical
difficulty of increasing the spectrum of immune cells engrafted
while reducing the mouse innate immune response (Shultz et al.,
2012). The impact that these humanized mouse models will have on
research into metastasis remains unclear at present.
Genetically engineered mouse models
Genetically engineered mouse models (GEMMs) (see Glossary,
Box 1) display de novo tumor progression and metastasis formation,
usually in an immune-competent tumor microenvironment. This
enables both the tumor cell-autonomous and stromal influences on
Box 1. Glossary
Allograft: The transplant of cells or organs from one individual to another individual of the same species.
Cancer-associated fibroblast (CAF): Fibroblasts found within or in close proximity to a tumor. Usually derived from normal fibroblasts but can also be
formed from pericytes (contractile cells that line capillaries) and smooth muscle cells, among other cell types.
Circulating tumor cell (CTC): Tumor cells that have left the primary tumor and entered the circulatory system.
Colonization: The processes (e.g. survival and proliferation) which allow disseminated tumor cells to form large macrometastases.
Cre recombinase/loxP : Cre recombinase enzymatically removes sequences that are flanked (floxed) by inserted loxP sequences.
CRISPR/Cas9: Gene-editing technology that enables precise genomic modifications. This technology can be used to generate gene modifications,
deletions and insertions, by using a synthetic guide RNA to introduce a double-strand break at specific sites in DNA, mediated by Cas9 endonuclease.
Disseminated tumor cell (DTC): Tumor cells that have settled in distant organs away from the primary tumor site after exiting the circulatory system.
Ectopic: The transplantation of a cell type to a location in which it is not found under normal physiological circumstances.
Epithelial-to-mesenchymal transition (EMT): Loss of cell-cell adhesion complexes and cell polarity by an epithelial cell, and the gain of an invasive,
migratory, mesenchymal phenotype.
Exosome: Extracellular vesicles that are released from cells after the fusion of multivesicular bodies with the plasma membrane.
Extracellular matrix (ECM): The acellular support surrounding tissues.
Extravasation: The process by which a tumor cell leaves the circulatory system and enters a secondary site away from the primary tumor.
Genetically engineeredmousemodel (GEMM): Amousewith a genome altered by genetic engineering techniques, including gene deletion, mutation or
addition. This can be performed in a tissue- or cell-specific manner and may also be inducible.
Immunocompromised mice: Mice in which specific elements of the immune system have been removed to allow engraftment of human material.
Integrin: Transmembrane receptor protein that cells use to adhere and respond to the extracellular matrix.
Intravasation: The process by which a tumor cell leaves the primary tumor and enters the circulation.
Invadopodium: Actin-rich protrusion present at the membrane of invasive cancer cells that extends and degrades the extracellular matrix.
Micrometastasis: Small clusters of cancer cells in secondary organs that are too small to detect through screening.
Organoids (tumor): three-dimensional cultures of tumor cells.
Orthotopic: The transplantation of a cell type or organ to a location in which it would be found under normal physiological circumstances.
Patient-derived xenograft (PDX): A model in which human patient tumor material is implanted into an immunocompromised host, most commonly the
mouse.
Seeding: In the context of metastasis, seeding refers to the process whereby tumor cells ‘seed’ new tumors in distant organs. Originally described in
Stephen Paget’s ‘seed and soil’ hypothesis of cancer metastasis (Paget, 1989). The seeding process includes tumor cell adherence to the blood vessel in
the distal organ, extravasation, migration to the tissue parenchyma, and survival.
Syngeneic: In transplantation biology, this refers to individuals or tissues that are genetically identical or closely related, allowing the transplantation of
tissues from the strain of origin into immunocompetent mice.
Transendothelial migration: Movement of tumor cells through the endothelial barrier either paracellularly (through the endothelial cell junctions) or
transcellularly (through the endothelial cell body).
Tumor-associated macrophage (TAM): A macrophage found within or in close proximity to a tumor that actively promotes tumor growth through the
secretion of cytokines and chemokines.
Tumor microenvironment: All elements that make up the surroundings of the tumor, including other cell types, vasculature and the extracellular matrix.
Xenograft: The transplant of cells or organs from one species into an individual of a different species.
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all stages of the metastatic cascade to be modeled, making GEMMs
an invaluable resource for studying metastasis. Their use in cancer
research has been widely reviewed (Kabeer et al., 2016; Kersten
et al., 2016; Saxena and Christofori, 2013). Here, we provide an
overview of the models available and discuss their potential for
modeling metastatic disease.
The first transgenic models used tissue-specific promoters, such as
the mammary-specific MMTV promoter, to drive expression of
oncogenes such as v-ErbB2 and v-HRas (Muller et al., 1988; Sinn
et al., 1987). This was followed by the generation of tumor suppressor
gene knockout mice (e.g. Trp53) that have a predisposition to tumor
formation (Donehower et al., 1992). Although these models have
given insight into many fundamental aspects of cancer biology, it is
difficult to model sporadic cancer development seen in humans due
to lack of tissue specificity of gene knockouts and control of
transgene expression in specific cell lineages (Kersten et al., 2016).
More advanced models allow conditional activation of
oncogenes and/or inactivation of tumor suppressor genes in
somatic cells. The Cre recombinase/loxP system (see Glossary,
Box 1) is used widely for this. Using this system, genes that are
flanked by loxP recombination sites are deleted following activation
of Cre recombinase (Gu et al., 1993). Use of tissue-specific
promoters to drive Cre recombinase expression, combined with
expression of oncogenes that are known to be associated with
development of human tumors in those tissues, has resulted in the
generation of models that recapitulate many of the molecular
characteristics and histopathological features of the human disease
(Hingorani et al., 2003; Holen et al., 2017; Jackson et al., 2001;
Shibata et al., 1997). These have been invaluable in dissecting the
complexities of human cancer and its progression.
Further control can be achieved by using regulatable systems such as
the Cre-ER system, in which the hormone-binding domain of the
estrogen receptor (ER) is fused to Cre recombinase: treatment of mice
with the estrogen analogue tamoxifen leads to activation of Cre
recombinase in a temporal manner (Lewandoski, 2001). The
tetracycline-inducible system also permits the switching on or off
(Tet-On/Tet-Off system) of a specific gene of interest in a tissue- and
time-specificmanner following administration ofdoxycyline (Gunther
et al., 2002). This temporal and spatial control of gene activation and
inactivation is useful for overcoming unwanted effects that could
impact on organ-specific development or result in embryonic lethality,
as seen upon deletion of the Rb1 tumor suppressor (Lee et al., 1992).
These models can also be used to address the importance of genetic
changes at specific times during tumor progression.
An important limitation of GEMMs is the low incidence of
metastatic spread that often does not reflect the organ tropism seen
in the human disease (Kabeer et al., 2016; Kersten et al., 2016).
Although identification of the most appropriate tissue-specific
Box 2. Pre-metastatic niche
Pre-metastatic niches are organ-specific supportive biological
environments that support survival of CTCs in distal organs and
promote metastatic outgrowth. The formation of the pre-metastatic
niche is governed by secreted factors from the primary tumor, including
growth factors and inflammatory cytokines and chemokines. Recent
studies found that tumor-derived exosomes can also promote niche
establishment and determine organ specificity in some types of cancer;
however, whether it is a common feature for pre-metastatic niche
formation remains unclear. These tumor-derived secreted factors induce
changes in distant pre-metastatic sites while also mobilizing bone
marrow-derived cells, the recruitment of which – along with a number of
other types of immune cell – to the niche leads to remodeling of the local
environment and formation of the pre-metastatic niche. This involves
interactions with local resident stromal cells, such as endothelial cells,
macrophages and fibroblasts, and also the extracellular matrix, which all
cooperate to form a permissive environment for tumor outgrowth. For
example, activated fibroblasts remodel the ECM by secreting matrix
components such as fibronectin andmetalloproteinases that break down
existing ECM. Increased fibronectin in the niche enhances adhesion of
recruited bone marrow-derived cells. Lysyl oxidase, an enzyme that
cross-links collagen and elastins in the ECM, is also important in the
formation of the pre-metastatic niche; by remodeling the ECM, this
enzyme enhances myeloid cell infiltration. For further information,
readers are directed to two reviews on the formation and role of the
pre-metastatic niche (Liu and Cao, 2016; Peinado et al., 2017).
Table 1. Strengths and weaknesses of mouse models of metastasis
Type of model Strengths Weaknesses
Tumor transplantation:
spontaneous metastasis
Metastatic disease development from primary tumor
site mimics human disease progression
Models all stages of the metastatic cascade
Immunocompetent host if allograft
Low cost
Mouse microenvironment
Applicable to limited number of cell lines
Poor tropism of metastasis in reference to the clinical setting
Asynchronous metastatic development
Removal of primary tumor to allow development of metastases can be
performed only on certain tumor types such as breast, prostate, pancreas
and ectopic transplants
Immunocompromised host if xenograft
Tumor transplantation:
experimental metastasis
Rapid and reproducible development of metastases
Site-specific development of metastases
Applicable to a wide number of cell lines and tumor
models
Immunocompetent host if allograft
Low cost
Mouse microenvironment
Only models late stages of the metastatic cascade
Immunocompromised host if xenograft
GEMM Metastatic spread of spontaneous de novo tumors,
mimicking human disease
Tumors develop in natural microenvironment
Tumors display genetic heterogeneity
Tumors resemble the molecular and
histopathological characteristics of the
human disease
Models have the potential to model all stages of the
metastatic cascade
Immunocompetent host
Mouse rather than human microenvironment
Genetics (promoter and oncogenes) often not truly representative of the
human disease
Promoters not well defined to a specific lineage
Can have low penetrance and long latency of metastatic disease
development
Poor tropism of metastasis in reference to the clinical setting
Extensive breeding programs often required (cost and time implications)
Asynchronous metastatic development
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promoters and the correct combination of genetic alterations has
provided more representative models (Derksen et al., 2006;
Hingorani et al., 2003), tumor spread to some metastatic sites
has been more difficult to model. For example, it has been
challenging to model the development of bone metastases, a
common site of secondary lesions in prostate and breast cancer
(Rampetsreiter et al., 2011). A second drawback of GEMMs is
that in many cases the long latency requires mice to be sacrificed
due to primary tumor burden before metastatic lesions have
developed. This can be overcome by removal of the primary
tumor, after which the subsequent development of metastases can
be monitored (Coffelt et al., 2015; Doornebal et al., 2013).
Applications of mouse models in metastatic research
Despite the limitations discussed above, mouse models have made
important contributions to our understanding of cancer progression




Cells/tumors transplanted in mice or
genotypic details of GEMM strain Site of metastasis References
Spontaneous metastasis
Allograft, orthotopic Melanoma Mouse B16 cells (C57BL/6 mice) Lungs (Fidler, 1973)
Allograft, orthotopic Mammary Mouse K14Cre; Cdh1F/F; Trp53F/F (KEP)
cell line and tumor fragments
(FVB mice)
Lungs, lymph nodes, liver, spleen,
gastrointestinal and urogenital tract,
pancreas, mesenterium and peritoneum
(Coffelt et al., 2015; Derksen
et al., 2006; Doornebal
et al., 2013)
Mouse 4T1 cells (BALB/c mice) Lungs and liver (Aslakson and Miller, 1992)
Allograft, ectopic
(subcutaneous)
Lung Mouse Lewis lung carcinoma (LLC1)
cells (C57B1 mice)
Lungs (Bertram and Janik, 1980)
Xenograft, orthotopic Mammary Human MDA-MB-231 cells
(NOD/SCID mice)
Lungs, liver, lymph nodes (Munoz et al., 2006)
Human SUM1315 cells (NOD/SCID
mice)
Lung and human bone implant (Kuperwasser et al., 2005)
Xenograft, orthotopic Colon Human HCT116, SW-620, DLD-1 cells
(Swiss Nu/Nu)
Peritoneum, diaphragm, lymph nodes,
pancreas, liver and lungs
(Céspedes et al., 2007)
Xenograft, orthotopic Melanoma Human 113/6-4Lmelanomacells derived
from WM239A (CB17-SCID mice)
Central nervous system (Cruz-Munoz et al., 2008)
PDXs, orthotopic Mammary Primary breast tumors and metastases
[NOD/SCID mice and NOD/SCID
Il2rg−/− (NSG) mice]
Lung, lymph nodes, peritoneum (DeRose et al., 2011)
PDXs, ectopic
(subcutaneous)
Mammary Primary breast tumors and metastases
[NOD/SCID Il2rg−/− (NSG) mice)]
Lung (Eyre et al., 2016)
PDXs, orthotopic Cervical Primary HER2-expressing cervical tumor
(athymic nu/nu nude mice)
Lung, lymph nodes, peritoneum, liver (Hiroshima et al., 2016)
PDXs, orthotopic Colon Primary colorectal tumors and liver
metastases (NOD/SCID mice)




Colon Primary colorectal tumors, peritoneal
carcinoses and metastases (Swiss
nude and CB17-SCID mice)
Hepatic, splenic, and mesenteric
lymph node
(Julien et al., 2012)
PDXs, ectopic
(intraperitoneal)
Ovarian Primary ovarian tumors [NOD/SCID
Il2rcnull (NSG) mice]
Lung (Bankert et al., 2011)
Experimental metastasis
Intra-venous Mammary Human MDA-MB-231 cells Lung (Minn et al., 2005)
Mammary Mouse Met-1 cells Lung (Qian et al., 2011)
Melanoma Human A7 and mouse B16 cells Lung (Gil-Bernabe et al., 2012)
Melanoma Mouse B16 cells Lung (Hiratsuka et al., 2002, 2006;
Kaplan et al., 2005)
(Hiratsuka et al., 2002, 2006;
Kaplan et al., 2005)
Lung Mouse Lewis lung carcinoma
(LLC) cells
Lung
Intra-cardiac Mammary Human MDA-MB-231 cells Brain (Bos et al., 2009)
Mammary Human MDA-MB-231 cells Bone (Kang et al., 2003)
Prostate Mouse RM1 cells Bone (Jung et al., 2013)
Intra-iliac artery Mammary Human MDA-MB-231, MCF-7,
MDA-MB-361 cells
Bone (Wang et al., 2015)
Intra-splenic Colon Human KM12 cells Lymph nodes and liver (Morikawa et al., 1988)
Intra-tibial Prostate Human PC-3 cells Bone (Fisher et al., 2002)
Intra-peritoneal Ovary Human SKOV3 and ES2 cells +/−
adipose-derived mesenchymal stem
cells derived from omentum
Mesentery (Chu et al., 2015)
GEMM
Spontaneous metastasis Mammary MMTV-PyMT Lungs and lymph nodes (Guy et al., 1992)
Spontaneous metastasis Mammary MMTV-Erbb2 Lungs and lymph nodes (Muller et al., 1988)
Conditional, Cre-loxP Pancreatic KPC [Lox-Stop-Lox (LSL)-KrasG12D;
LSL-Trp53R172H; Pdx1-Cre] model
Liver, lung, pleural nodules and
peripancreatic lymph node
(Hingorani et al., 2005)
Conditional, Cre-loxP
and Flp-FRT
Pancreatic R26CAG-CreERT2; FSF-R26CAG-CreERT2 Liver and lungs (Schönhuber et al., 2014)
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and metastasis. Here, we highlight some recent advances in which
mouse models have been instrumental in defining the key drivers
and features of metastatic cancer. We also outline the usefulness of
these models as preclinical drug development tools.
Stromal cell interactions at the primary tumor site
In vivo metastasis models are important tools to investigate the
interaction of tumor cells with tumor-associated stromal
components. Within this complex microenvironment, several
immune cell populations have been shown to promote tumor
invasion and metastasis (Fig. 2) and GEMMs and syngeneic
models, both of which have intact immune systems, have provided
many valuable insights into how the immune system regulates
metastatic progression. Macrophages are often the most abundant
infiltrating immune cells in the tumor. These tumor-associated
macrophages (TAMs) (see Glossary, Box 1) play multiple roles in
promoting cancer metastasis and are associated with metastasis and
poor prognosis (Kitamura et al., 2015; Qian and Pollard, 2010).
Intra-vital imaging studies have proven useful in elucidating the
complex role of TAMs. In a spontaneous GEMM of mammary
cancer, MMTV-PyMT (Table 2), cancer cells invade surrounding
tissues together with TAMs (Wyckoff, 2004). In this process, TAMs
secrete epidermal growth factor (EGF) to activate the EGF receptor
on cancer cells, and enhance their motility and invasive potential by
increasing invadopodium formation and ECM degradation (Zhou
et al., 2014). Reciprocally, tumor cells produce colony-stimulating
factor 1 (CSF1) to recruit and activate TAMs. Ablation of this
paracrine signal loop significantly inhibited tumor cell invasion in
MMTV-PyMT tumors and subsequent lung metastasis without
affecting primary tumor growth (Wang et al., 2009). Intra-vital
imaging ofMMTV-PyMT tumors has also illustrated that tumor cell
intravasation occurs in association with perivascular TAMs
(Wyckoff et al., 2007). Via direct interactions, invasive tumor
cells, perivascular macrophages and endothelial cells form
micro-anatomic structures within the tumor (termed ‘tumor
microenvironment for metastasis’ or ‘TMEM’) (Pignatelli et al.,
2014). The frequency with which these TMEMs occur has been
shown to predicate metastasis of ER+ breast cancer in a case-control
study with >3700 patient samples (Rohan et al., 2014). These
TMEM structures control tumor cell intravasation by transiently
increasing local vascular permeability in a vascular endothelial
growth factor (VEGF)-dependent manner, as illustrated by recent
studies using high-resolution two-photon intra-vital microscopy
(Harney et al., 2015). These data strongly indicate that the local
tumor microenvironment and macrophage interactions play a central
role in promotion of tumor cell intravasation, and highlight the
importance of using intra-vital microscopy to visualize these
processes.
Neutrophils have also been shown to contribute to invasion and
metastasis. Using a combination of GEMM and transplant models
of melanoma, UV radiation was shown to promote neutrophil
infiltration through secretion of high-mobility group protein B1
(HMGB1) derived from UV-damaged keratinocytes. This
neutrophil recruitment led to enhanced tumor migration and
invasion resulting in distal metastasis (Bald et al., 2014). More
recently, a role for neutrophils in the pre-metastatic niche within the
lung was established using the MMTV-PyMT model (Wculek and
Malanchi, 2015). This was mediated through secretion of
leukotrienes from neutrophils in the pre-metastatic niche, which
promoted metastatic formation. In the KPC (Lox-Stop-Lox (LSL)-
KrasG12D; LSL-Trp53R172H; Pdx1-Cre) GEMM of pancreatic
cancer, where mutations in Kras and Trp53 drive the development
of spontaneous pancreatic ductal adenocarcinomas (Gopinathan
et al., 2015), neutrophils have also been shown to promote
metastasis (Steele et al., 2016).
Among adaptive immune cells, Th2 cells, CD4+ T helper cells
expressing Type 2 cytokines [e.g. interleukin (IL) 4, IL10], have
been shown to promote tumor progression via activation of humoral
immunity and inflammation (Shurin et al., 1999). Using the
MMTV-PyMT model, it was found that CD4+ T helper cells can
induce alternative activation of TAMs and secretion of EGF, to
directly promote tumor invasion and egress from the primary tumor
as a result of IL4 activation (DeNardo et al., 2009). By utilizing
existing and emerging mouse models, future experiments could
uncover the role of other lymphocyte populations in tumor
progression and invasion.
Coffelt et al. (2015) used a GEMM of invasive lobular breast
cancer, the K14Cre; Cdh1F/F; Trp53F/F (KEP) model, and
transplanted tumor fragments from this KEP model into recipient
mice. Metastatic development was monitored following resection of
the primary tumor, and the authors observed that systemic
expansion of neutrophils significantly promoted spontaneous
metastasis to the lungs and lymph nodes by suppressing a CD8+
T cell-mediated anti-tumor immune response (Coffelt et al., 2015).
Mechanistically, this involves IL17 expression from γδ T cells that
leads to expansion of neutrophils via granulocyte colony stimulating
factor (G-CSF). IL17 derived from a subset of CD4+ T helper cells
has also been shown to promote anti-tumor immune responses
through the recruitment of dendritic cells and cytotoxic cells in
several murine tumor models (reviewed in Zou and Restifo, 2010).
Thus, the role of IL17 in metastasis may be dependent on the cancer
type and/or specific tissue environment.
Cells of mesenchymal origin, most notably mesenchymal stem
cells (MSCs) and cancer-associated fibroblasts (CAFs) (see
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Fig. 2. Stromal influences in the primary tumor. Stromal cells such as
MSCs, fibroblasts and myeloid cells (including monocytes, macrophages and
neutrophils) promote metastasis and modulate the tumor microenvironment.
MSCs remodel the ECM and support invasion. Macrophages can promote
tumor invasion via several paracrine signaling factors. For example, in
response to tumor cell-derived CSF1, TAMs secrete EGF, which is permissive
for tumor cell invasion and migration. A subset of CD4+ T cells contributes to
tumor progression, while CD8+ T cells mainly mediate anti-tumor immune
responses. During intravasation, perivascular macrophages interact with
tumor cells directly to help subsequent tumor cells to transit the endothelial
barrier and initiate the journey of metastatic dissemination. See Glossary in
Box 1 for an explanation of key terms.
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Glossary, Box 1) can also promote metastasis through direct
interaction with tumor cells. For example, MSCs have been shown
to promote peritoneal dissemination of ovarian cancer cells via
activation of the matrix metalloproteinases (MMPs) MMP2 and
MMP9 (Chu et al., 2015). In xenograft and allograft models of
prostate cancer, chemokine (C-X-C motif ) ligand 16 (CXCL16)/
CXC receptor 6 (CXCR6) chemokine signaling promotes
recruitment of bone marrow-derived MSCs and their
differentiation into CAFs, which in turn promote prostate tumor
cell invasion and metastasis through production of chemokines such
as CXCL12 (Jung et al., 2013; Mognetti et al., 2013) and
chemokine (C-C motif ) ligand 5 (CCL5) (Luo et al., 2015). CAF-
derived MMPs can promote ECM remodeling and tumor cell
invasion (Kalluri and Zeisberg, 2006), and in an orthotopic model
of colon cancer, CAFs promote formation of distal metastases
through secretion of the glycoprotein stanniocalcin 1 (STC1) which
regulates intravasation of the tumor cells (Pena et al., 2013). CAFs
can also generate mechanical pressure and paracrine signaling to
promote tumor invasion and metastasis (Karagiannis et al., 2012),
and through remodeling of the ECM (Kaushik et al., 2016).
In summary, in vivo metastasis models have provided important
insights into the interactions of tumor and stromal cells that
contribute significantly to tumor invasion and metastasis. Of note,
only a minority of cancer cells are migratory, as revealed by intra-
vital imaging studies across multiple tumor models, even in
aggressive tumors (Condeelis et al., 2005; Scheele et al., 2016).
Thus, specific interactions of the tumor microenvironment with
these migratory tumor cells could be attractive targets to treat
metastatic disease.
Systemic influence on metastasis
The metastatic process is not only influenced by cell-cell
interactions within the adjacent primary tumor microenvironment
but also systemic alterations induced by the presence of tumor cells.
Experimental metastasis assays in tumor-bearing animals have been
key in demonstrating that primary tumor-derived systemic factors,
such as cytokines and immune cell chemoattractants, can alter
metastatic target tissues and influence the subsequent seeding (see
Glossary, Box 1) of tumor cells in these tissues (Hiratsuka et al.,
2002, 2006; Kaplan et al., 2005). More recently, elegant mouse
experiments again using experimental metastasis models have
shown that tumor-derived exosomes (see Glossary, Box 1) induce
pro-metastatic progenitor cells in the bone marrow through receptor
tyrosine kinase MET signaling (Peinado et al., 2012), and that
exosomal integrins (see Glossary, Box 1) can direct organ-specific
colonization by priming the metastatic niche (Box 2) (Hoshino
et al., 2015). Such advances will impact on how we can harness the
ability to measure specific systemic factors in clinical samples to
allow more careful monitoring of tumor progression.
Systemic influences can also promote colonization after metastatic
seeding. For example, a study using an esophageal cancer model
showed that lung metastatic colonization (following tail vein
injection of tumor cells) can be significantly promoted by distal
tumors in an insulin growth factor (IGF)-II-dependent manner (Li
et al., 2014). Using a xenograft model in which human breast cancer
cell lines with different tumorigenic potential were injected
contralaterally into the same mouse, pro-angiogenic cytokines
secreted by human luminal breast cancer cells have been shown to
mobilize pro-angiogenic vascular endothelial growth factor receptor
2 (VEGFR2)+ bone marrow-derived cells into distal tumors to
promote angiogenesis (Kuznetsov et al., 2012). However, systemic
influences can also be anti-metastatic. Using human prostate and
breast cancer cells, and a combination of spontaneous and
experimental metastasis models, an earlier study suggested that the
presence of a primary tumor can inhibit metastatic seeding. This was
mediated through secretion of prosaposin (a precursor of saposins,
which function as cofactors for sphingolipid hydrolases), which
stimulates expression of the angiogenic factor thrombospondin-1 in
lung stromal cells (Kang et al., 2009). Thus, models that faithfully
mimic systemic influences in patients are required to better
understand the influence of secreted factors on metastasis.
Immune rejection is a key factor that limits the efficiency of tumor
engraftment in immune-competent preclinical models, even when
the tumor and host are both from the same syngeneic background
(Dunn et al., 2006). It is probably not surprising that immune
suppression generated by established tumors enhances engraftment
efficiency of subsequent (secondary) tumors (Mullen et al., 1985;
Reilly et al., 2000). Careful experiment design is essential to study
tumor-tumor and tumor-host interaction in these models.
Role of epithelial-to-mesenchymal transition in metastasis
Epithelial-to-mesenchymal transition (EMT) (see Glossary, Box 1)
is a developmental program that occurs during embryogenesis
(Thiery et al., 2009). It involves the loss of cell-cell adhesions,
apical-basal polarity and the conversion to a mesenchymal
phenotype that is typified by increased motility and invasiveness
and plays a role in the invasion of tumor cells, an early event in the
metastatic cascade (Valastyan and Weinberg, 2011). It is tightly
controlled by a number of pathways that activate the EMT
transcription factors Snail, Slug, Twist, Zeb1 and Zeb2 (Thiery
et al., 2009). However, there is debate concerning the extent to
which EMT contributes to the different stages of the metastatic
cascade, much of which has arisen from difficulties in
demonstrating that mesenchymal cells persist in metastatic lesions
(Lambert et al., 2017; Yeung and Yang, 2017). This is confounded
by the inherent plasticity exhibited by tumor cells and the
reversibility of the EMT program. Since the use of Cre
recombinase technology has become more prevalent, the
opportunity to study EMT in mouse models and address these
issues has advanced greatly. Prior to this, GEMMs to address the
causal connection between EMT and metastasis implicated in
in vitro studies were lacking.
Utilizing Cre recombinase to perform lineage-tracing
experiments has provided useful insights into the contribution of
EMT to the metastatic process (Fig. 3). One such study involved the
widely used KPC model. In these mice, EMT was identified in
premalignant lesions, and the process was found to be associated
with invasion of the surrounding basement membrane (Rhim et al.,
2012). In addition, inflammation enhanced EMT and entry of tumor
cells into the circulation. However, using the same KPC model,
direct involvement of EMT in the metastatic process was not
supported; conditional deletion of Snai1 or Twist1, the genes that
encode Snail and Twist, respectively, in the primary tumor resulted
in a reduced number of cells undergoing EMT, but this had no
impact on the metastatic spread (Zheng et al., 2015). More recently,
it was shown that loss of Zeb1 in the KPC model is sufficient to
significantly reduce metastatic spread (Krebs et al., 2017). This
highlights the specificity and lack of redundancy between EMT
transcription factors in controlling metastatic spread in this model.
Using mammary tumor models driven by MMTV-PyMT or
human epidermal growth factor receptor 2 (HER2) oncogenes,
Fischer and colleagues also established that EMT and metastasis
might not be as intricately linked as first thought (Fischer et al.,
2015). By using a mesenchymal-specific (Fsp1) promoter to drive
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Cre recombinase-dependent expression of a green fluorescent
protein (GFP) reporter, they observed no enrichment of tumor
cells expressing GFP in the metastatic site, and thus no indication of
an EMT, although there was an enrichment of GFP-expressing
CTCs. A key limitation of this study is the reliance on a single
‘EMT-associated’ promoter to drive the Cre recombinase, as EMT
is controlled and characterized by a plethora of transcriptional
changes. In addition, it does not address the inherent plasticity and
reversibility within the system: EMT does not represent an on-off
switch but is a continuumwith many cells expressing both epithelial
and mesenchymal markers at a given time. Indeed, in a model of
HER2-driven mammary cancer, early dissemination of tumor cells
was associated with a partial EMT, wherein some epithelial cell
properties were retained (Harper et al., 2016).
The use of intra-vital imaging has helped unravel the
complexities associated with tumor cell plasticity and metastatic
spread. In the MMTV-PyMT mammary tumor model, Beerling and
colleagues used a fluorescent epithelial marker (E-cadherin-CFP)
combined with intra-vital imaging to show that EMT is a reversible,
plastic process and that mesenchymal cells that reach secondary
sites can rapidly regain an epithelial phenotype (Beerling et al.,
2016). In contrast with many other studies, it was possible to
demonstrate this plasticity in vivo without experimental modulation
of genes commonly thought to regulate EMT. Models that are able
to accurately recapitulate the metastatic cascade without
experimental gene modulation are key tools in uncovering the
events involved, but in a way that reflects in situ processes as closely
as possible. The use of lineage tracing to assess the contribution of
EMT to metastasis has the potential to help uncover the gene
signature of cells that are able to colonize secondary sites.
Unraveling the polyclonal nature of metastasis
The increasing use of deep-sequencing analysis has helped
elucidate the evolutionary history of metastatic lesions and has
shed light on whether metastatic dissemination follows a linear or
parallel model (Turajlic and Swanton, 2016). Evidence from a
HER2-driven mouse mammary tumor model supports a parallel
model of evolution and also highlights the importance of mouse
models in demonstrating that early disseminated tumor cells are
critical to the formation of metastatic lesions (Hosseini et al., 2016).
Lineage tracing of CTCs and clusters of CTCs has also proven
invaluable in the investigation of the origins of these clusters and
single cells. By using a convertible double-fluorescent mammary
tumor model, ROSAmT/mG; MMTV-PyMT, from which organoids
(see Glossary, Box 1) were injected into the mammary fat pad of
nonfluorescent hosts, Cheung et al. (2016) evidenced the polyclonal
origin of a lesion in the lung, showing that it contained at least two
separate clones based on the fluorescent reporters present. They
found multicolored cell clusters at all stages of the metastatic
cascade, including local disseminated and CTC clusters. The
advent of Brainbow-2.1 (Livet et al., 2007) has allowed the
detailed tracing of multiple cells by utilizing Cre recombinase and
the stochastic expression of four fluorescent proteins from
multiple copies of a single transgene, which can generate up to
90 distinguishable colors when multiple copies of Brainbow-2.1
are present per cell, due to the differential expression of each
transgene (Fig. 3). By combining the transgene with Cre
recombinase placed under tissue-specific promoters, it will be
possible to more fully assess the clonal heterogeneity of a
metastatic lesion using imaging alone (Fig. 3) or in combination
with deep-sequencing techniques. One such example of this is
Prorainbow, a novel fluorescently labeled mouse strain (PB-Cre4;
Pkd1lox/lox; Ptenlox/lox; CMV-XFP/+) that can be used to model
prostate cancer (Fang et al., 2015). Although this model has not
yet been used to look at the metastatic process, initial
characterization indicates that it is an extremely promising
advance in technology to allow assessment of metastatic
colonization in many different mouse models.
A B 
Fig. 3. Lineage tracing allows identification of the clonal nature of metastatic lesions. (A) The Brainbow-2.1 construct contains two tandem invertible DNA
segments, each flanked by loxP sequences (indicated with black arrowheads). Inversion (i-iii) and excision (iv,v) recombination events create four expression
possibilities, with the fluorescent protein that follows the promoter being uniquely expressed. Expression of the different fluorescent proteins at different ratios
within each cell provides a unique color combination for each cell. Adapted from Livet et al. (2007), with permission from Macmillan Publishers Ltd. (B) Cre-
mediated recombination during primary tumorigenesis allows identification of metastatic lesions of a single color, indicating derivation from single cells or clusters
from a single cell, or multicolored cell clusters consisting of many different colored cells.
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Arrest, extravasation and colonization at distant organs
Experimental metastasis assays have illustrated that multiple stromal
components can be hijacked by tumor cells in the process of
metastatic seeding, as detailed below. Platelets play an important
role in facilitating metastatic dissemination. In addition to protecting
cells in the bloodstream from natural killer (NK) cells, interaction of
platelet integrins with collagen at specific regions of the
endothelium may help tumor cell adherence at secondary organs
and determine the site of metastatic tumor cell extravasation (Gay
and Felding-Habermann, 2011; Ruggeri and Mendolicchio, 2007).
A recent study identified that platelets promote tumor cell
extravasation through adenosine triphosphate (ATP)-dependent
activation of the endothelial P2Y2 receptor, which opens the
vessel barrier to enable tumor cell extravasation and metastatic
seeding (Schumacher et al., 2013). This was identified by utilizing
both spontaneous and experimental metastasis models in syngeneic
C57BL/6J mice. The utility of experimental metastasis models in
studying these early events when tumor cells first reach the
metastatic site was further highlighted by another group, who were
able to show that metastatic seeding is promoted by coagulation
pathways, in particular tissue factor (TF). By imaging myeloid-
tumor cell interactions within the lung following intravenous
injection of tumor cells, they demonstrated that TF-induced platelet
clots attract recruitment of bone marrow-derived macrophages to
support the survival of metastatic melanoma cells and inhibit NK
cell-mediated destruction of micrometastases in the lung (Gil-
Bernabe et al., 2012).
Using both spontaneous and experimental lung metastasis
models of breast cancer, a distinct population of metastasis-
associated macrophages (MAMs) has been characterized in the
target organ (lung). Depletion of these MAMs using transgenic
CD11b-diphtheria toxin receptor (DTR) mice significantly reduces
metastatic seeding and persistent growth of breast cancer cells (Qian
et al., 2011). One caveat of this approach is that administration of
diphtheria toxin to CD11b-DTR mice selectively kills CD11b-
expressing monocytes as well as macrophages (Stoneman et al.,
2007). However, ex vivo intact lung imaging in the same model
revealed that macrophages (and not monocytes) directly contact the
extravasating tumor cells, and depletion of these macrophages
significantly reduces the number of tumor cells that complete
extravasation (Qian et al., 2009).
Adhesion signaling also plays an important role in the survival of
tumor cells within the metastatic niche. Using an innovative method
of experimental bone metastasis in which breast cancer cells were
injected into the iliac artery of mice (both allograft and xenograft
models), Wang et al. (2015) showed that bone seeding of multiple
human and murine breast cancer cells is dependent on heterotypic
adherens junctions between cancer cells and osteogenic cells.
Thus, a number of models and experimental approaches have
demonstrated the importance of the interaction of tumor cells with
stromal cells in the metastatic niche that is required to support the
outgrowth of secondary tumors.
Dormancy in the metastatic niche
Metastases can arise fromDTCsmany years after the initial treatment
and/or surgical removal of the primary tumor. This is because at the
time of diagnosis, metastatic spread has already occurred but the
resulting DTCs have entered a state of quiescence (Sosa et al., 2014).
Thesemetastases may be resistant to current therapies that are directed
at proliferating cells; therefore, targeting dormant DTCs or preventing
their reactivation from dormancy may be of clinical benefit. The
factors that control tumor dormancy are poorly understood, but using
a spontaneousmodel of breast cancer metastasis, DTCswere found to
reside on the microvasculature of different organs and subsequent in
vitro experiments demonstrated that distinct endothelial niches can
induce dormancy through the secretion of thrombospondin-1 (Ghajar
et al., 2013). A gain-of-function screen in an allograft model ofmouse
mammary carcinoma identified the bone morphogenetic protein
(BMP) inhibitor Coco as a mediator of DTC reactivation (Gao et al.,
2012). Coco stimulated the proliferation of DTC in the lungs through
induction of a discrete gene expression signature that was associated
with relapse to the lung but not to other organs where BMP is not
active. This highlights the organ specificity of signals that control
reactivation of DTCs in the metastatic niche. Bragado et al. (2013)
provided further support to this by tracing spontaneous DTCs
following subcutaneous transplantation of a head and neck squamous
cell carcinoma cell line. They showed that transforming growth
factor beta 2 (TGFβ2) signaling in the bone marrow initiates tumor
dormancy, while the low levels of TGFβ2 signaling found in the
lungs prevented long-term dormancy, resulting in outgrowth of
metastatic lesions (Bragado et al., 2013). These studies support the
concept of dormancy-permissive and -restrictive microenvironments
that determine whether DTCs divide or remain quiescent. The
collection and analysis of CTCs and DTCs from patients at different
stages of the metastatic journey will provide important information
and clinical validation of the functional regulators linked to the
emergence of overt metastatic disease. This should provide an
iterative framework for the further refinement of mouse models.
Therapeutics and translation
Although mouse models have been invaluable in enhancing our
understanding of the biology that drives the metastatic cascade, their
utility as preclinical drug development tools is less well defined.
The approval rate of oncology drugs remains poor, with recent
research indicating that only 7.5% of oncology drugs that entered
phase I clinical development, and 33.2% of drugs that entered phase
III trials, were eventually approved (Toniatti et al., 2014). This
highlights the need for more predictive and improved preclinical
mouse models. The majority of preclinical studies that support
clinical evaluation rely on the use of established cell lines grown
ectopically in immune-deficient mice. These cell lines show limited
tumor heterogeneity, and combined with the lack of appropriate
human stroma and an intact immune system (Table 1), this
contributes to the poor clinical predictivity of these models (Singh
and Ferrara, 2012; Toniatti et al., 2014). In most studies, regression
of primary tumor growth is used as an endpoint and no
consideration is given to effects on metastatic disease (in most
cases metastatic disease is not even modeled). By contrast, the
majority of early clinical trials will involve patients with advanced
metastatic disease and as the genetic and epigenetic landscape of
metastases differ from the primary tumor, which is reflected in the
response to treatment, identifying the most effective way to model
this will have an impact on drug development programs. The ability
to model this in preclinical models is challenging, but the resistance
of metastatic disease to current therapies and the realization that
>90% of cancer-related mortality is due to metastatic disease
progression highlights the need for new approaches to be
considered. In addition to developing improved models, a better
understanding of how best to implement currently available models
could provide benefits (Francia et al., 2011; Steeg, 2016). For
example, experimental metastasis models have been used widely,
but what needs to be considered is the cell population that is being
targeted in these models. Do they reflect the outgrowth of latent
tumor cells or the subsequent growth of macrometastatic lesions?
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Such nuances are currently difficult to address in most models and
are not often considered when carrying out drug intervention
studies.
Despite the limitations associated with the use of established cell
lines in immune-deficient animals, they can provide important
insights into the potential clinical activity of drugs, for which
differential responses to therapies have been reported between
primary and metastatic lesions, thus reflecting what is seen in the
clinic (Francia et al., 2011). Another important consideration is how
closely we can recapitulate clinically relevant intervention
strategies. Surgical removal of the primary tumor followed by
adjuvant treatment to prevent recurrence is widely used in clinical
practice. Spontaneous metastasis models that utilize cell lines
(xenograft, allograft) are particularly amenable to modeling
adjuvant treatments, although they are limited to a few models
where the primary tumor can be easily resected (e.g. Cruz-Munoz
et al., 2008; Ebos et al., 2009). Although these experiments can be
technically challenging and time-consuming, they have provided
useful insight into the activity of drugs in the clinical setting. For
example, studies with transplantable models have helped to unravel
the effects of anti-angiogenic therapies in the adjuvant setting
(Kerbel et al., 2013) and shed light on the possible mechanisms
responsible for the disappointing results of recent Phase III clinical
trials in metastatic breast cancer (Bridgeman et al., 2017).
The benefits of GEMMs in generating tumors that develop in the
organ of origin (autochthonous) in immune competent hosts has led
to their adoption for preclinical assessment of drug response and
mechanisms of resistance (Gopinathan et al., 2015; van Miltenburg
and Jonkers, 2012). GEMMs are very useful for studying early and
late stages of disease, and studies showing the clinical predictivity
of lung and pancreatic cancer GEMMs to chemotherapy are
encouraging (Singh et al., 2010), but this needs to be more widely
validated in other models and the impact on metastatic disease
evaluated. These models are often limited by growth of the primary
tumor, which necessitates cull of the animals and thus true effects on
metastasis-associated survival cannot be monitored (Karim et al.,
2013). Most GEMMs are not amenable to resection of the primary
tumor and thus dissecting effects on primary tumor growth from
specific effects on metastatic disease are complicated, as neoadjuvant
and adjuvant studies cannot be carried out although excision of
primary pancreatic tumors in the KPC model is being trialed
(Gopinathan et al., 2015). In addition, in the context of mammary
tumors, the development of transplantation models in which
fragments of tumors are re-implanted into recipient mice allows
resection of the primary tumor and the subsequent monitoring of
metastatic spread. This reduces the latency and variability in
metastatic dissemination making this approach more amenable to
drug studies. This opens up the possibility of using these models for
testing adjuvant therapies and importantly for assessing the potential
of new immunotherapies (Coffelt et al., 2015).
PDX models are also predicted to be a major advance in
preclinical testing platforms as they recapitulate the tumor
heterogeneity that plays such an important role in tumor biology,
including response to therapy. A number of therapeutic studies have
demonstrated their value in linking response with genetic alterations
and identifying mechanisms of resistance and biomarkers, while use
of humanized mice recipients will further enhance their value as we
look at the potential for testing immunotherapies (Byrne et al.,
2017). However, the cost and length of time required to conduct
studies in PDX models is restrictive and, as yet, their utility in
assessing effects on metastatic spread is not clear. Although
spontaneous metastases do develop, this is limited to a relatively
small number of PDX models, with orthotopic injection of tumor
fragments being more successful in modeling metastatic spread
(Pompili et al., 2016). Moreover, the asynchronous development of
metastatic disease in these models would require large cohorts of
animals, which further increases the cost of such studies. Generation
of PDX from primary tumors and metastatic sites from the same
patient that can be transplanted orthotopically would allow direct
evaluation of drugs in the metastatic setting.
The increasing use of imaging modalities that allow noninvasive
longitudinal monitoring of metastases will help more accurate
detection and quantification of metastatic disease in deep tissue
sites. This technology is thus likely to enhance the usability of
GEMMs and PDXs. Recent advances in preclinical magnetic
resonance imaging (MRI), computed tomography (CT), positron
emission tomography (PET) and single-photon emission computed
tomography (SPECT) are showing promise (Fleten et al., 2017;
Marien et al., 2017; Sanches et al., 2015; Taromi et al., 2016).
A greater understanding of the pathways that drive metastatic
spread and what is achievable in the clinical setting gives hope that
anti-metastatic therapies will be viable in the future. For example,
targeting metastatic colonization, which is often the rate-limiting
step in the metastatic cascade holds great potential, but it will be
important to provide robust preclinical evidence of activity in
appropriate animal models that accurately reflect the clinical
scenario in which the therapy will ultimately be tested in. Careful
thought to clinical trial design with appropriate primary endpoints is
also essential.
Future outlook
Mouse models have been essential in advancing our understanding of
the biological processes that drive tumor progression. However,
metastatic cancer remains the main cause of cancer-related deaths,
with new treatments desperately needed. Increasing our understanding
of what drives metastatic spread is key to achieving this goal. This will
require the further development and refinement of mouse models to
more faithfully mimic human disease and progression.
A number of technological advances have allowed the further
development of GEMMs. These include combined use of the Cre-
loxP and Flp-FRT systems (Schönhuber et al., 2014) that allow
sequential activation or inactivation of genes, thereby enabling
human disease progression to be mimicked more closely, which
may provide more representative metastatic progression models.
This also opens up the possibility of targeting both tumor and
stromal cells in the samemodel, which is an important consideration
when studying metastatic progression. In addition, the CRISPR/
Cas9 gene editing system (see Glossary, Box 1) has been used to
successfully introduce targeted mutations in GEMMs, enabling
more rapid validation and characterization of putative cancer genes
that are being uncovered by the large-scale sequencing efforts
currently underway using human tissue samples (Annunziato et al.,
2016; Chiou et al., 2015; Sánchez-Rivera et al., 2014; Weber et al.,
2015). It is hoped that this will help in the design of better GEMMs
that more readily recapitulate the metastatic tropism seen in human
disease. The development of humanized mouse models that
incorporate human-derived stromal components, including CAFs
and immune cell populations, will help with regards to metastasis to
particular sites (Shultz et al., 2012). For example, human bone discs
and engineered human bone environments have been used to model
bone metastases (Holen et al., 2015; Wright et al., 2016). RNA
interference and CRISPR/Cas9 screens have been used to identify
metastatic drivers in in vivo transplantation models (Chen et al.,
2015; Murugaesu et al., 2014); the validation of these and
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improvements in such screening approaches will help in the
development of future GEMMs.
The design of more biologically relevant in vitro models that try
to recapitulate the complexity of the tumor microenvironment is a
major area of ongoing research. Models include co-culture of tumor
cells with different stromal cell types and 3D engineered matrixes,
with developments in 3D bioprinting and microfluidics platforms
having the potential to significantly impact on the design and
reconstruction of the complex tumor microenvironment (Albritton
andMiller, 2017). Coupled with the use of high-resolution real-time
imaging, microfluidics devices have been used to study different
components of the metastatic cascade such as intra- and
extravasation (Jeon et al., 2015; Zervantonakis et al., 2012). The
design of these models could be geared towards addressing specific
questions about the biology that drives metastatic behavior.
Importantly, such in vitro models have the potential to be used as
drug screening platforms and could guide the preclinical testing of
new agents in mouse models.
Advances in intra-vital imaging have shown great potential for
elucidation of the close interplay between tumor and host cells
(Cuccarese et al., 2017; Hawkins et al., 2016; Headley et al., 2016;
Lee et al., 2015; Szulczewski et al., 2016), and fundamental aspects
of the metastatic process. For example, use of a Cre recombinase-
driven reporter system has allowed the visualization of extracellular
vesicle exchange between tumor cells and has provided further
insight into the biological consequences and potential impact on
metastatic potential (Zomer et al., 2015). The use of optical
windows to allow imaging in the metastatic niche provides both
spatial and temporal information on the behavior of cancer cells;
another major advance (Entenberg et al., 2015; Headley et al., 2016;
Ritsma et al., 2012; Rodriguez-Tirado et al., 2016). The ability of
such imaging approaches to shed light on the localization
and activity of drugs within the tumor microenvironment
(Dubach et al., 2016; Junankar et al., 2015; Tipping et al., 2016)
also provides a more sophisticated platform for evaluation of new
therapies.
Although much is known about the biological pathways that
control the individual steps in the metastatic cascade, a number
of important questions remain. Uncovering the underlying
mechanisms that govern the enormous diversity in the onset and
target organs affected in patients and identifying whether there are
common mechanisms at play will be important. In addition,
understanding the fundamental differences between primary and
secondary tumors and the drivers of metastatic colonization is
essential to identifying strategies for targeting metastatic disease,
and would have a major impact on the survival of cancer patients.
The technological advances in the generation of mouse models that
better mimic human disease, combined with advances in imaging,
will allow for the translation of such research into meaningful
treatments.
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Céspedes, M. V., Espina, C., Garcıá-Cabezas, M. A., Trias, M., Boluda, A.,
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